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Abstract 
The purpose of oral toxicity study C in the EU project G-TwYST was to assess the effects of genetically 
modified (GM) maize NK 603, grown both with and without the use of RoundUp, when fed to rats for 
a period of 90 days at GM incorporation rates of 11%, 33% and 50% in the feed, if needed 
supplemented with near-isogenic non-GM maize to total maize inclusion rates of 33% or 50%.  
Differences between feeding groups were compared, using a recently developed method for 
equivalence testing, to differences between non-GM feeds obtained in previous studies performed in 
the EU project GRACE.  
Given tentative settings for regulatory parameters, for a set of 648 comparisons involving body and 
organ weights, haematology and clinical chemistry, equivalence was established in 99% of cases, 
higher than the minimal nominal confidence level of the test which was 95%. Equivalence was found 
to be more likely than lack of equivalence in 100% of cases.  
In addition to this primary analysis, the report also contains results for equivalence testing using 
external target effect sizes for a limited set of variables, results for classical statistical analysis of 
differences, graphs of standardised effect sizes such as performed in the GRACE study, results of 
factorial analysis, graphs showing correlations between variables associated with liver or kidney 
damage, and a post-hoc power analysis comparing trials with 33% and 50% maize inclusion rates.   
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1 Introduction 
The purpose of oral toxicity study C in the EU project G-TwYST was to assess the effects of genetically 
modified (GM) maize NK 603, grown both with and without the use of RoundUp, when fed to rats for 
a period of 90 days at GM incorporation rates of 11%, 33% and 50% in the feed. The effects were 
assessed relative to the responses for rats fed the near-isogenic non-GM maize with total maize 
inclusion rates 33% or 50%, and these two maize inclusion rates were also compared.  
This report describes the results of the statistical analysis of the data from Study C. In principle, the 
statistical analysis was performed according to section 8 of the study plan (Zeljenková and Steinberg 
2015). Deviations from the study plan were as follows: 
• The study plan specified a statistical analysis of data for males and females together, unless 
there were prior biological arguments or statistical indications to analyse males and females 
separately. However, toxicologists preferred separate statistical analysis of males and 
females for all variables, because it was thought that any specific non-target effect might be 
sex-specific. 
• The study plan anticipated pre-specified limits for use in equivalence testing. However, such 
limits could not be established in an early phase of the project. Therefore, an alternative 
method for equivalence testing was developed (van der Voet et al 2017) and applied. This 
method makes use of historical non-GM data to obtain reference values for acceptable and 
normal variation in the observed variables. For the analysis of the data in G-TwYST, the data 
from non-GM varieties in the preceding GRACE project were available as historical data. 
Target effect sizes for a few variables were recently proposed by Hong et al (2017). Although 
these values have no formal status, equivalence tests were also performed using these effect 
sizes as originally planned. 
Four schemes of statistical analysis were employed: 
1. Equivalence tests, following the method developed in the G-TwYST project (van der Voet et 
al, 2017). 
2. For a small number of variables: equivalence tests, based on target effect sizes suggested in 
Hong et al (2017). 
3. Classical tests, in line with OECD Guidance document 116 (2012). 
4. Standardised effect sizes, following the methods used in the GRACE project (Schmidt et al, 
2016, 2017). 
In addition, results from more integrated analyses were obtained: 
5. Factorial analysis, employing the fact that the six GM feeding groups form a 2 × 3 factorial 
structure. 
6. Correlation analysis, showing co-variation of effects for variables related to the same target 
organ. 
This report is organised as follows. Section 2 describes the data, both the data from the current study 
and the non-GM data from the GRACE studies A-E as used in the equivalence tests. Section 3 
describes data pre-processing procedures, such as summarising the growth and food intakes over 
time, outlier identification and assumptions checking. Section 4 presents the main results according 
to the six schemes of statistical analysis. Section 5 gives a summary and some evaluation of the 
methodology. Appendices to this report are provided as a separate document. 
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2 Data 
2.1 Data in G-TwYST study C 
Study C is a 90-day (sub-chronic) toxicity study in rats fed GM maize NK603. A full description of the 
data that have been measured is given in the study plan (document 632165 C/2017/GLP, Zeljenková 
and Steinberg 2015). There are eight feeding groups which are administrated to cages with 2 rats in 
each cage. Experimental units, i.e. cages, are organized in blocks of 8 cages, and the feeding groups 
are randomized within blocks. The design is thus a complete randomized block design with cage as 
the experimental unit. There are eight blocks with male rats and eight other blocks with female rats. 
Most of the measurements are on individual animals, only feed intake is measured on the cage level. 
All animals survived for three months. 
The available files for G-TwYST study C are given in Table 1. The randomisation was provided in the 
two “Random” Excel files.  The data in these files was converted to a single Excel file with blocking 
information “00-Design-G-TwYST-Study-C.xlsx”. Organ weights were provided as absolute weights in 
Excel files “Tab_9” and “Tab_11” and as relative weights with respect to the final body weight in 
Excel files “Tab_10” and “Tab_12”. It was checked that the data in these files were equivalent.  
Table 1 Data files for G-TwYST study C. 
Data files in G-TwYST study C Date Time Size (b) 
00-Design-G-TwYST-Study-C.xlsx 17-02-2018 11:38 12,199 
Random__G-TwYST_C_Females.xlsx 15-02-2018 16:53 19,445 
Random__G-TwYST_C_Males.xlsx 15-02-2018 16:53 18,948 
Rev_1_Tab_1_Body weight_90_day_st_2C_G_TwYST_Mal.xlsx 20-02-2018 13:40 212,091 
Rev_1_Tab_2_Body weight_90_day_st_2C_G_TwYST_Femal.xlsx 20-02-2018 13:36 213,393 
Tab_3_Feed consumpt_90_day_st_2C_G_TwYST_Mal.xlsx 16-06-2017 06:56 164,951 
Tab_4_Feed consumpt_90_day_st_2C_G_TwYST_Femal.xlsx 16-06-2017 08:06 166,046 
Tab_5_Haematology_90_day_st_2C_G_TwYST_Mal.xlsx 29-06-2017 07:06 65,223 
Tab_6_Haematology_90_day_st_2C_G_TwYST_Femal.xlsx 29-06-2017 07:20 66,634 
Tab_7a_Clinical chem_bl_90_day_st_2C_G_TwYST_Mal.xlsx 20-09-2017 08:29 78,847 
Tab_7b_Clinical chem_ur_90_day_st_2C_G_TwYST_Mal.xlsx 23-08-2017 13:51 62,428 
Tab_8a_Clinical chem_bl_90_day_st_2C_G_TwYST_Femal.xlsx 23-08-2017 13:16 78,861 
Tab_8b_Clinical chem_ur_90_day_st_2C_G_TwYST_Femal.xlsx 23-08-2017 13:46 62,155 
Tab_9_Absolute weight organs_90_day_st_2C_G_TwYST_Mal.xlsx 06-07-2017 10:13 98,465 
Tab_10_Relative weight organs_90_day_st_2C_G_TwYST_Mal.xlsx 06-07-2017 10:16 111,643 
Tab_11_Absolute weight organs_90_day_st_2C_G_TwYST_Femal.xlsx 24-08-2017 13:22 96,590 
Tab_12_Relative weight organs_90_day_st_2C_G_TwYST_Femal.xlsx 24-08-2017 13:38 109,590 
Blood_urine_3 month_MC_G_TwYST_90day st2_C_Fem_time 
image_necr.xlsx 03-08-2017 08:36 94,801 
Blood_urine_3 month_MC_G_TwYST_90day st2_C_Mal_time 
image_necr.xlsx 03-08-2017 08:34 101,501 
CD markers G-TwYST C  - database 9.2.2018.xlsx 12-02-2018 17:21 43,699 
LTT- GTwYST C  database 18.2.18.xlsx 18-02-2018 18:32 81,724 
Phagocyt G-TwYST C 12.12.17 final.xlsx 13-12-2017 15:03 25,470 
 
The definition of the eight feeding groups is given in Table 2. This includes the coding of the blinded 
treatments. In this report the Group labels (Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- 
NK33+), or shortened versions when necessary, will mostly be used.  
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Table 2 Feeding groups used in study C. 
Factor Levels/Labels 
Treat (blinded) C E A D B G F H 
Group Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
FeedType non-GM GM GM GM GM non-GM GM GM 
AmountMaize 50 50 50 50 50 33 33 33 
AmountNK 0 11 50 11 50 0 33 33 
RoundUp No No No Yes Yes No No Yes 
 
Male and female rats were analysed separately. Since cage is the experimental unit an analysis of 
variance employs cage means with degrees of freedom as in Table 3. The main interest is in the 
difference between each of the six GM maize feeding groups and the two control non-GM feeding 
groups. 
Table 3 Skeleton analysis of variance with degrees of freedom for cage means for a single sex. 
Source of variation 
8 cages/group 6 cages/group 5 cages/group 
d.f. d.f. d.f. 
Block stratum 7 5 4 
Block.Cage stratum 
 Group 
 Residual 
 
7 
49 
 
7 
35 
 
7 
28 
Total 63 47 39 
 
The observed variables in Study C are given in Table 4; this table includes the grouping of variables. 
All variables are measured on the animal level; only feed intake is measured on the cage level. The 
Immunology and CellPhenotype measurement are only available for a subset of 9-12 animals per 
feeding group, i.e. 5 to 6 cages per feeding group. All other variables are available for 16 animals, i.e. 
for 8 cages, although there are occasionally missing values. Some ALP, ALT, CHOL and cHGB were 
given as bounds; the number of such values are given in Table 5. For most Urine variables only a 
limited number of values have been observed, see Table 6. It is evident that a statistical analysis of 
the Urine variables uColour, uBil, uNit, uProtein, uGlu, uHemogl and uUrobili is not very useful. 
Therefore, only the Urine variables uVol, uVolW, uLeu, uOsmoll, uKeton and upH were statistically 
analysed. 
All variables were transformed to the natural logarithmic scale and then averaged to the cage level. 
This implies that, rather than looking at differences between feeding group means, ratios between 
the GM feeds and the corresponding Control feed are of interest. Only pH as measured in urine was 
not log transformed because the pH is already measured on the log scale. Since uLeu, uHemogl and 
uKeton have zero values, half of the smallest positive value was added to all observations before 
taking the logarithm.  
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Table 4 List of grouped variables with abbreviated names, descriptions and measurement units. 
Grouping is indicated by the headers in the first column. The Grace column indicates 
whether the same variable was measured in the GRACE study. Urine variables given in 
red are not statistically analysed because only a limited number of values was observed 
(see Table 6 for details). 
Weights Description Unit Grace 
Weight 0-13 Body weight at weeks 0, 1 … 13 g/animal X 
Feed 1-13 Feed intake in week 1, 2 … 13 g/cage X 
BodyWeight Body weight at the end of the trial, i.e. at week 13 g/animal X 
growthRate Growth rate fitted to the weight over all weeks  1/week X 
FeedMean Mean of feed intake over 13 weeks g/animal/day X 
Haematology Description Unit Grace 
WBC white blood cells 109/L X 
RBC red blood cells 1012/L X 
HGB haemoglobin g/dL X 
HCT haematocrit % X 
MCV mean cell volume fL X 
MCH mean corpuscular haemoglobin pg X 
MCHC mean corpuscular haemoglobin concentration g/dL X 
PLT platelets 109/L X 
LYMR  relative lymphocytes count % - 
LYMA absolute count of lymphocytes 103/uL X 
ClinChem Description Unit Grace 
ALP alkaline phosphatase μkat/L X 
ALT alanine aminotransferase μkat/L X 
AST aspartate aminotransferase μkat/L X 
BIL bilirubin μmol/L - 
ALB albumin g/L X 
TP total protein g/L X 
Glu glucose mmol/L X 
CHOL cholesterol mmol/L X 
TAG triglycerides mmol/L X 
Crea creatinine mmol/L X 
Urea urea mmol/L X 
cHGB haemoglobin mg/dL - 
Ca calcium mmol/L X 
Cl chloride mmol/L X 
K potassium mmol/L X 
Na sodium mmol/L X 
P phosphorus mmol/L X 
Urine Description Unit Grace 
uVol Urine Volume ml  
uVolW Urine Volume / bodyweight ml /100g  
uColour Urine Colour (1 – light yellow; 2 – yellow; 3 – dark yellow) -  
uBil bilirubin μmol/L   
uLeu leukocytes leu/uL  
uNit nitrites neg/pos  
uOsmoll osmolality mOsm  
uProtein total protein g/L   
uGlu glucose mmol/L   
uHemogl haemoglobin ery/uL  
uKeton ketone mmol/L  
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upH pH -   
uUrobili urobilinogen μmol/L   
Organs Description; all as percentage of BodyWeight Unit Grace 
Kidney  Percentage weight of kidney % X 
Spleen Percentage weight of spleen % X 
Liver Percentage weight of liver % X 
AdrenGl Percentage weight of adrenal gland % X 
Heart Percentage weight of heart % X 
Thymus Percentage weight of thymus % X 
Testis Percentage weight of testis (males) % X 
Epididymis Percentage weight of epididymis (males) % X 
Uterus Percentage weight of uterus (females) % X 
Ovary Percentage weight of ovary (females) % X 
Brain Percentage weight of brain % X 
Immunology Description Unit Grace 
Monocytes Phagocytic activity of monocytes  %  
Granulocytes Phagocytic activity of granulocytes  %  
RespirBurst Respiratory burst of phagocytes %  
Con Proliferative activity of lymphocytes stimulated 
with mitogen Concanavalin A 
cpm (counts 
per minute)  
PHA Proliferative activity of lymphocytes stimulated with mitogen 
phytohaemmagglutinin 
cpm  
PWM Proliferative activity of lymphocytes stimulated with 
pokeweed mitogen  
cpm  
Med3d Proliferative activity of non-stimulated lymphocytes 3 day-
cultivation 
cpm  
IprConA Ratio of proliferative activity of lymphocytes stimulated with 
concanavalin A /  
proliferative activity of non-stimulated lymphocytes 
- 
 
IprPHA Ratio of proliferative activity of lymphocytes stimulated with 
phytohaemmagglutinin /  
proliferative activity of non-stimulated lymphocytes 
- 
 
IprPWM Ratio of proliferative activity of lymphocytes stimulated with 
pokeweed mitogen /  
proliferative activity of non-stimulated lymphocytes 
- 
 
G4c1 Proliferative activity of lymphocytes stimulated with maize 
G4 protein, concentration 1 
cpm  
G4c2 Proliferative activity of lymphocytes stimulated with maize 
G4 protein, concentration 2 
cpm  
G4c3 Proliferative activity of lymphocytes stimulated with maize 
G4 protein, concentration 3 
cpm  
NG2c1 Proliferative activity of lymphocytes stimulated with maize 
NG2 protein, concentration 1 
cpm  
NG2c2 Proliferative activity of lymphocytes stimulated with maize 
NG2 protein, concentration 2 
cpm  
NG2c3 Proliferative activity of lymphocytes stimulated with maize 
NG2 protein, concentration 3 
cpm  
A6c1 Proliferative activity of lymphocytes stimulated with maize 
A6 protein, concentration 1 
cpm  
A6c2 Proliferative activity of lymphocytes stimulated with maize 
A6 protein, concentration 2 
cpm  
A6c3 Proliferative activity of lymphocytes stimulated with maize 
A6 protein, concentration 3 
cpm  
Med6d Proliferative activity of non-stimulated lymphocytes 6 day-
cultivation 
cpm  
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IprG4c1 Ratio of proliferative activity of lymphocytes stimulated with 
maize G4 protein, concentration 1 / proliferative activity of 
non-stimulated lymphocytes 
- 
 
IprG4c2 Ratio of proliferative activity of lymphocytes stimulated with 
maize G4 protein, concentration 2 / proliferative activity of 
non-stimulated lymphocytes 
- 
 
IprG4c3 Ratio of proliferative activity of lymphocytes stimulated with 
maize G4 protein, concentration 3 / proliferative activity of 
non-stimulated lymphocytes 
- 
 
IprNG2c1 Ratio of proliferative activity of lymphocytes stimulated with 
maize NG2 protein, concentration 1 / proliferative activity of 
non-stimulated lymphocytes 
- 
 
IprNG2c2 Ratio of proliferative activity of lymphocytes stimulated with 
maize NG2 protein, concentration 2 / proliferative activity of 
non-stimulated lymphocytes 
- 
 
IprNG2c3 Ratio of proliferative activity of lymphocytes stimulated with 
maize NG2 protein, concentration 3 / proliferative activity of 
non-stimulated lymphocytes 
- 
 
IprA6c1 Ratio of proliferative activity of lymphocytes stimulated with 
maize A6 protein, concentration 1 / proliferative activity of 
non-stimulated lymphocytes 
- 
 
IprA6c2 Ratio of proliferative activity of lymphocytes stimulated with 
maize A6 protein, concentration 2 / proliferative activity of 
non-stimulated lymphocytes 
- 
 
IprA6c3 Ratio of proliferative activity of lymphocytes stimulated with 
maize A6 protein, concentration 3 / proliferative activity of 
non-stimulated lymphocytes 
- 
 
CellPhenotype Description Unit Grace 
sp3 Spleen: percentage of cells, not labelled with monoclonal 
antibody anti-rat CD3 
%  
sp3-4 Spleen: percentage of T-cytotoxic lymphocytes, cells double 
labelled with monoclonal antibodies anti-rat CD3 and anti-
rat CD4 
%  
sp3-8 Spleen: percentage of T-helper lymphocytes, cells double 
labelled with monoclonal antibodies anti-rat CD3 and anti-
rat CD8 
%  
sp3-45 Spleen: percentage of B-lymphocytes, cells anti-rat CD3 
antigen negative and anti-rat CD45R antigen positive 
%  
sp3-161 Spleen: percentage of NK-cells, cells anti-rat CD3 antigen 
negative and anti-rat CD161 antigen positive  
%  
ln3 Lymph node: percentage of cells, not labelled with 
monoclonal antibody anti-rat CD3 
%  
ln3-4 Lymph node: percentage of T-cytotoxic lymphocytes, cells 
double labelled with monoclonal antibodies anti-rat CD3 
and anti-rat CD4 
%  
ln3-8 Lymph node: percentage of T-helper lymphocytes, cells 
double labelled with monoclonal antibodies anti-rat CD3 
and anti-rat CD8 
%  
ln3-45 Lymph node: percentage of B-lymphocytes, cells anti-rat 
CD3 antigen negative and anti-rat CD45R antigen positive 
%  
ty3 Thymus: percentage of cells, not labelled with monoclonal 
antibody anti-rat CD3 
%  
ty3-4 Thymus: percentage of T-cytotoxic lymphocytes, cells 
double labelled with monoclonal antibodies anti-rat CD3 
and anti-rat CD4 
%  
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ty3-8 Thymus: percentage of T-helper lymphocytes, cells double 
labelled with monoclonal antibodies anti-rat CD3 and anti-
rat CD8 
%  
bm3 Bone marrow: percentage of cells, not labelled with 
monoclonal antibody anti-rat CD3 
%  
bm3-45 Bone marrow: percentage of T-cytotoxic lymphocytes, cells 
double labelled with monoclonal antibodies anti-rat CD3 
and anti-rat CD4 
%  
 
Table 5 Number of animals for which bounded values were provided. These bounds are given in 
the first column. 
Male rats 
Variable Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
ALT < 0.12 - - - 1 - - - - 
cHGB > 522.5 - 2 - 1 - - - - 
Female rats 
Variable Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
ALP < 0.17 - - - - - - - 1 
ALT < 0.05 - - - - - - - 1 
CHOL < 1.16 2 5 5 4 10 3 1 3 
cHGB < 27.5 - - 1 - - - - - 
cHGB > 522.5 - 1 - 1 1 - - 2 
 
Table 6 Urine variables with only a limited set of observed values which are given in the heading 
of each sub-table. The table entries give the number of times each value occurs for male 
and female rats. Only uLeu and uKeton were statistically analysed. 
uColour 1 2   
Male - 128   
Female 1 127   
uBil 0 50   
Male 127 1   
Female 128 -   
uLeu 0 25 100 500 
Male 81 45 2 - 
Female 117 9 1 1 
uNit 0    
Male 127    
Female 128    
uProtein 0.00 0.25   
Male 125 3   
Female 128 -   
uGlu 1    
Male 128    
Female 128    
uHemogl 0 10 25 50 
Male 126 - 1 1 
Female 127 1 - - 
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uKeton 0.0 0.5 1.5  
Male 77 24 27  
Female 117 7 4  
uUrobili 1 17   
Male 127 1   
Female 128 -   
 
The variables in Table 4 exclude the following measurements in comparison to the study plan: 
• Histopathological data. Reason: these were excluded from this statistical analysis in the study 
plan, and will be separately reported by the histopathological expert in the G-TwYST project. 
• Periodic health status observations: morbidity, mortality, clinical signs. Rats were inspected 
twice daily for evidence of reaction to treatment or ill-health. The following clinical findings 
were observed at the end of the experiment 
1. Male animal 7 (NK50-) skin: alopecia- r.coli ventralis, r.trachealis (1-2cm) 
2. Male animal 58 (NK33+) skin: alopecia- r.abdominis lateralis sinister (3x2cm) 
3. Female animal 265 (NK11-/50) skin: alopecia- ventromedial area (3x1cm) 
4. Female animal 266 (NK11-/50) skin: alopecia- ventromedial area (3x1cm), r.inguinalis 
sin. 2x1cm) 
5. Female animal 287 (NK33-) skin: alopecia- ventromedial area (2x1cm) 
6. Female animal 228 (NK50+) skin: alopecia- r. colli dorsalis 
7. Female animal 328 (NK33+) skin: alopecia- r. lumbalis  
It was assumed that these findings were not related to the experiment. 
• Organ weights: sternum with bone marrow, thyroid, parathyroid. These were not determined 
and this is in line with the OECD Test Guideline 408, which does not foresee such 
measurements. These measurement were erroneously included in the original study plan. 
• In addition to the measurements in urine specified in the study plan, also bilirubine, leukocytes, 
nitrites, haemoglobin, ketone and urobilinogen were measured in urine. 
• In addition to the measurements specified in the study plan, immunological measurements and 
measurements on the spleen, lymph node, thymus and bone marrow cell phenotypes were 
performed. 
2.2 Reference data in GRACE studies 
Data from the GRACE project are used as historic data to set equivalence limits. These data have 
been analysed before as part of the GRACE project (Schmidt and Schmidtke 2014, Schmidt et al 
2015ab, 2016, 2017, Zeljenková et al 2014, 2016). Note that in the GRACE studies a completely 
randomized design, i.e. without blocking, was used. The GRACE data were retrieved from the Cadima 
website (https://www.cadima.info) at 29-11-2016. In GRACE five studies were conducted with 
several control (or reference) feeds as given in Table 7, see Schmidt et al (2017). In studies D and E 
only a single reference feed was used and, since the equivalence analysis corrects for differences 
between studies, these studies do not contribute to the between reference variation. In GRACE 
studies A, B and C, the reference feeds DKC6666 and SY-NEPAL were replicated. The degrees of 
freedom associated with the between reference feeds variance therefore equals 4. The degrees of 
freedom associated with the residual (between cages) variance varies between 50 and 78 since not 
all measurements were done on all rats in every study.  
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Table 7 Feeds which were used in the five GRACE studies with reference feeds in bold. 
GRACE Study Control 11% GMO 33% GMO 33% Conv-1 33% Conv-2 
A DKC6666 DKC6667-YG-11 DKC6667-YG-33 PR33W82 SY-NEPAL 
B PR32T16 PR33D48-11 PR33D48-33 PR32T83 DKC6815 
C DKC6666 DKC6667-YG-11 DKC6667-YG-33 - SY-NEPAL 
D DKC6666 DKC6667-YG-11 DKC6667-YG-33 - - 
E PR32T16 PR33D48-11 PR33D48-33 - - 
 
We re-analysed the GRACE data to enable a comparison with the G-TwYST data. This re-analysis is 
different from the analysis in the GRACE reports in the following ways: 
• For the re-analysis all variables were transformed to the natural logarithmic scale and then 
averaged to the cage level; the thus obtained cage means were used in the statistical analysis; 
• the exponential growth model (see section 3.1) was fitted to the weights observed in GRACE to 
obtain an estimate of the growth rate 𝛾𝛾; 
• The sum of the weights of organ pairs was analysed rather than the left and right organs; 
• outliers were identified by applying Grubbs’ outlier test at the 1% level on residuals of a 
one-way ANOVA which is conducted separately for each study. These outliers were set to 
missing. 
Details of the re-analysis are given in the report on G-TwYST Study B (Goedhart & van der Voet, 
2017). In Table 4 it is indicated which G-TwYST variables in Study C have also been measured in the 
GRACE studies. 
3 Data pre-processing 
GenStat programs “00-Males.gen” and “00-Females.gen” were used to combine all the data given in 
Table 1 into single Excel files, separately for males and females. All animals survived the experiment. 
3.1 Growth curves and feed intake 
For each individual rat an exponential growth curve 𝐴𝐴 + 𝐵𝐵 𝑅𝑅𝑊𝑊𝑊𝑊𝑊𝑊𝑘𝑘 was fitted to the observed weights. 
A re-parameterization of this curve is given by 𝐴𝐴 + 𝐵𝐵 exp(−𝛾𝛾 𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊) with the growth rate 𝛾𝛾 defined 
by 𝛾𝛾 = − log(𝑅𝑅). Appendix 1 displays, for each rat separately, the observed weights along with the 
fitted curve and, in the bottom right corner, the resulting estimate of the growth rate 𝛾𝛾. In general 
the exponential curve fits very well and it was therefore decided to only analyse the final weight 
observed after week 13, further called BodyWeight, and the estimated growth rate 𝛾𝛾, further called 
growthRate. The mean weight for each feeding group is given in Figure 1, while the mean weight gain 
per day per animal in each week is given in Figure 2. Feed consumption for each cage in units 
g/animal/day is graphically depicted in Appendix 2. The mean feed consumption for each feeding 
group is given in Figure 3.  
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Figure 1 Mean body weights versus week for each feeding group for male rats (left) and for 
female rats (right). 
 
 
Figure 2 Mean body weights gain (g/day/animal) versus week for each feeding group for male 
rats (left) and for female rats (right). 
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Figure 3 Mean feed consumption (g/day/animal) versus week for each feeding group for male 
rats (left) and for female rats (right). 
3.2 Outliers and checking of ANOVA assumptions 
The cage means, after log transformation, for each observed variable are statistically analysed by 
means of an analysis of variance using the model “Block + Group” according to the randomized block 
design. Grubbs’ outlier test at the 1% level was applied to the residuals to detect outliers. This 
resulted in a number of outliers, given in Table 8, which were presented to the G-TwYST coordinator 
along with the blinded feeding group. Outliers were classified as either (1) typos or physiologically 
improbable values, or (2) values that might be realistic, or (3) values that should be kept. For the first 
category the values were set to missing, effectively removing the outlier completely. For the second 
category a statistical analysis without and with these outlier was performed. Values in the third 
category were kept in the dataset. The analyses presented in this report are without the outliers. 
Analyses including outliers are presented in Appendix 14.  
Table 8 Values that have been modified, deleted, or were considered as possible outliers, before 
unblinding of the feeding groups. The values were presented to the G-TwYST 
coordinator. He decided which values should be deleted (red), which values should be 
considered as possible outliers (yellow), and which values should be kept (white). 
Comments by the authors of this report are given in the last column. 
Sex Variable Animal Cage oldValue newValue Comment 
Male LYMR 109 55 45.6 * 
The two smallest values occur in the 
same Cage; five smallest are 45.6, 55.8, 
58.4, 61.2, 61.6 
Male LYMR 110 55 55.8 * 
The two smallest values occur in the 
same Cage; five smallest are 45.6, 55.8, 
58.4, 61.2, 61.7 
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Male ALT 3 2 3.06 * 
Large value; five largest are 0.86, 0.92, 
1.80, 2.22, 3.06. In StudyA24 values 5.92 
and 6.18 were considered outliers 
Male ALT 58 29 0.12 * 
Small value (ALT,BIL,ALB,TP,K); five 
smallest are 0.12, 0.28, 0.37, 0.37, 0.37. 
In StudyA24 the value 0.08 was deleted 
Male ALT 61 31 2.22 2.22 Large value; five largest are 0.86, 0.92, 1.80, 2.22, 3.06 
Male BIL 58 29 84.8 * 
Large value (ALT,BIL,ALB,TP,K); five 
largest are 13.3, 13.6, 25.6, 56.9, 84.8. In 
StudyA24 values 76 and 86 were deleted 
Male BIL 76 38 56.9 * 
Large value (BIL,ALP,TP); five largest are 
13.3, 13.6, 25.6, 56.9, 84.8.  In StudyA24 
values 76 and 85.9 were deleted 
Male ALB 58 29 58.7 58.7 Large value (ALT,BIL,ALB,TP,K); five largest are 41.9, 41.9, 42.7, 52.9, 58.7 
 
Male ALB 76 38 52.9 52.9 Large value (BIL,ALP,TP); five largest are 41.9, 41.9, 42.7, 52.9, 58.7 
 
Male TP 58 29 91.4 * 
Large value (ALT,BIL,ALB,TP,K); five 
largest are 70.8, 70.9, 73.2, 83.7, 91.4. In 
StudyA24 values 96 and 100 are deleted 
Male TP 76 38 83.7 * 
Large value (BIL,ALP,TP); five largest are 
70.8, 70.9, 73.2, 83.7, 91.4. In StudyA24 
values 96 and 100 are deleted 
Male K 58 29 10.1 * 
Large value (ALT,BIL,ALB,TP,K); five 
largest are 5.8, 6.1, 6.9, 9.3 and 10.1 
Male AdrenGl_R 68 34 0.00181 * 
Small value for Cage mean; five smallest 
are 0.0064, 0.0075, 0.0088, 0.0094, 
0.0100 
Male AdrenGl_L 68 34 0.00454 * 
Small value for Cage mean; five smallest 
are 0.0064, 0.0075, 0.0088, 0.0094, 
0.0100 
Male Testis_R 39 20 0.1921 * Small value for Cage mean; five smallest are 0.378, 0.698, 0.717, 0.720, 0.725 
Male Testis_L 39 20 0.1855 * Small value for Cage mean; five smallest are 0.378, 0.698, 0.717, 0.720, 0.725 
Sex Variable Animal Cage oldValue newValue Comment 
Female Ovary_R 286 110 1.416 * Definitively Out of Range 
Female RBC 286 110 6.06 * Small value (RBC,HCT); five smallest are 6.06, 6.79, 7.05, 7.10, 7.12 
Female HCT 286 110 35.2 * 
Small value (RBC,HCT); five smallest are 
35.2, 40.5, 40.7, 41.1, 41.4. in StudyA24 
the value 27.7 was considered an outlier 
Female PLT 247 91 189.0 * 
Small value; five smallest are 155, 189, 
262, 420, 464. In StudyA24 the value 156 
was considered an outlier 
Female PLT 277 106 420.0 * 
Small value; five smallest are 155, 189, 
262, 420, 464. In StudyA24 the value 156 
was considered an outlier 
Female PLT 323 129 155.0 * 
Small value; five smallest are 155, 189, 
262, 420, 464. In StudyA24 the value 156 
was considered an outlier 
Female PLT 324 129 262.0 * 
Small value; five smallest are 155, 189, 
262, 420, 464. In StudyA24 the value 156 
was considered an outlier 
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Female ALT 317 126 0.05 0.05 
Small value; five smallest are 0.05, 0.19, 
0.22, 0.22, 0.28 
 
Female ALB 289 112 4.1 * Small value; five smallest are 4.1, 36.4, 37.6, 37.7, 38.5 
Female cHGB 323 129 522.5 * Upper limit reached for 5 animals in total; only a single value in this cage 
Female Heart 250 92 0.175 * Small value; five smallest are 0.175, 0.260, 0.261, 0.263, 0.264 
 
Residual plots which include the outliers (i.e. including the yellow values in Table 8) are given in 
Figure 4. From this it is clear that these are indeed outliers. Residual plots for the variables for which 
Grubbs’ outlier test is significant at the 1% level but which were not considered as outliers, i.e. the 
values with a white background in Table 8, are given in  
Without these outliers, plots of cage means per feeding group on the original scale are given in 
Appendix 3, while plots of cage means after a log transformation of the individual data are given in 
Appendix 4. Normal probability plots of the ANOVA residuals, of an analysis on cage means after log 
transformation, are given in Appendix 5. To aid interpretation a 99% envelope is added to the 
probability plots, such that only values outside the envelop might be suspicious. Appendix 6 gives 
plots of residuals versus fitted values after the same analysis of variance. These residual plots are 
generally satisfactory implying that the ANOVA assumptions, homogeneity of variance and less 
importantly normality, are generally fulfilled. 
3.3 Summary tables  
Summary tables, on the original non-transformed scale, of means, standard deviations and 
coefficients of variation (%), classified by the feeding groups, are given in Table 9 for males and in 
Table 10 for females. These tables were obtained by first calculating cage means and then calculating 
the summary statistics. The number of cages per feeding group for which measurements are 
available is generally 8, except for the Immunology and CellPhenotype variables with 6 cages.  
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Figure 4 Residuals along the y-axis versus fitted values 
along the x-axis resulting from an analysis of 
variance on log transformed cage means. Solid 
symbols denote outliers found by Grubbs’ outlier 
test at the 1% level applied to the residuals; these 
values were considered to be outliers (the values 
with a yellow background in Table 8). 
 
 
 
Figure 5 Residuals along the y-axis versus fitted values along the x-axis resulting from an analysis 
of variance on log transformed cage means. Solid symbols denote outliers found by 
Grubbs’ outlier test at the 1% level applied to the residuals; these values were not 
considered to be outliers (the values with a white background in Table 8). 
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Table 9 Summary statistics for male rats classified by the feeding groups: means (Mean), standard deviations (Sd) and coefficients of variation (CV). The 
summary statistics are obtained from cage means. Some variables are scaled. 
 The number of cages (N) is given in subheadings. Exceptions from these numbers are for males for the following feeding groups: Control33 (LYMR, 
7 cages), NK33- (Immunology, CellPhenotype, 5 cages), NK11+ (ln3-45, 5 cages) and NK50+ (Immunology, CellPhenotype, 5 cages).  
Weights Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
Male (N=8) Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV 
Bodyweight 462 28.0 6.0 443 29.5 6.7 438 17.9 4.1 459 26.8 5.8 453 32.8 7.2 441 26.7 6.1 444 30.1 6.8 444 25.7 5.8 
growthRate 0.17 0.012 7.5 0.17 0.025 14.5 0.16 0.020 12.7 0.17 0.023 13.9 0.16 0.012 7.5 0.17 0.019 11.3 0.15 0.013 8.3 0.17 0.014 8.4 
FeedMean 2.77 0.16 5.8 2.66 0.15 5.6 2.63 0.12 4.7 2.83 0.17 5.9 2.74 0.18 6.6 2.65 0.15 5.8 2.61 0.16 6.0 2.68 0.15 5.6 
Haematology Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
Male (N=8) Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV 
WBC 7.98 1.53 19.2 8.01 1.31 16.4 8.56 1.56 18.2 7.41 1.01 13.6 8.46 1.45 17.2 8.36 2.06 24.7 8.24 1.15 14.0 8.22 1.53 18.6 
RBC 8.63 0.14 1.6 8.67 0.21 2.4 8.54 0.17 2.0 8.71 0.21 2.4 8.54 0.20 2.3 8.63 0.21 2.4 8.64 0.18 2.0 8.79 0.20 2.2 
HGB 15.7 0.47 3.0 16.1 0.41 2.6 15.7 0.22 1.4 16.2 0.36 2.2 15.9 0.48 3.0 15.9 0.40 2.5 16.0 0.28 1.8 15.8 0.32 2.1 
HCT 46.8 1.27 2.7 47.3 1.17 2.5 46.5 0.72 1.5 47.8 0.88 1.8 46.9 1.09 2.3 46.9 0.84 1.8 47.2 0.84 1.8 47.0 1.00 2.1 
MCV 54.3 0.94 1.7 54.6 0.79 1.5 54.4 0.54 1.0 54.9 1.14 2.1 55.0 0.94 1.7 54.4 0.85 1.6 54.6 0.75 1.4 53.5 0.68 1.3 
MCH 18.2 0.38 2.1 18.6 0.33 1.8 18.4 0.26 1.4 18.6 0.54 2.9 18.6 0.26 1.4 18.5 0.53 2.9 18.5 0.40 2.2 18.0 0.43 2.4 
MCHC 33.6 0.46 1.4 34.1 0.33 1.0 33.8 0.28 0.8 33.9 0.47 1.4 33.9 0.39 1.2 34.0 0.56 1.6 33.9 0.45 1.3 33.6 0.59 1.8 
PLT 737 66 8.9 792 80 10.1 859 166 19.3 776 68 8.7 829 76 9.2 770 94 12.2 763 78 10.2 843 83 9.9 
LYMR 74.5 3.13 4.2 74.5 2.88 3.9 76.3 2.27 3.0 75.7 3.00 4.0 75.8 2.62 3.5 75.2 2.99 4.0 77.9 3.13 4.0 73.0 3.74 5.1 
LYMA 5.92 1.13 19.1 5.97 1.08 18.0 6.52 1.08 16.6 5.61 0.93 16.6 6.40 1.00 15.7 5.94 1.27 21.4 6.41 0.84 13.1 5.99 1.06 17.7 
ClinChem Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
Male (N=8) Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV 
ALP 1.28 0.19 15.1 1.47 0.32 22.0 1.19 0.15 12.7 1.20 0.21 17.6 1.33 0.30 22.5 1.39 0.29 20.6 1.29 0.18 13.8 1.35 0.22 16.5 
ALT 0.54 0.10 18.2 0.66 0.17 26.2 0.53 0.08 15.9 0.64 0.34 53.4 0.57 0.10 17.7 0.53 0.07 13.1 0.52 0.08 14.3 0.55 0.07 12.2 
AST 2.37 0.37 15.8 2.92 1.01 34.6 2.46 0.54 22.0 2.67 0.68 25.6 2.57 0.71 27.5 2.42 0.45 18.7 2.28 0.30 13.1 2.39 0.24 9.9 
BIL 7.47 0.72 9.6 8.92 3.22 36.1 7.86 1.57 20.0 8.04 1.39 17.3 8.21 0.94 11.4 7.50 0.91 12.1 7.59 0.81 10.7 7.72 0.78 10.1 
ALB 37.5 0.64 1.7 39.3 2.95 7.5 38.3 0.82 2.1 39.0 3.75 9.6 38.4 0.67 1.8 38.4 1.58 4.1 38.2 1.48 3.9 38.3 1.36 3.5 
TP 64.2 0.76 1.2 65.5 2.10 3.2 65.4 0.67 1.0 64.6 1.71 2.6 65.6 1.01 1.5 66.2 2.26 3.4 65.4 1.26 1.9 65.7 1.69 2.6 
Glu 5.58 0.90 16.2 5.45 0.84 15.5 5.22 0.76 14.6 5.70 0.48 8.4 5.03 0.69 13.7 5.74 0.61 10.7 5.40 0.33 6.2 5.29 0.33 6.2 
CHOL 2.13 0.26 12.1 2.11 0.17 8.2 2.23 0.14 6.2 2.25 0.09 3.9 2.26 0.26 11.6 2.15 0.24 11.3 2.08 0.17 8.4 2.11 0.22 10.6 
TAG 1.13 0.30 26.1 1.12 0.17 15.5 1.18 0.17 14.6 1.18 0.23 19.4 1.20 0.24 19.7 1.07 0.24 22.5 1.27 0.24 18.5 1.12 0.22 19.2 
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Crea 33.4 5.31 15.9 32.3 3.34 10.3 34.9 6.61 18.9 32.2 7.05 21.9 33.3 5.95 17.9 36.2 5.35 14.8 34.4 4.11 12.0 33.3 7.31 22.0 
Urea 4.96 0.56 11.3 4.91 0.90 18.2 4.69 0.39 8.4 5.50 0.79 14.4 4.86 0.70 14.3 5.46 0.97 17.8 4.84 0.87 18.0 5.31 0.57 10.8 
cHGB 66 15.2 23.0 138 98.2 71.1 89 42.0 47.2 106 78.7 74.2 107 37.7 35.2 87 18.1 20.8 74 21.5 29.1 89 25.8 29.1 
Ca 2.39 0.041 1.7 2.37 0.043 1.8 2.40 0.038 1.6 2.39 0.041 1.7 2.39 0.034 1.4 2.39 0.035 1.4 2.40 0.047 2.0 2.39 0.036 1.5 
Cl 100 1.03 1.0 100 1.90 1.9 101 2.19 2.2 100 2.63 2.6 99 1.36 1.4 99 1.95 2.0 100 2.42 2.4 100 2.31 2.3 
K 4.44 0.21 4.8 4.89 0.88 18.1 4.66 0.37 7.9 4.50 0.24 5.2 4.56 0.21 4.7 4.56 0.27 5.9 4.51 0.37 8.2 4.43 0.19 4.4 
Na 144 1.75 1.2 143 1.67 1.2 145 1.70 1.2 143 2.10 1.5 143 2.41 1.7 144 2.43 1.7 143 1.77 1.2 145 2.40 1.7 
P 2.00 0.14 7.0 2.11 0.26 12.3 1.99 0.23 11.4 2.02 0.42 20.7 2.04 0.19 9.2 2.19 0.41 18.6 2.22 0.19 8.4 2.22 0.21 9.4 
Urine Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
Male (N=8) Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV 
uVol 23.8 7.96 33.5 23.0 7.24 31.5 25.2 5.56 22.1 25.3 7.23 28.5 25.5 9.05 35.5 18.9 3.65 19.3 21.1 5.02 23.8 20.7 8.10 39.0 
uVolW 5.31 1.53 28.8 5.48 1.85 33.8 6.14 1.31 21.4 5.75 1.52 26.5 5.80 1.79 30.8 4.53 1.06 23.4 4.94 1.00 20.2 4.84 1.83 37.9 
uLeu 12.5 11.6 92.6 9.4 8.8 94.3 4.7 6.5 138.0 7.8 9.3 119.0 6.2 9.4 151.2 12.5 6.7 53.5 9.4 8.8 94.3 20.3 24.0 118.3 
uOsmoll 458 140 30.5 417 133 32.0 395 156 39.4 405 113 27.8 433 141 32.5 432 55 12.7 422 83 19.8 516 196 38.1 
uKeton 0.50 0.60 119.5 0.34 0.38 109.5 0.37 0.33 87.3 0.22 0.53 240.0 0.47 0.65 138.0 0.31 0.44 140.2 0.62 0.46 74.1 0.44 0.42 95.4 
upH 6.94 0.32 4.6 6.91 0.13 1.9 6.94 0.46 6.6 7.12 0.23 3.2 6.72 0.34 5.0 7.09 0.44 6.2 7.03 0.21 3.0 7.25 0.40 5.5 
Organs Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
Male (N=8) Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV 
Kidney * 10 5.35 0.32 6.0 5.55 0.32 5.7 5.47 0.38 7.0 5.61 0.19 3.4 5.54 0.21 3.8 5.43 0.27 4.9 5.33 0.44 8.3 5.79 0.44 7.6 
Spleen * 10 1.63 0.14 8.3 1.62 0.13 8.1 1.70 0.16 9.3 1.68 0.19 11.1 1.70 0.17 10.1 1.67 0.16 9.7 1.67 0.16 9.8 1.68 0.17 9.9 
Liver * 10 22.7 0.98 4.3 22.2 0.93 4.2 23.4 0.99 4.2 23.4 0.85 3.6 23.0 0.87 3.8 23.5 0.95 4.0 22.9 0.75 3.3 22.9 0.77 3.4 
AdrenGl * 10 0.14 0.021 15.3 0.14 0.019 13.5 0.14 0.015 11.1 0.14 0.015 11.2 0.14 0.015 10.6 0.14 0.013 9.6 0.13 0.019 14.0 0.13 0.016 12.3 
Heart * 10 2.50 0.10 4.1 2.48 0.18 7.1 2.58 0.07 2.6 2.56 0.24 9.3 2.55 0.11 4.3 2.56 0.08 3.3 2.42 0.13 5.5 2.61 0.17 6.4 
Thymus * 10 0.95 0.11 11.3 0.90 0.12 12.9 0.97 0.13 13.3 1.01 0.16 15.4 0.92 0.11 12.0 0.96 0.14 14.4 0.87 0.14 15.9 0.96 0.11 11.5 
Testis * 10 8.19 0.61 7.4 8.30 0.52 6.2 8.83 0.50 5.7 8.63 0.37 4.3 8.55 0.51 5.9 8.64 0.47 5.4 8.46 0.79 9.3 8.33 0.68 8.1 
Epididymis * 10 2.80 0.28 9.9 2.80 0.29 10.3 2.98 0.22 7.5 2.96 0.13 4.3 2.91 0.18 6.1 2.93 0.14 4.9 2.80 0.30 10.8 2.90 0.14 4.7 
Brain * 10 4.93 0.19 3.8 5.06 0.34 6.6 5.22 0.27 5.2 5.02 0.24 4.7 5.00 0.42 8.3 5.11 0.22 4.4 5.09 0.24 4.7 5.10 0.24 4.7 
Immunology Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
Male (N=6) Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV 
Monocytes 62.5 4.9 7.8 65.4 6.0 9.2 66.2 6.7 10.1 61.4 8.2 13.4 67.6 3.7 5.4 63.4 7.3 11.6 66.7 10.0 15.1 68.8 5.4 7.8 
Granulocytes 82.4 2.58 3.1 80.3 4.46 5.6 82.8 4.44 5.4 81.9 6.73 8.2 81.5 4.63 5.7 82.7 2.98 3.6 83.9 4.28 5.1 84.0 2.45 2.9 
RespirBurst 76.0 8.2 10.7 79.8 8.4 10.5 72.3 8.4 11.6 76.7 5.1 6.6 76.7 10.8 14.1 74.2 7.5 10.1 73.0 11.1 15.2 75.0 8.3 11.1 
Con / 1000 88 64 72.6 105 78 74.2 136 112 82.8 129 64 49.7 98 48 48.5 155 56 36.3 176 49 27.7 135 74 54.7 
PHA / 1000 45.6 33.1 72.6 50.3 34.6 68.8 51.2 48.4 94.7 68.9 35.2 51.1 38.4 30.3 78.7 59.3 41.2 69.4 77.7 27.6 35.5 52.0 36.3 69.8 
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PWM / 1000 31.8 19.1 60.0 40.6 26.9 66.3 54.9 50.8 92.6 41.6 17.5 42.0 31.2 11.9 38.2 38.6 10.7 27.6 52.5 22.9 43.7 51.5 36.7 71.2 
Med3d / 1000 1.83 1.46 79.6 2.28 2.21 97.1 3.15 3.21 101.9 2.16 1.30 60.1 1.47 0.69 46.7 2.63 1.23 46.8 3.65 1.08 29.7 3.18 3.12 98.3 
IprConA 49.2 21.7 44.1 52.2 17.3 33.1 47.3 20.5 43.3 63.5 13.8 21.7 62.1 25.1 40.5 62.1 13.2 21.3 50.3 6.8 13.6 63.2 24.6 38.9 
IprPHA 29.9 13.4 44.7 30.3 19.2 63.5 21.6 10.9 50.7 34.6 15.5 44.7 27.4 21.8 79.6 26.4 16.2 61.5 24.7 12.0 48.6 31.4 25.6 81.6 
IprPWM 23.9 7.5 31.6 22.3 9.8 44.2 24.2 9.8 40.3 24.7 8.7 35.4 23.9 9.5 40.0 17.3 6.0 34.6 16.9 3.8 22.6 24.3 11.4 46.8 
G4c1 / 1000 1.99 2.32 116.4 1.85 2.36 127.1 2.23 1.74 78.2 2.23 1.51 67.5 1.49 0.70 47.1 2.21 1.16 52.5 3.18 1.19 37.4 1.69 1.09 64.2 
G4c2 / 1000 2.34 2.78 118.7 2.22 2.91 131.2 2.23 1.87 83.6 2.44 1.53 62.7 2.21 1.74 78.6 2.67 1.79 67.1 3.95 1.32 33.5 1.73 1.15 66.7 
G4c3 / 1000 2.63 2.78 105.5 2.17 2.12 97.8 2.63 2.36 89.9 3.26 1.72 52.7 3.53 3.32 93.9 3.27 1.32 40.4 4.05 0.54 13.4 2.12 1.08 50.8 
NG2c1 / 1000 1.98 2.25 113.7 2.05 2.15 105.2 2.45 1.92 78.5 2.26 1.53 67.7 2.12 1.18 55.9 2.20 0.98 44.7 3.65 1.18 32.4 1.97 1.26 64.1 
NG2c2 / 1000 2.44 2.60 106.6 2.13 2.32 108.8 2.38 1.88 79.0 2.55 1.75 68.8 2.44 1.61 66.0 3.04 1.49 49.0 4.12 1.31 31.8 1.96 1.20 61.3 
NG2c3 / 1000 2.42 2.37 98.0 2.26 2.43 107.7 2.45 2.05 83.7 2.97 1.49 50.1 3.95 4.47 113.1 3.45 1.31 38.1 4.62 0.67 14.5 2.19 0.97 44.4 
A6c1 / 1000 2.33 2.71 116.2 2.47 2.91 118.1 2.30 1.88 81.9 2.62 1.74 66.4 2.16 1.00 46.3 3.12 1.49 47.7 4.26 1.28 30.1 2.14 1.53 71.7 
A6c2 / 1000 2.45 2.71 110.9 2.73 3.29 120.5 2.20 1.77 80.4 2.60 1.78 68.4 3.05 1.76 57.7 3.20 1.59 49.8 4.16 1.75 42.1 2.24 1.59 70.8 
A6c3 / 1000 2.32 2.48 107.0 2.12 1.96 92.7 2.20 1.86 84.6 2.60 1.30 50.0 3.88 4.43 114.1 3.19 1.12 35.1 3.52 0.46 13.1 2.06 1.02 49.5 
Med6d / 1000 2.29 2.92 127.5 1.82 2.14 117.7 1.95 1.64 84.3 1.99 1.30 65.3 1.94 1.10 56.5 2.50 1.75 70.1 3.49 1.18 33.8 1.74 1.23 70.5 
IprG4c1 1.34 0.74 55.7 1.40 0.79 56.6 2.00 1.26 63.1 1.21 0.24 20.0 1.13 0.44 38.7 1.12 0.63 56.2 0.92 0.12 13.5 1.08 0.23 21.3 
IprG4c2 1.33 0.44 33.3 1.37 0.56 41.1 1.70 0.84 49.3 1.19 0.20 16.5 1.15 0.27 23.3 1.13 0.25 22.0 1.35 0.45 33.2 1.06 0.15 14.2 
IprG4c3 1.73 0.67 38.9 2.05 1.46 71.2 1.70 0.88 51.8 1.91 0.37 19.3 1.73 0.94 54.4 1.69 0.92 54.2 1.45 0.44 30.2 1.58 0.67 42.2 
IprNG2c1 1.29 0.75 58.0 1.42 0.78 54.9 1.90 1.08 56.9 1.47 0.58 39.5 1.33 0.29 22.1 1.10 0.42 38.3 1.08 0.08 7.4 1.24 0.26 21.0 
IprNG2c2 1.66 0.62 37.1 1.42 0.28 19.9 1.73 0.71 41.3 1.21 0.22 18.6 1.26 0.16 12.5 1.28 0.48 37.3 1.26 0.20 15.9 1.28 0.22 17.3 
IprNG2c3 1.77 0.82 46.3 1.82 0.94 51.9 1.64 0.75 46.0 1.79 0.40 22.5 1.81 0.98 54.3 1.68 0.90 53.2 1.58 0.50 31.8 1.69 0.75 44.1 
IprA6c1 1.36 0.59 43.7 1.70 0.72 42.3 1.60 0.81 50.7 1.57 0.48 30.6 1.36 0.44 32.3 1.46 0.41 28.1 1.29 0.17 13.4 1.23 0.20 16.0 
IprA6c2 1.56 0.66 42.5 1.49 0.42 28.3 1.57 0.63 40.2 1.29 0.28 21.3 1.90 1.32 69.4 1.40 0.25 18.1 1.25 0.27 21.9 1.40 0.38 27.2 
IprA6c3 1.53 0.65 42.7 1.84 0.92 50.1 1.38 0.49 35.3 1.57 0.50 31.9 1.77 0.99 56.0 1.65 0.74 44.6 1.30 0.43 32.9 1.54 0.62 40.4 
CellPhenotype Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
Male (N=6) Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV 
sp3 45.9 12.0 26.2 42.1 9.2 21.9 46.6 11.4 24.4 44.4 5.4 12.2 46.2 6.3 13.7 44.7 9.1 20.4 45.0 2.5 5.6 41.8 5.0 12.1 
sp3-4 31.5 11.2 35.5 28.6 9.1 31.8 32.5 10.7 32.7 29.9 6.8 22.8 31.8 3.6 11.2 31.8 4.4 13.8 31.2 2.5 8.0 28.9 3.5 12.2 
sp3-8 12.8 5.12 39.9 12.9 4.37 33.8 13.4 5.04 37.5 13.4 3.70 27.7 14.4 2.34 16.3 14.2 4.32 30.5 15.0 1.77 11.8 14.2 2.49 17.5 
sp3-45 24.9 3.67 14.7 28.5 5.31 18.6 26.2 5.85 22.3 23.9 5.16 21.6 24.9 7.50 30.1 23.4 3.84 16.4 25.3 5.67 22.5 25.0 6.10 24.4 
sp3-161 7.87 1.79 22.8 8.20 2.16 26.4 7.38 1.38 18.6 7.98 1.40 17.6 7.92 1.09 13.7 7.90 1.83 23.2 7.13 1.23 17.3 8.09 1.44 17.8 
ln3 47.4 9.08 19.2 46.0 3.63 7.9 47.7 7.31 15.3 46.8 9.87 21.1 48.4 9.64 19.9 49.0 5.96 12.2 45.2 5.92 13.1 45.2 7.37 16.3 
ln3-4 34.5 6.53 18.9 35.1 3.64 10.4 36.2 5.22 14.4 34.7 7.31 21.1 36.3 7.24 19.9 36.9 3.98 10.8 32.2 2.54 7.9 33.6 6.13 18.2 
ln3-8 11.0 1.10 10.0 10.8 1.01 9.3 11.0 2.33 21.1 11.7 2.29 19.6 11.8 2.09 17.7 12.1 2.38 19.6 13.2 3.87 29.3 11.2 1.68 15.0 
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ln3-45 29.7 3.2 10.9 33.5 14.2 42.5 27.8 11.9 42.9 31.5 8.2 26.2 32.6 13.8 42.4 35.3 11.9 33.8 31.3 8.5 27.3 31.6 15.7 49.6 
ty3 21.1 3.72 17.6 18.4 2.44 13.2 19.8 0.61 3.1 19.8 3.50 17.6 19.7 2.37 12.0 18.2 3.84 21.1 20.1 2.80 14.0 19.6 1.73 8.8 
ty3-4 17.5 2.76 15.7 15.5 1.95 12.6 17.1 0.38 2.2 16.8 2.50 14.9 16.4 2.35 14.3 15.4 2.49 16.1 17.7 2.85 16.1 17.0 1.81 10.7 
ty3-8 11.3 1.41 12.5 9.5 2.81 29.7 9.7 2.21 22.8 11.3 3.49 30.9 9.5 1.93 20.4 9.4 3.09 32.8 9.1 1.73 19.0 10.3 2.40 23.4 
bm3 7.7 5.8 75.1 9.2 9.2 99.5 7.2 5.8 79.8 5.9 3.7 62.6 6.3 4.5 71.3 12.5 11.7 93.9 5.7 3.6 62.4 13.7 11.1 81.1 
bm3-45 53.9 20.4 37.8 57.2 20.6 36.0 60.2 24.2 40.3 57.9 19.0 32.8 59.3 22.4 37.8 57.8 20.5 35.5 66.5 6.9 10.3 60.8 9.4 15.5 
 
Table 10 Summary statistics for female rats classified by the feeding groups: means (Mean), standard deviations (Sd) and coefficients of variation (CV). The 
summary statistics are obtained from cage means. Some variables are scaled. 
 The number of cages (N) is given in subheadings. For females there are only 5 observations available for the Immunology and CellPhenotype variables 
for feeding groups NK11-, NK33-, NK11+ and NK50+. In addition 7 cages, instead of 8, are available for PLT and cHGB in feeding group NK33+.  
Weights Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
Female (N=8) Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV 
Bodyweight 247 20.0 8.1 249 18.9 7.6 249 19.3 7.7 261 20.8 8.0 246 13.4 5.5 256 10.3 4.0 255 12.0 4.7 250 18.2 7.3 
growthRate 0.13 0.021 16.3 0.16 0.034 21.8 0.16 0.035 22.2 0.13 0.020 15.1 0.14 0.026 18.4 0.15 0.038 24.9 0.14 0.028 20.7 0.15 0.034 22.7 
FeedMean 1.83 0.15 8.2 1.86 0.15 7.8 1.86 0.11 5.7 2.03 0.16 8.0 1.89 0.14 7.6 1.90 0.09 4.9 1.92 0.10 5.3 1.86 0.10 5.2 
Haematology Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
Female (N=8) Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV 
WBC 5.01 0.69 13.8 5.34 0.80 15.0 4.95 1.00 20.2 5.25 0.98 18.8 4.91 1.09 22.3 4.99 0.91 18.3 5.17 1.21 23.4 4.81 1.02 21.2 
RBC 7.64 0.14 1.8 7.68 0.17 2.2 7.78 0.31 3.9 7.69 0.14 1.8 7.70 0.17 2.3 7.64 0.20 2.7 7.70 0.23 2.9 7.84 0.10 1.3 
HGB 15.1 0.42 2.8 15.1 0.25 1.7 15.2 0.49 3.2 15.4 0.28 1.8 15.1 0.24 1.6 15.0 0.24 1.6 15.0 0.74 4.9 15.2 0.26 1.7 
HCT 44.0 0.86 2.0 43.7 1.08 2.5 44.4 1.65 3.7 44.5 0.98 2.2 43.9 1.16 2.7 43.9 0.90 2.0 44.0 1.57 3.6 44.2 0.73 1.7 
MCV 57.6 0.95 1.7 56.9 0.68 1.2 57.1 0.56 1.0 57.9 1.04 1.8 57.0 0.92 1.6 57.5 1.09 1.9 57.2 0.85 1.5 56.5 0.90 1.6 
MCH 19.8 0.46 2.3 19.7 0.22 1.1 19.6 0.35 1.8 20.0 0.38 1.9 19.6 0.45 2.3 19.7 0.48 2.5 19.7 0.50 2.5 19.4 0.42 2.1 
MCHC 34.4 0.37 1.1 34.5 0.35 1.0 34.3 0.52 1.5 34.6 0.50 1.5 34.4 0.69 2.0 34.3 0.40 1.2 34.4 0.56 1.6 34.3 0.58 1.7 
PLT 787 36.2 4.6 807 57.3 7.1 745 92.7 12.4 734 68.6 9.3 760 58.3 7.7 785 45.7 5.8 773 74.8 9.7 824 46.2 5.6 
LYMR 79.4 3.72 4.7 78.1 3.71 4.7 79.8 7.18 9.0 77.5 2.48 3.2 79.6 4.97 6.2 77.9 4.08 5.2 79.2 3.44 4.3 78.0 4.08 5.2 
LYMA 3.97 0.59 15.0 4.16 0.61 14.7 3.96 0.89 22.4 4.05 0.66 16.2 3.92 1.09 27.7 3.91 0.89 22.8 4.09 0.98 23.9 3.79 0.92 24.3 
ClinChem Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
Female (N=8) Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV 
ALP 0.66 0.14 22.0 0.59 0.11 18.5 0.64 0.13 20.2 0.63 0.13 20.0 0.68 0.10 14.7 0.64 0.08 13.1 0.72 0.14 19.5 0.62 0.16 25.5 
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ALT 0.48 0.058 12.1 0.48 0.062 12.7 0.49 0.070 14.2 0.48 0.043 9.0 0.50 0.079 16.0 0.50 0.077 15.4 0.47 0.055 11.5 0.43 0.099 23.1 
AST 2.22 0.45 20.1 2.36 0.57 24.2 2.44 0.60 24.7 2.29 0.58 25.3 2.29 0.43 18.8 2.40 0.30 12.4 2.21 0.38 17.4 2.48 0.67 26.8 
BIL 6.2 1.61 25.9 8.7 5.71 66.0 6.6 0.90 13.6 9.0 4.94 55.0 8.1 5.16 64.1 6.5 1.06 16.4 8.0 4.20 52.5 10.4 8.46 81.2 
ALB 44.0 2.00 4.5 42.7 1.48 3.5 44.7 1.87 4.2 43.1 1.59 3.7 42.7 2.54 5.9 44.4 2.39 5.4 46.1 3.07 6.7 44.7 2.08 4.7 
TP 69.2 2.44 3.5 68.6 1.98 2.9 70.4 2.27 3.2 68.4 2.05 3.0 68.6 4.49 6.5 70.4 3.06 4.3 72.1 4.36 6.0 70.1 3.21 4.6 
Glu 5.24 0.90 17.2 4.95 0.76 15.3 5.01 0.77 15.3 5.25 1.03 19.7 5.36 0.88 16.4 4.87 0.56 11.5 5.16 0.50 9.7 5.05 0.72 14.2 
CHOL 1.63 0.23 14.4 1.57 0.41 26.1 1.65 0.44 26.9 1.54 0.30 19.2 1.34 0.19 14.2 1.83 0.34 18.7 1.95 0.35 17.7 1.68 0.29 17.5 
TAG 0.52 0.09 16.9 0.51 0.13 25.4 0.48 0.06 11.5 0.48 0.09 18.9 0.43 0.11 26.2 0.56 0.12 21.0 0.56 0.07 12.8 0.54 0.15 28.7 
Crea 36.5 3.11 8.5 38.5 6.08 15.8 37.7 4.34 11.5 37.6 3.50 9.3 34.0 4.00 11.8 35.4 3.91 11.1 35.3 3.06 8.7 37.6 3.58 9.5 
Urea 5.93 0.59 10.0 6.47 0.80 12.4 5.87 0.64 10.8 6.36 0.54 8.6 5.85 0.81 13.8 5.48 0.33 6.1 5.96 0.76 12.8 5.90 0.55 9.3 
cHGB 73 32.1 43.8 98 88.1 90.0 78 20.1 25.9 110 90.0 82.2 101 77.0 76.5 67 18.7 27.7 65 22.7 34.7 100 97.6 97.1 
Ca 2.46 0.031 1.2 2.43 0.048 2.0 2.46 0.042 1.7 2.43 0.039 1.6 2.42 0.031 1.3 2.46 0.049 2.0 2.49 0.059 2.4 2.41 0.034 1.4 
Cl 103 1.87 1.8 102 1.83 1.8 102 0.99 1.0 102 1.45 1.4 102 1.35 1.3 101 1.41 1.4 102 2.20 2.2 101 1.33 1.3 
K 4.19 0.23 5.6 4.31 0.46 10.6 4.09 0.34 8.3 4.17 0.46 11.1 4.15 0.46 11.0 4.09 0.20 4.9 4.24 0.48 11.3 4.32 0.67 15.5 
Na 144 1.28 0.9 143 1.69 1.2 144 1.39 1.0 143 0.90 0.6 143 1.51 1.1 143 2.11 1.5 144 1.49 1.0 144 1.62 1.1 
P 1.65 0.40 24.0 1.63 0.32 19.8 1.64 0.17 10.6 1.66 0.30 18.3 1.71 0.36 21.1 1.62 0.36 22.4 1.84 0.30 16.1 1.87 0.38 20.5 
Urine Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
Female (N=8) Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV 
uVol 19.9 4.27 21.4 21.1 7.05 33.5 18.1 5.30 29.3 16.5 4.53 27.4 19.9 7.50 37.6 15.3 3.23 21.1 22.6 5.17 22.9 20.1 5.19 25.9 
uVolW 8.49 1.69 19.8 9.11 3.88 42.6 7.73 2.21 28.6 6.73 2.24 33.2 8.59 3.02 35.1 6.38 1.38 21.7 9.38 2.33 24.9 8.49 2.43 28.6 
uLeu 0.0 0.0  3.1 8.8 282.8 9.4 21.9 233.7 1.6 4.4 282.8 32.8 87.9 267.8 3.1 8.8 282.8 1.6 4.4 282.8 0.0 0.0  
uOsmoll 340 85 25.1 384 156 40.8 435 182 41.8 429 89 20.7 340 106 31.2 423 69 16.4 322 74 23.0 347 73 20.9 
uKeton 0.12 0.27 213.8 0.03 0.09 282.8 0.19 0.35 185.2 0.09 0.27 282.8 0.06 0.12 185.2 0.03 0.09 282.8 0.06 0.12 185.2 0.00 0.00  
upH 6.44 0.26 4.0 6.44 0.32 5.0 6.44 0.18 2.7 6.53 0.25 3.8 6.56 0.18 2.7 6.53 0.25 3.8 6.78 0.34 5.0 6.75 0.35 5.2 
Organs Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
Female (N=8) Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV 
Kidney * 10 5.81 0.36 6.2 5.89 0.48 8.2 6.00 0.29 4.8 6.01 0.49 8.1 6.28 0.41 6.5 5.77 0.23 4.0 5.79 0.50 8.6 5.88 0.42 7.2 
Spleen * 10 2.14 0.07 3.5 2.20 0.31 14.1 2.33 0.32 13.8 2.22 0.20 9.2 2.26 0.25 10.9 2.13 0.20 9.6 2.23 0.21 9.6 2.09 0.12 5.7 
Liver * 10 24.0 0.65 2.7 24.1 2.30 9.5 24.6 1.37 5.6 23.5 1.28 5.4 23.8 1.12 4.7 24.4 1.01 4.2 25.1 1.90 7.6 23.5 0.71 3.0 
AdrenGl * 10 0.30 0.010 3.5 0.29 0.022 7.6 0.32 0.034 10.8 0.31 0.024 7.7 0.31 0.026 8.5 0.31 0.031 10.0 0.30 0.035 11.8 0.30 0.021 7.0 
Heart * 10 3.02 0.13 4.3 2.97 0.13 4.5 3.13 0.15 4.8 3.12 0.21 6.8 3.20 0.26 8.1 3.13 0.25 8.1 3.01 0.18 6.0 2.98 0.09 3.1 
Thymus * 10 1.34 0.16 12.0 1.34 0.20 14.8 1.31 0.18 13.8 1.16 0.12 9.9 1.24 0.16 12.5 1.31 0.22 16.5 1.26 0.16 12.8 1.27 0.11 8.9 
Uterus * 10 2.59 0.70 26.8 2.98 0.83 28.0 2.73 0.70 25.7 2.49 0.55 22.2 2.57 0.59 23.1 2.53 0.40 15.7 2.70 0.66 24.5 2.62 0.62 23.7 
Ovary * 10 0.40 0.053 13.4 0.39 0.052 13.4 0.40 0.063 16.0 0.40 0.034 8.5 0.46 0.087 19.0 0.40 0.028 6.9 0.37 0.058 15.7 0.39 0.065 16.7 
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Brain * 10 8.55 0.49 5.7 8.53 0.69 8.1 8.58 0.72 8.4 8.23 0.56 6.8 8.68 0.77 8.9 8.07 0.20 2.4 8.32 0.43 5.2 8.33 0.56 6.7 
Immunology Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
Female (N=6) Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV 
Monocytes 63.8 8.8 13.8 65.8 6.4 9.7 59.8 11.0 18.3 62.5 9.1 14.5 56.9 8.4 14.8 64.3 6.5 10.0 63.0 6.5 10.4 61.3 7.0 11.5 
Granulocytes 80.7 4.68 5.8 78.9 4.87 6.2 73.8 4.80 6.5 76.4 7.57 9.9 74.4 4.99 6.7 78.9 3.63 4.6 77.0 4.18 5.4 76.9 3.43 4.5 
RespirBurst 81.0 7.6 9.4 79.6 4.6 5.8 73.1 6.5 8.9 77.1 9.4 12.2 74.9 6.2 8.3 76.8 5.5 7.2 74.4 8.0 10.8 73.4 10.0 13.7 
Con / 1000 76 19.8 26.1 69 61.2 89.1 81 40.9 50.5 117 76.4 65.2 55 32.7 59.8 79 41.6 53.0 63 57.2 91.5 60 31.4 52.0 
PHA / 1000 26.9 14.6 54.3 31.0 21.5 69.5 34.0 23.3 68.5 53.8 44.9 83.4 15.7 2.8 17.8 32.7 21.4 65.4 26.0 28.3 108.6 22.3 18.0 80.8 
PWM / 1000 20.9 4.5 21.7 26.5 21.7 82.0 25.1 14.6 58.3 36.7 27.3 74.3 15.0 3.9 26.0 24.9 11.7 46.8 18.4 11.6 62.9 20.0 12.6 62.8 
Med3d / 1000 1.98 0.47 23.7 1.92 1.11 57.7 3.12 1.66 53.2 3.24 1.36 41.8 1.65 1.21 73.2 1.77 1.08 61.3 1.56 0.91 58.6 1.65 0.88 53.5 
IprConA 34.2 7.1 20.9 31.9 17.7 55.4 28.3 15.8 56.0 32.9 12.5 37.9 36.6 17.5 47.8 42.5 11.8 27.7 35.0 17.3 49.6 34.8 12.3 35.3 
IprPHA 12.7 6.7 52.4 17.6 11.1 63.2 15.5 10.3 66.7 15.9 9.0 56.3 15.2 7.0 45.8 23.6 18.3 77.3 14.4 10.1 69.8 14.4 7.4 51.4 
IprPWM 11.1 1.61 14.6 15.1 4.59 30.4 9.5 3.81 40.3 10.6 4.53 42.7 13.0 4.78 36.9 15.9 5.97 37.5 12.5 2.84 22.7 12.8 2.98 23.3 
G4c1 / 1000 2.32 0.31 13.4 2.17 1.32 60.5 2.54 0.94 37.2 3.48 1.57 45.1 1.99 0.81 40.9 1.89 0.44 23.2 1.89 1.01 53.3 2.24 0.98 43.7 
G4c2 / 1000 2.53 0.52 20.5 2.53 1.45 57.0 2.83 0.82 28.9 3.41 1.52 44.7 2.43 1.07 44.1 2.16 0.65 30.1 2.37 0.96 40.4 2.59 1.03 39.7 
G4c3 / 1000 2.77 0.66 23.9 2.59 0.79 30.5 2.78 0.81 29.1 3.12 1.27 40.5 2.33 1.30 55.8 2.17 0.59 27.2 2.47 1.09 43.9 2.80 0.89 31.7 
NG2c1 / 1000 2.30 0.31 13.7 2.16 0.90 41.7 2.47 1.00 40.4 3.43 1.99 58.0 1.93 0.80 41.3 1.96 0.47 23.8 2.22 0.89 40.2 2.39 0.64 26.7 
NG2c2 / 1000 2.56 0.49 19.3 2.58 1.25 48.3 2.88 1.30 45.2 3.31 1.34 40.5 2.36 1.00 42.5 2.18 0.71 32.5 2.64 0.93 35.1 2.81 0.74 26.3 
NG2c3 / 1000 2.67 0.73 27.1 2.59 0.55 21.1 2.94 1.36 46.3 3.27 1.23 37.6 2.50 1.26 50.2 2.15 0.59 27.4 2.69 0.99 36.8 2.79 0.82 29.2 
A6c1 / 1000 2.44 0.91 37.1 2.54 0.62 24.5 2.86 0.92 32.1 3.29 0.99 30.0 1.86 0.84 45.0 2.18 0.71 32.6 2.66 0.91 34.3 2.91 0.95 32.6 
A6c2 / 1000 1.98 0.77 38.8 2.73 0.56 20.7 2.70 0.93 34.5 3.20 1.43 44.6 2.60 1.36 52.6 1.97 0.56 28.4 2.72 0.90 33.1 2.81 0.75 26.9 
A6c3 / 1000 2.42 0.59 24.3 2.34 0.36 15.3 2.72 1.21 44.3 3.16 1.40 44.4 2.16 0.90 41.7 1.95 0.50 25.8 2.44 0.73 29.7 2.49 1.02 41.0 
Med6d / 1000 2.57 0.68 26.4 2.45 0.87 35.4 2.48 0.81 32.5 2.66 1.03 38.8 1.70 0.95 56.2 1.91 0.62 32.3 2.18 0.95 43.8 2.31 0.97 41.9 
IprG4c1 0.95 0.31 32.4 0.93 0.34 36.3 1.08 0.27 24.7 1.43 0.32 22.0 1.32 0.44 33.1 1.00 0.21 21.1 0.99 0.45 45.7 1.02 0.31 30.1 
IprG4c2 1.10 0.25 22.3 1.13 0.41 36.2 1.32 0.26 19.6 1.34 0.34 25.4 1.50 0.43 28.6 1.18 0.20 16.9 1.30 0.59 45.1 1.22 0.38 30.7 
IprG4c3 1.17 0.39 33.3 1.26 0.25 19.4 1.38 0.24 17.2 1.21 0.26 21.5 1.42 0.43 30.6 1.27 0.28 22.1 1.24 0.38 30.5 1.29 0.21 16.0 
IprNG2c1 1.00 0.35 34.7 0.98 0.27 28.0 1.11 0.36 32.3 1.37 0.56 41.0 1.31 0.30 22.9 1.10 0.25 22.4 1.07 0.28 25.8 1.11 0.40 36.5 
IprNG2c2 1.19 0.21 17.8 1.21 0.34 28.2 1.22 0.39 32.3 1.35 0.24 17.5 1.63 0.52 31.6 1.27 0.31 24.5 1.31 0.36 27.8 1.48 0.64 43.2 
IprNG2c3 1.35 0.72 52.9 1.26 0.33 26.5 1.33 0.39 29.1 1.28 0.27 21.0 1.73 0.82 47.3 1.39 0.36 25.9 1.42 0.57 40.1 1.48 0.41 27.5 
IprA6c1 1.08 0.19 17.7 1.23 0.22 17.7 1.26 0.20 15.7 1.42 0.47 33.0 1.23 0.43 35.5 1.24 0.24 19.8 1.34 0.37 27.3 1.49 0.24 16.0 
IprA6c2 1.00 0.27 27.1 1.38 0.23 16.6 1.42 0.41 28.6 1.27 0.45 35.2 1.67 0.50 29.7 1.30 0.32 24.5 1.48 0.60 40.3 1.56 0.55 34.9 
IprA6c3 1.08 0.24 22.3 1.12 0.25 22.7 1.24 0.35 28.0 1.26 0.24 19.4 1.49 0.70 47.4 1.27 0.37 29.2 1.32 0.45 34.0 1.24 0.45 36.0 
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CellPhenotype Con50 NK11-/50 NK50- NK11+/50 NK50+ Con33 NK33- NK33+ 
Female (N=6) Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV Mean Sd CV 
sp3 50.7 17.7 34.9 52.0 15.7 30.3 50.9 14.9 29.3 52.8 18.3 34.6 58.6 13.9 23.7 52.7 13.9 26.4 44.5 19.3 43.3 46.9 18.3 39.0 
sp3-4 25.6 2.66 10.4 26.7 5.12 19.2 26.2 3.92 15.0 24.8 2.63 10.6 26.5 1.19 4.5 27.2 3.27 12.0 22.6 4.00 17.7 24.8 1.91 7.7 
sp3-8 10.9 1.69 15.5 12.3 2.28 18.5 12.8 2.73 21.3 12.2 1.61 13.2 12.1 2.50 20.7 12.8 2.69 21.0 11.2 2.96 26.3 11.1 3.37 30.4 
sp3-45 32.1 3.95 12.3 28.3 3.20 11.3 27.9 3.11 11.1 31.0 1.85 6.0 29.8 5.41 18.2 28.2 3.49 12.4 28.6 5.78 20.2 28.0 3.10 11.1 
sp3-161 7.30 0.91 12.5 6.68 0.79 11.8 6.30 0.74 11.7 7.62 1.23 16.2 6.42 0.60 9.4 6.92 0.96 13.9 7.29 0.78 10.7 7.16 0.71 9.9 
ln3 53.2 7.72 14.5 50.5 5.03 10.0 55.1 5.59 10.1 49.4 8.75 17.7 56.4 4.16 7.4 53.1 7.18 13.5 51.7 6.24 12.1 52.0 8.26 15.9 
ln3-4 38.1 5.94 15.6 36.8 2.58 7.0 39.8 5.63 14.1 35.6 5.00 14.1 43.2 3.57 8.3 38.5 5.49 14.2 39.0 4.65 11.9 36.7 5.35 14.6 
ln3-8 14.1 2.17 15.4 13.1 2.78 21.2 15.2 2.04 13.4 14.1 3.25 23.0 12.7 1.26 9.9 14.0 3.02 21.6 13.0 1.87 14.4 14.2 3.48 24.5 
ln3-45 27.8 5.7 20.6 24.0 6.5 27.3 24.7 5.2 21.1 33.5 13.0 38.8 20.2 3.2 15.9 21.0 4.9 23.2 28.3 8.2 28.9 31.4 6.8 21.6 
ty3 17.2 1.71 9.9 18.0 2.77 15.3 18.4 3.74 20.4 18.8 2.93 15.6 18.5 2.02 10.9 18.8 1.76 9.4 19.4 3.34 17.2 19.4 2.96 15.2 
ty3-4 15.5 1.23 7.9 16.9 3.07 18.2 16.5 3.17 19.3 17.3 2.53 14.6 16.8 1.77 10.6 17.1 2.15 12.6 16.9 3.09 18.2 17.7 2.75 15.5 
ty3-8 8.60 1.34 15.6 7.97 1.15 14.5 7.90 0.85 10.8 9.95 3.11 31.3 8.66 1.04 12.0 8.33 0.60 7.2 8.90 1.32 14.8 8.78 2.41 27.4 
bm3 11.2 4.6 41.3 13.9 5.4 38.6 16.3 10.1 61.9 15.8 8.8 55.9 16.7 4.8 28.6 18.0 9.6 53.5 7.9 2.8 35.8 16.1 3.1 19.5 
bm3-45 62.3 7.88 12.7 62.6 8.90 14.2 60.7 5.54 9.1 59.7 5.12 8.6 53.9 4.96 9.2 55.6 7.18 12.9 62.8 4.57 7.3 55.8 4.01 7.2 
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4 Statistical analysis 
A main interest in G-TwYST Study C was whether maize inclusion rate 33% can be replaced by a 
maize inclusion rate of 50% in order to establish a higher exposure. There was thus a primary interest 
in the comparison between feeds with 50% maize and the corresponding feed with 33% maize. In 
addition the GM feeds with 50% maize were compared to the non-GM control feed with 50% maize, 
and similarly for the feeds with 33% inclusion rate. Therefore the following nine comparisons were 
statistically tested: 
1. NK11-/50  vs  Con50 
2. NK50-  vs  Con50 
3. NK11+/50  vs  Con50 
4. NK50+  vs  Con50 
5. Con50  vs  Con33 
6. NK50-  vs  NK33- 
7. NK50+  vs  NK33+ 
8. NK33-  vs  Con33 
9. NK33+  vs  Con33 
The comparisons 1-4 are grouped in the Figures and Tables below, and so are the comparisons 5-9. 
In section 4.7 a post-hoc power analysis is performed in which the power of a trial with only 50% 
maize feeds is compared to the power of a trial with only 33% maize feeds.  
4.1 Equivalence testing using historical data 
4.1.1 Method 
Equivalence testing was introduced for GM safety assessment for compositional data in the EFSA 
guidance for risk assessment of food and feed from GM plants (EFSA 2011a). In the context of 90-day 
studies in rodents, EFSA (2014) recognized the potential advantages of equivalence testing and 
recommended further investigation. In response to this , an equivalence test was developed in the 
G-TwYST project. This test compares the difference between a test (T) and a control (C) feed, 
obtained simultaneously in a current study, to the typical differences between reference (R) varieties 
obtained in one or more historical studies (van der Voet et al, 2017). The equivalence test is 
corrected for between-study differences, and the within-study variation between references R is 
used to set equivalence limits for the difference between T and C in the current study. The so-called 
Distribution Wise Equivalence (DWE) criterion is used in this test. An equivalence limit for the current 
study is set using the concept of desired power in a simplified situation, where there is no between-
reference variation, where the historical and current studies have the same residual variance, and 
where the current study is assumed to have a sample size as approved by a regulator. The method is 
fully described in van der Voet et al (2017) .  
The equivalence test of van der Voet et al (2017) requires, employing the historic GRACE studies, 
calculation of the within-study between reference feeds sums of squares (𝑆𝑆𝑆𝑆𝑅𝑅), the residual sums of 
squares (𝑆𝑆𝑆𝑆𝐸𝐸) and their associated degrees of freedom 𝑑𝑑𝑓𝑓𝑅𝑅 and 𝑑𝑑𝑓𝑓𝐸𝐸. It also involves the effective unit 
replication 𝑛𝑛𝑊𝑊𝑒𝑒𝑒𝑒 which is necessary to estimate the between reference variance employing the mean 
squares for feeds and for residuals. The required values based on the five GRACE studies A-E are 
given in Appendix 7. The test also requires, for the current G-TwYST study, estimates of differences 
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between the GMO feeds and the control feed, as well as the residual sums of squares and the 
associated degrees of freedom resulting from an analysis of variance. These are given in Appendix 8.  
The equivalence limit 𝜃𝜃0 for the DWE criterion is only based on the design values of the historical 
studies and on three regulatory values: the minimal regulatory sample size 𝑛𝑛0, a probability 𝛼𝛼 which 
defines a 100(1− 𝛼𝛼)% confidence interval for the difference in the current study, and a probability 
𝛽𝛽 which defines the desired power 1 − 𝛽𝛽 for the equivalence test. We used values 𝑛𝑛0 = 8, 𝛼𝛼 = 0.05 
and 𝛽𝛽 = 0.05 resulting in a power of 0.95. Note that the regulatory sample size 𝑛𝑛0 = 8 equals the 
replication, i.e. the number of cages, for most variables in both the GRACE and the G-TwYST studies. 
Furthermore the equivalence limit 𝜃𝜃0 is calculated by simulating a large number of datasets in a 
simplified situation, where for each datasets an upper 100(1 − 𝛼𝛼)% percentile, 𝜃𝜃𝑢𝑢𝑢𝑢𝑢𝑢0 , for the DWE 
criterion is approximated by a large number of so-called GPQ samples. We simulated 40,000 datasets 
with 15,000 GPQ samples for each dataset. Note that 𝜃𝜃0 is calculated as the upper 100(1− 𝛽𝛽)% 
percentile of the thus obtained 40.000 values of 𝜃𝜃𝑢𝑢𝑢𝑢𝑢𝑢0 . The DWE criterion for the current dataset was 
approximated by means of 100,000 GPQ samples. Note that the equivalence limit 𝜃𝜃0 is calculated 
assuming a regulatory sample size 𝑛𝑛0 = 8 which implies 14 degrees of freedom for error in the 
current study. The current G-TwYST study indeed has replication 8 but has 49 degrees of freedom for 
error. 
The DWE equivalence test results in a DWE interval as a so-called equivalence limit scaled difference 
(ELSD), which can be used both for difference and for equivalence testing. The hypothesis of no 
difference is rejected in case the interval does not contain zero, while the non-equivalence 
hypothesis is rejected when the interval fully lies inside the interval (-1,1). For further interpretation, 
the confidence intervals are also presented at the original ratio scale, with inclusion of the estimated 
equivalence limits (red bars) and their uncertainty (blue bars). Note that the latter graphs cannot be 
used directly for performing the equivalence test. However, they show the effects and equivalence 
limits at a more familiar scale. 
4.1.2 Results 
All equivalence tests assume that the historical GRACE precision results, which were obtained for 
maize inclusion rates of 33%, also apply to feeds in this study, including to feeds with a maize 
inclusion rate of 50%. The DWE intervals showing the main results of the equivalence tests for 36 
variables are given in Figure 6 to Figure 9. For further interpretation the 95% confidence intervals for 
the ratios are given in Table 11 to Table 14. These intervals are based on an ANOVA with all eight 
feeding groups. Intervals and limits at the ratio scale are given in Figure 10 to Figure 18. 
The DWE equivalence test depends, among other things, on the ratio of the residual variance of the 
current study and the residual variance of the historical studies. In case this ratio is small the 
corresponding DWE interval will generally be short. The ratio of the residual variances is given in 
Figure 19. Most ratios are around 100% or less, indicating that the current G-TwYST Study C is at least 
as precise as the historical GRACE studies. Ratios larger than 150% were observed for ALT and AST in 
males, and for ALP, CHOL, P, Kidney and Uterus in females. These endpoints are labelled by means of 
a golden background in Figure 6 to Figure 18.  
Among 324 equivalence tests for males (36 variables × 9 comparisons), there were no failures to 
prove equivalence (i.e. the hypothesis of non-equivalence is always rejected). For females there were 
five (1.5%) of such failures: three failures for CHOL (NK50+ vs Con50, NK50- vs NK33-, and NK50+ vs 
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NK33+), one for P (NK33+ vs Con33) and one for Kidney (NK50+ vs Con50). In all these five female 
cases the median estimate was within the equivalence limits, therefore equivalence is still more likely 
than lack of equivalence according to the terminology of EFSA (2011a). From Figure 19 it can be seen 
that these are all cases where the G-TwYST study C was less precise than the historical studies on 
average (residual variance more than 1.5 higher than in the historical GRACE studies). 
Although not the primary result of the equivalence analysis, it can also be observed from the graphs 
and tables that, for those variables for which the equivalence test is performed, the number of 
significant differences, employing t-tests, equals 46 (7.1% of 648 difference tests), which is close to 
the 5% level of the test. Only in four of these cases (3 × CHOL and 1 × Kidney) there was both a 
significant difference and a failure to show equivalence. 
For all 1584 difference tests, i.e. including those for which the equivalence test was not performed, 
90 t-tests were significant at the 5% significance level which is 5.7% of the tests (see Table 11 to 
Table 14).
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Figure 6 Equivalence testing of GM 50% maize feeds versus the corresponding non-GM control 50% maize feed for males. For estimates on the left of 
zero the 50% feed has a smaller mean than the corresponding control feed. Also see Table 11 / Figure 10 / Figure 11. 
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Figure 7 EQ testing of 50% maize feeds versus the corresponding 33% feeds for males, and for the GM 33% feeds versus the non-GM 33% feed. For 
estimates on the left of zero the 50% feed has a smaller mean than the 33% feed. Also see Table 12 / Figure 18 / Figure 12 / Figure 13. 
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Figure 8 Equivalence testing of GM 50% maize feeds versus the corresponding non-GM control 50% maize feed for females. For estimates on the left of 
zero the 50% feed has a smaller mean than the corresponding control feed. Also see Table 13 / Figure 14 / Figure 15. 
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Figure 9 EQ testing of 50% maize feeds versus the corresponding 33% feeds for females, and for the GM 33% feeds versus the non-GM 33% feed. For 
estimates on the left of zero the 50% feed has a smaller mean than the 33% feed. Also see Table 14 / Figure 18 / Figure 16 / Figure 17.
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Table 11 95% Confidence interval plus estimate for the ratio Δ of the GMO feeds with 50% maize 
inclusion rate versus the corresponding non-GM control feed for males. Ratios with 
corresponding 95/99% intervals that do not encompass the value 1 are coloured 
red/gold; this is equivalent to a significant difference according to a 5/1% t-test. 
Weights NK11-/50 vs Con50 NK50- vs Con50 NK11+/50 vs Con50 NK50+ vs Con50 
Males low ratio upp low ratio upp low ratio upp low ratio upp 
BodyWeight 0.91 0.96 1.01 0.90 0.95 1.00 0.94 0.99 1.05 0.93 0.98 1.03 
growthRate 0.99 1.01 1.03 0.98 0.99 1.01 0.98 1.00 1.02 0.97 0.99 1.01 
FeedMean 0.91 0.96 1.01 0.91 0.95 1.00 0.97 1.02 1.07 0.94 0.99 1.04 
Haematology NK11-/50 vs Con50 NK50- vs Con50 NK11+/50 vs Con50 NK50+ vs Con50 
Males low ratio upp low ratio upp low ratio upp low ratio upp 
WBC 0.85 1.01 1.19 0.91 1.08 1.27 0.79 0.93 1.10 0.90 1.07 1.26 
RBC 0.98 1.00 1.03 0.97 0.99 1.01 0.99 1.01 1.03 0.97 0.99 1.01 
HGB 1.00 1.03 1.05 0.98 1.00 1.02 1.01 1.03 1.05 0.99 1.01 1.03 
HCT 0.99 1.01 1.03 0.97 0.99 1.01 1.00 1.02 1.04 0.98 1.00 1.02 
MCV 0.99 1.01 1.02 0.99 1.00 1.02 1.00 1.01 1.03 1.00 1.01 1.03 
MCH 1.00 1.02 1.05 0.99 1.01 1.03 1.00 1.02 1.04 1.00 1.02 1.04 
MCHC 1.00 1.02 1.03 0.99 1.01 1.02 1.00 1.01 1.02 1.00 1.01 1.02 
PLT 0.97 1.09 1.23 1.03 1.16 1.31 0.94 1.07 1.20 1.01 1.14 1.29 
LYMR 0.96 1.00 1.04 0.99 1.03 1.06 0.98 1.02 1.06 0.98 1.02 1.06 
LYMA 0.86 1.01 1.19 0.94 1.11 1.30 0.81 0.95 1.11 0.92 1.09 1.28 
ClinChem NK11-/50 vs Con50 NK50- vs Con50 NK11+/50 vs Con50 NK50+ vs Con50 
Males low ratio upp low ratio upp low ratio upp low ratio upp 
ALP 0.95 1.13 1.34 0.78 0.93 1.11 0.76 0.90 1.07 0.86 1.03 1.22 
ALT 0.99 1.15 1.34 0.86 1.00 1.16 0.94 1.10 1.28 0.92 1.07 1.25 
AST 0.96 1.17 1.42 0.84 1.03 1.25 0.90 1.10 1.34 0.87 1.06 1.29 
BIL 1.01 1.13 1.28 0.92 1.04 1.17 0.94 1.06 1.20 0.97 1.09 1.23 
ALB 1.00 1.04 1.09 0.98 1.02 1.07 0.99 1.03 1.08 0.98 1.02 1.07 
TP 1.00 1.02 1.04 1.00 1.02 1.04 0.98 1.01 1.03 1.00 1.02 1.05 
Glu 0.86 0.97 1.09 0.83 0.94 1.05 0.92 1.03 1.15 0.80 0.90 1.01 
CHOL 0.89 0.99 1.09 0.95 1.05 1.16 0.96 1.06 1.17 0.96 1.06 1.17 
TAG 0.82 1.00 1.22 0.87 1.07 1.30 0.86 1.06 1.29 0.88 1.07 1.31 
Crea 0.86 0.97 1.10 0.93 1.04 1.17 0.85 0.96 1.08 0.88 1.00 1.12 
Urea 0.89 0.99 1.09 0.86 0.95 1.06 1.00 1.11 1.23 0.89 0.98 1.09 
cHGB 1.09 1.52 2.12 0.84 1.17 1.63 0.92 1.28 1.78 1.09 1.51 2.11 
Ca 0.98 0.99 1.01 0.99 1.01 1.02 0.98 1.00 1.01 0.99 1.00 1.02 
Cl 0.98 0.99 1.01 0.99 1.01 1.02 0.99 1.00 1.02 0.97 0.99 1.00 
K 1.00 1.08 1.16 0.98 1.05 1.12 0.94 1.01 1.09 0.96 1.03 1.10 
Na 0.99 1.00 1.01 1.00 1.01 1.02 0.99 1.00 1.01 0.99 1.00 1.01 
P 0.94 1.05 1.18 0.89 1.00 1.12 0.89 1.00 1.12 0.91 1.02 1.14 
Urine NK11-/50 vs Con50 NK50- vs Con50 NK11+/50 vs Con50 NK50+ vs Con50 
Males low ratio upp low ratio upp low ratio upp low ratio upp 
uVol 0.75 1.00 1.33 0.84 1.13 1.51 0.85 1.14 1.52 0.79 1.06 1.42 
uVolW 0.78 1.04 1.38 0.90 1.20 1.59 0.87 1.15 1.53 0.82 1.08 1.44 
uLeu 0.58 0.87 1.32 0.47 0.71 1.07 0.54 0.81 1.23 0.50 0.76 1.15 
uOsmoll 0.71 0.92 1.19 0.66 0.86 1.10 0.71 0.92 1.18 0.72 0.93 1.19 
uKeton 0.44 0.77 1.35 0.51 0.90 1.57 0.37 0.64 1.12 0.53 0.93 1.63 
upH 0.69 0.97 1.37 0.71 1.00 1.41 0.86 1.21 1.70 0.57 0.80 1.13 
Organs NK11-/50 vs Con50 NK50- vs Con50 NK11+/50 vs Con50 NK50+ vs Con50 
Males low ratio upp low ratio upp low ratio upp low ratio upp 
Kidney 0.97 1.04 1.11 0.96 1.02 1.09 0.98 1.05 1.12 0.97 1.04 1.10 
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Spleen 0.90 0.99 1.09 0.95 1.04 1.14 0.93 1.02 1.12 0.94 1.04 1.14 
Liver 0.94 0.98 1.01 0.99 1.03 1.07 0.99 1.03 1.07 0.97 1.01 1.05 
AdrenGl 0.92 1.02 1.13 0.90 1.00 1.11 0.89 0.99 1.10 0.91 1.01 1.12 
Heart 0.94 0.99 1.05 0.98 1.03 1.09 0.97 1.02 1.08 0.97 1.02 1.08 
Thymus 0.81 0.93 1.06 0.90 1.02 1.16 0.92 1.05 1.19 0.84 0.96 1.10 
Testis 0.95 1.01 1.08 1.01 1.08 1.15 0.99 1.05 1.12 0.98 1.04 1.11 
Epididymis 0.93 1.00 1.08 0.99 1.07 1.15 0.98 1.06 1.15 0.97 1.04 1.13 
Brain 0.97 1.03 1.08 1.00 1.06 1.11 0.97 1.02 1.07 0.96 1.01 1.07 
Immunology NK11-/50 vs Con50 NK50- vs Con50 NK11+/50 vs Con50 NK50+ vs Con50 
Males low ratio upp low ratio upp low ratio upp low ratio upp 
Monocytes 0.94 1.03 1.13 0.94 1.03 1.13 0.89 0.98 1.07 0.93 1.03 1.13 
Granulocytes 0.92 0.97 1.02 0.94 0.99 1.04 0.95 0.99 1.04 0.92 0.97 1.03 
RespirBurst 0.93 1.01 1.09 0.91 0.98 1.06 0.94 1.01 1.09 0.90 0.97 1.06 
Con 0.57 1.32 3.05 0.54 1.23 2.81 0.82 1.84 4.15 0.41 1.00 2.45 
PHA 0.54 1.15 2.43 0.52 1.09 2.29 0.70 1.45 2.99 0.42 0.93 2.06 
PWM 0.64 1.14 2.04 0.67 1.19 2.10 0.74 1.29 2.26 0.46 0.84 1.56 
Med3d 0.52 1.09 2.28 0.54 1.12 2.31 0.59 1.21 2.48 0.36 0.79 1.73 
IprConA 0.85 1.21 1.72 0.78 1.10 1.56 1.08 1.51 2.13 0.88 1.27 1.85 
IprPHA 0.69 1.06 1.63 0.64 0.98 1.50 0.79 1.19 1.81 0.75 1.18 1.87 
IprPWM 0.72 1.05 1.54 0.74 1.07 1.55 0.74 1.06 1.53 0.72 1.07 1.60 
G4c1 0.49 1.08 2.42 0.56 1.23 2.71 0.64 1.39 3.03 0.46 1.08 2.54 
G4c2 0.41 1.05 2.73 0.42 1.07 2.73 0.52 1.32 3.31 0.40 1.10 3.02 
G4c3 0.46 1.12 2.70 0.37 0.88 2.09 0.68 1.60 3.76 0.54 1.39 3.54 
NG2c1 0.52 1.19 2.73 0.54 1.23 2.76 0.70 1.56 3.46 0.57 1.36 3.28 
NG2c2 0.34 0.91 2.41 0.35 0.92 2.40 0.41 1.06 2.72 0.36 1.02 2.88 
NG2c3 0.44 1.08 2.69 0.36 0.88 2.15 0.63 1.51 3.65 0.52 1.38 3.63 
A6c1 0.52 1.28 3.15 0.42 1.01 2.45 0.66 1.58 3.78 0.47 1.23 3.21 
A6c2 0.37 0.99 2.65 0.34 0.90 2.35 0.46 1.19 3.08 0.48 1.36 3.86 
A6c3 0.48 1.20 2.96 0.35 0.85 2.06 0.61 1.45 3.49 0.57 1.49 3.91 
Med6d 0.36 1.05 3.09 0.30 0.87 2.51 0.48 1.36 3.87 0.40 1.27 3.99 
IprG4c1 0.67 1.03 1.60 0.92 1.41 2.17 0.67 1.02 1.56 0.53 0.85 1.36 
IprG4c2 0.74 1.00 1.36 0.91 1.23 1.66 0.72 0.97 1.30 0.62 0.87 1.20 
IprG4c3 0.69 1.06 1.64 0.66 1.01 1.54 0.78 1.18 1.78 0.69 1.09 1.73 
IprNG2c1 0.78 1.14 1.65 0.97 1.40 2.02 0.80 1.14 1.63 0.72 1.07 1.59 
IprNG2c2 0.62 0.86 1.20 0.76 1.05 1.46 0.56 0.78 1.07 0.56 0.80 1.14 
IprNG2c3 0.73 1.03 1.46 0.71 1.01 1.42 0.79 1.11 1.56 0.75 1.08 1.57 
IprA6c1 0.85 1.22 1.75 0.81 1.16 1.65 0.82 1.16 1.64 0.66 0.97 1.42 
IprA6c2 0.65 0.95 1.38 0.71 1.03 1.49 0.61 0.87 1.26 0.72 1.07 1.60 
IprA6c3 0.79 1.14 1.65 0.67 0.97 1.40 0.74 1.06 1.52 0.79 1.18 1.74 
CellPhenotype NK11-/50 vs Con50 NK50- vs Con50 NK11+/50 vs Con50 NK50+ vs Con50 
Males low ratio upp low ratio upp low ratio upp low ratio upp 
sp3 0.77 0.96 1.21 0.83 1.03 1.29 0.79 0.99 1.23 0.84 1.07 1.37 
sp3-4 0.71 0.95 1.27 0.79 1.05 1.40 0.75 1.00 1.32 0.82 1.11 1.52 
sp3-8 0.76 1.10 1.58 0.75 1.08 1.54 0.76 1.08 1.54 0.93 1.37 2.02 
sp3-45 0.87 1.04 1.24 0.86 1.03 1.22 0.80 0.95 1.13 0.80 0.96 1.16 
sp3-161 0.74 0.90 1.10 0.78 0.94 1.14 0.84 1.02 1.24 0.74 0.91 1.12 
ln3 0.78 0.92 1.08 0.88 1.03 1.21 0.83 0.97 1.13 0.84 1.00 1.18 
ln3-4 0.81 0.96 1.12 0.91 1.07 1.25 0.84 0.98 1.15 0.85 1.01 1.20 
ln3-8 0.77 0.94 1.14 0.85 1.03 1.24 0.87 1.05 1.26 0.87 1.07 1.31 
ln3-45 0.73 0.96 1.28 0.75 0.98 1.30 0.76 1.01 1.35 0.73 0.99 1.34 
ty3 0.75 0.90 1.08 0.81 0.96 1.15 0.79 0.94 1.13 0.76 0.92 1.11 
ty3-4 0.76 0.90 1.05 0.83 0.97 1.14 0.82 0.96 1.13 0.76 0.91 1.08 
ty3-8 0.73 0.90 1.11 0.75 0.92 1.14 0.81 0.99 1.22 0.70 0.88 1.10 
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bm3 0.75 1.21 1.95 0.67 1.07 1.71 0.56 0.89 1.42 0.56 0.93 1.54 
bm3-45 0.95 1.04 1.13 0.96 1.05 1.14 1.01 1.11 1.21 0.99 1.09 1.20 
 
Table 12 95% Confidence interval plus estimate for the ratio Δ of the feeds with 50% maize 
inclusion rate versus the corresponding 33% inclusion rate for males, and for the GM 
33% feeds versus the non-GM 33% feed. Ratios with corresponding 95/99% intervals 
that do not encompass the value 1 are coloured red/gold; this is equivalent to a 
significant difference according to a 5/1% t-test. 
Weights Con50 vs Con33 NK50- vs NK33- NK50+ vs NK33+ NK33- vs Con33 NK33+ vs Con33 
Males low ratio upp low ratio upp low ratio upp low ratio upp low ratio upp 
BodyWeight 1.00 1.05 1.10 0.94 0.98 1.04 0.97 1.02 1.07 0.96 1.01 1.06 0.96 1.01 1.06 
growthRate 0.98 1.00 1.02 0.99 1.01 1.02 0.97 0.99 1.00 0.97 0.99 1.00 0.99 1.00 1.02 
FeedMean 1.00 1.05 1.10 0.96 1.01 1.06 0.97 1.02 1.07 0.94 0.99 1.04 0.97 1.01 1.06 
Haematology Con50 vs Con33 NK50- vs NK33- NK50+ vs NK33+ NK33- vs Con33 NK33+ vs Con33 
Males low ratio upp low ratio upp low ratio upp low ratio upp low ratio upp 
WBC 0.82 0.96 1.14 0.87 1.03 1.22 0.88 1.04 1.23 0.85 1.01 1.19 0.84 0.99 1.17 
RBC 0.98 1.00 1.02 0.97 0.99 1.01 0.95 0.97 0.99 0.98 1.00 1.02 1.00 1.02 1.04 
HGB 0.96 0.99 1.01 0.96 0.98 1.01 0.98 1.01 1.03 0.98 1.00 1.02 0.97 0.99 1.01 
HCT 0.98 1.00 1.02 0.97 0.99 1.01 0.98 1.00 1.02 0.99 1.01 1.03 0.98 1.00 1.02 
MCV 0.98 1.00 1.01 0.98 1.00 1.01 1.01 1.03 1.04 0.99 1.00 1.02 0.97 0.98 1.00 
MCH 0.96 0.99 1.01 0.97 1.00 1.02 1.01 1.04 1.06 0.98 1.00 1.02 0.95 0.97 0.99 
MCHC 0.97 0.99 1.00 0.99 1.00 1.01 1.00 1.01 1.02 0.98 1.00 1.01 0.97 0.99 1.00 
PLT 0.85 0.96 1.08 0.98 1.11 1.25 0.87 0.98 1.11 0.89 1.00 1.13 0.98 1.11 1.25 
LYMR 0.95 0.99 1.03 0.95 0.98 1.02 1.00 1.04 1.08 1.00 1.03 1.07 0.93 0.97 1.01 
LYMA 0.85 1.00 1.18 0.86 1.01 1.19 0.92 1.08 1.27 0.93 1.09 1.28 0.86 1.01 1.18 
ClinChem Con50 vs Con33 NK50- vs NK33- NK50+ vs NK33+ NK33- vs Con33 NK33+ vs Con33 
Males low ratio upp low ratio upp low ratio upp low ratio upp low ratio upp 
ALP 0.79 0.95 1.13 0.79 0.94 1.11 0.82 0.98 1.17 0.79 0.94 1.12 0.83 0.99 1.18 
ALT 0.85 0.99 1.15 0.87 1.01 1.18 0.90 1.05 1.22 0.84 0.98 1.14 0.88 1.02 1.19 
AST 0.81 0.98 1.20 0.88 1.07 1.30 0.86 1.05 1.28 0.78 0.95 1.15 0.82 1.00 1.21 
BIL 0.88 0.99 1.12 0.91 1.02 1.15 0.94 1.06 1.19 0.89 1.01 1.14 0.91 1.03 1.16 
ALB 0.94 0.98 1.02 0.96 1.00 1.05 0.96 1.00 1.05 0.95 1.00 1.04 0.96 1.00 1.04 
TP 0.95 0.97 0.99 0.98 1.00 1.02 0.98 1.00 1.02 0.97 0.99 1.01 0.97 0.99 1.02 
Glu 0.86 0.97 1.08 0.86 0.96 1.08 0.84 0.94 1.06 0.84 0.94 1.05 0.82 0.92 1.03 
CHOL 0.90 0.99 1.09 0.97 1.07 1.18 0.97 1.07 1.18 0.88 0.97 1.07 0.89 0.98 1.08 
TAG 0.87 1.07 1.30 0.79 0.96 1.17 0.87 1.07 1.30 0.97 1.18 1.45 0.88 1.08 1.31 
Crea 0.82 0.92 1.04 0.89 1.01 1.14 0.90 1.01 1.14 0.85 0.96 1.08 0.81 0.91 1.02 
Urea 0.82 0.91 1.01 0.88 0.98 1.09 0.83 0.92 1.02 0.80 0.89 0.99 0.88 0.98 1.09 
cHGB 0.55 0.77 1.07 0.76 1.06 1.48 0.88 1.22 1.70 0.61 0.84 1.17 0.68 0.95 1.32 
Ca 0.98 1.00 1.01 0.99 1.00 1.02 0.98 1.00 1.01 0.99 1.00 1.02 0.99 1.00 1.02 
Cl 0.99 1.01 1.02 1.00 1.01 1.02 0.97 0.99 1.00 0.99 1.00 1.02 1.00 1.01 1.02 
K 0.91 0.97 1.05 0.96 1.03 1.11 0.96 1.03 1.10 0.92 0.99 1.06 0.91 0.97 1.05 
Na 0.99 1.00 1.01 1.00 1.01 1.02 0.98 0.99 1.00 0.99 1.00 1.01 0.99 1.00 1.01 
P 0.82 0.92 1.04 0.80 0.90 1.01 0.82 0.92 1.03 0.92 1.03 1.15 0.91 1.02 1.15 
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Urine Con50 vs Con33 NK50- vs NK33- NK50+ vs NK33+ NK33- vs Con33 NK33+ vs Con33 
Males low ratio upp low ratio upp low ratio upp low ratio upp low ratio upp 
uVol 0.86 1.15 1.53 0.88 1.17 1.57 0.89 1.19 1.60 0.82 1.10 1.47 0.76 1.02 1.36 
uVolW 0.82 1.09 1.45 0.90 1.20 1.59 0.88 1.17 1.55 0.82 1.09 1.45 0.76 1.01 1.35 
uLeu 0.66 1.00 1.51 0.54 0.81 1.23 0.47 0.71 1.07 0.58 0.87 1.32 0.71 1.07 1.62 
uOsmoll 0.77 0.99 1.28 0.68 0.88 1.14 0.65 0.84 1.08 0.75 0.96 1.24 0.85 1.10 1.41 
uKeton 0.79 1.39 2.43 0.43 0.74 1.30 0.61 1.07 1.87 0.96 1.68 2.93 0.69 1.21 2.11 
upH 0.61 0.86 1.21 0.65 0.91 1.28 0.42 0.59 0.83 0.67 0.94 1.32 0.83 1.17 1.65 
Organs Con50 vs Con33 NK50- vs NK33- NK50+ vs NK33+ NK33- vs Con33 NK33+ vs Con33 
Males low ratio upp low ratio upp low ratio upp low ratio upp low ratio upp 
Kidney 0.92 0.99 1.05 0.97 1.03 1.10 0.90 0.96 1.02 0.92 0.98 1.04 1.00 1.06 1.13 
Spleen 0.89 0.98 1.08 0.93 1.02 1.12 0.92 1.01 1.11 0.91 1.00 1.09 0.91 1.00 1.10 
Liver 0.93 0.97 1.00 0.98 1.02 1.06 0.96 1.00 1.04 0.94 0.97 1.01 0.94 0.97 1.01 
AdrenGl 0.91 1.01 1.12 0.92 1.02 1.13 0.94 1.04 1.15 0.89 0.99 1.10 0.88 0.98 1.08 
Heart 0.92 0.98 1.03 1.01 1.07 1.13 0.93 0.98 1.04 0.90 0.95 1.00 0.96 1.02 1.08 
Thymus 0.88 1.01 1.15 1.00 1.14 1.31 0.85 0.97 1.11 0.79 0.90 1.02 0.87 0.99 1.13 
Testis 0.89 0.95 1.01 0.98 1.05 1.12 0.97 1.03 1.10 0.92 0.98 1.04 0.90 0.96 1.02 
Epididymis 0.88 0.95 1.03 0.99 1.07 1.15 0.93 1.01 1.09 0.88 0.96 1.03 0.92 0.99 1.07 
Brain 0.92 0.97 1.02 0.97 1.03 1.08 0.93 0.98 1.03 0.95 1.00 1.05 0.95 1.00 1.05 
Immunology Con50 vs Con33 NK50- vs NK33- NK50+ vs NK33+ NK33- vs Con33 NK33+ vs Con33 
Males low ratio upp low ratio upp low ratio upp low ratio upp low ratio upp 
Monocytes 0.94 1.03 1.13 0.91 1.00 1.10 0.87 0.95 1.05 0.97 1.06 1.17 1.02 1.11 1.22 
Granulocytes 0.96 1.01 1.06 0.95 1.00 1.05 0.92 0.97 1.02 0.95 1.01 1.06 0.97 1.01 1.07 
RespirBurst 0.96 1.04 1.13 0.95 1.03 1.12 0.93 1.01 1.09 0.91 0.99 1.08 0.93 1.00 1.08 
Con 0.21 0.49 1.13 0.23 0.55 1.32 0.27 0.66 1.58 0.45 1.10 2.67 0.32 0.74 1.72 
PHA 0.33 0.71 1.50 0.26 0.58 1.26 0.32 0.70 1.52 0.60 1.34 2.96 0.45 0.94 2.00 
PWM 0.50 0.89 1.59 0.43 0.79 1.45 0.35 0.64 1.17 0.72 1.34 2.47 0.66 1.18 2.10 
Med3d 0.34 0.72 1.51 0.32 0.70 1.51 0.31 0.67 1.45 0.52 1.15 2.52 0.40 0.85 1.77 
IprConA 0.48 0.68 0.96 0.54 0.78 1.13 0.68 0.98 1.41 0.66 0.95 1.39 0.62 0.88 1.25 
IprPHA 0.64 0.98 1.50 0.53 0.83 1.29 0.66 1.04 1.62 0.74 1.16 1.83 0.73 1.12 1.71 
IprPWM 0.84 1.24 1.81 0.76 1.13 1.68 0.64 0.95 1.41 0.78 1.16 1.74 0.95 1.39 2.03 
G4c1 0.29 0.65 1.46 0.32 0.73 1.68 0.42 0.97 2.24 0.47 1.11 2.59 0.33 0.73 1.62 
G4c2 0.25 0.64 1.67 0.18 0.48 1.31 0.41 1.10 2.98 0.52 1.42 3.91 0.25 0.64 1.66 
G4c3 0.23 0.56 1.35 0.18 0.45 1.12 0.46 1.14 2.86 0.43 1.10 2.79 0.28 0.68 1.64 
NG2c1 0.28 0.64 1.46 0.25 0.59 1.40 0.44 1.04 2.46 0.55 1.32 3.17 0.37 0.83 1.90 
NG2c2 0.28 0.75 2.00 0.19 0.52 1.43 0.37 1.03 2.84 0.48 1.34 3.78 0.28 0.75 1.99 
NG2c3 0.23 0.56 1.40 0.15 0.38 0.99 0.41 1.07 2.77 0.49 1.29 3.38 0.29 0.72 1.80 
A6c1 0.21 0.52 1.29 0.18 0.45 1.15 0.41 1.06 2.71 0.45 1.18 3.07 0.25 0.61 1.50 
A6c2 0.22 0.60 1.60 0.18 0.50 1.40 0.45 1.25 3.46 0.38 1.07 3.03 0.25 0.66 1.75 
A6c3 0.20 0.50 1.25 0.17 0.43 1.11 0.45 1.15 2.95 0.38 0.98 2.56 0.27 0.65 1.62 
Med6d 0.20 0.57 1.69 0.14 0.43 1.32 0.36 1.11 3.42 0.37 1.17 3.67 0.22 0.66 1.92 
IprG4c1 0.73 1.14 1.77 1.08 1.70 2.69 0.55 0.87 1.38 0.59 0.94 1.50 0.72 1.11 1.72 
IprG4c2 0.82 1.12 1.52 0.82 1.13 1.56 0.72 0.99 1.37 0.88 1.22 1.68 0.72 0.98 1.33 
IprG4c3 0.63 0.97 1.50 0.67 1.05 1.64 0.65 1.03 1.61 0.59 0.94 1.48 0.68 1.04 1.60 
IprNG2c1 0.76 1.11 1.61 0.94 1.38 2.04 0.63 0.93 1.38 0.76 1.13 1.67 0.88 1.27 1.84 
IprNG2c2 0.94 1.31 1.83 0.85 1.21 1.70 0.65 0.92 1.30 0.81 1.15 1.63 0.82 1.14 1.59 
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IprNG2c3 0.69 0.98 1.39 0.62 0.90 1.29 0.67 0.96 1.39 0.76 1.10 1.59 0.78 1.10 1.57 
IprA6c1 0.63 0.91 1.31 0.72 1.05 1.53 0.65 0.95 1.38 0.69 1.01 1.48 0.65 0.93 1.33 
IprA6c2 0.72 1.05 1.53 0.79 1.18 1.75 0.75 1.12 1.66 0.61 0.91 1.37 0.69 1.00 1.46 
IprA6c3 0.61 0.88 1.27 0.69 1.01 1.49 0.70 1.03 1.52 0.57 0.84 1.24 0.69 1.00 1.45 
CellPhenotype Con50 vs Con33 NK50- vs NK33- NK50+ vs NK33+ NK33- vs Con33 NK33+ vs Con33 
Males low ratio upp low ratio upp low ratio upp low ratio upp low ratio upp 
sp3 0.78 0.98 1.24 0.80 1.01 1.29 0.92 1.17 1.49 0.79 1.00 1.28 0.72 0.90 1.13 
sp3-4 0.68 0.91 1.22 0.77 1.04 1.41 0.91 1.24 1.68 0.68 0.92 1.25 0.61 0.82 1.10 
sp3-8 0.55 0.80 1.15 0.61 0.90 1.31 0.83 1.21 1.77 0.65 0.96 1.41 0.63 0.91 1.31 
sp3-45 0.93 1.11 1.33 0.95 1.14 1.37 0.82 0.98 1.18 0.83 1.00 1.21 0.91 1.09 1.30 
sp3-161 0.90 1.09 1.33 0.87 1.07 1.31 0.74 0.91 1.12 0.78 0.96 1.18 0.89 1.09 1.32 
ln3 0.84 0.98 1.15 0.91 1.08 1.27 0.85 1.01 1.19 0.79 0.94 1.11 0.83 0.97 1.14 
ln3-4 0.81 0.95 1.12 0.97 1.14 1.35 0.85 1.01 1.20 0.75 0.89 1.06 0.81 0.95 1.12 
ln3-8 0.76 0.92 1.12 0.71 0.87 1.06 0.83 1.02 1.24 0.89 1.09 1.34 0.80 0.97 1.17 
ln3-45 0.72 0.95 1.26 0.70 0.94 1.26 0.75 1.01 1.35 0.74 1.00 1.35 0.71 0.94 1.24 
ty3 0.97 1.16 1.39 0.82 0.99 1.20 0.83 1.00 1.21 0.93 1.13 1.37 0.89 1.07 1.28 
ty3-4 0.98 1.15 1.35 0.84 0.99 1.17 0.82 0.97 1.15 0.95 1.13 1.34 0.92 1.08 1.26 
ty3-8 0.97 1.20 1.49 0.83 1.04 1.29 0.73 0.91 1.14 0.86 1.07 1.34 0.93 1.15 1.43 
bm3 0.32 0.52 0.83 0.56 0.92 1.52 0.36 0.59 0.97 0.36 0.60 0.99 0.50 0.81 1.30 
bm3-45 0.88 0.96 1.05 0.90 0.98 1.08 1.01 1.11 1.22 0.93 1.02 1.13 0.86 0.94 1.03 
 
Table 13 95% Confidence interval plus estimate for the ratio Δ of the GMO feeds with 50% maize 
inclusion rate versus the corresponding non-GM control feed for females. Ratios with 
corresponding 95/99% intervals that do not encompass the value 1 are coloured 
red/gold; this is equivalent to a significant difference according to a 5/1% t-test. 
Weights NK11-/50 vs Con50 NK50- vs Con50 NK11+/50 vs Con50 NK50+ vs Con50 
Females low ratio upp low ratio upp low ratio upp low ratio upp 
BodyWeight 0.95 1.01 1.07 0.95 1.01 1.07 1.00 1.06 1.12 0.94 1.00 1.06 
growthRate 1.00 1.03 1.06 1.00 1.03 1.06 0.98 1.01 1.04 0.98 1.01 1.04 
FeedMean 0.96 1.02 1.08 0.96 1.02 1.08 1.05 1.11 1.18 0.98 1.04 1.10 
Haematology NK11-/50 vs Con50 NK50- vs Con50 NK11+/50 vs Con50 NK50+ vs Con50 
Females low ratio upp low ratio upp low ratio upp low ratio upp 
WBC 0.90 1.09 1.32 0.83 1.01 1.22 0.88 1.07 1.29 0.81 0.98 1.18 
RBC 0.98 1.01 1.03 0.99 1.02 1.04 0.98 1.01 1.03 0.98 1.01 1.03 
HGB 0.97 1.00 1.03 0.98 1.01 1.04 0.99 1.02 1.05 0.97 1.00 1.03 
HCT 0.97 1.00 1.02 0.98 1.01 1.04 0.99 1.01 1.04 0.97 1.00 1.03 
MCV 0.97 0.99 1.00 0.98 0.99 1.01 0.99 1.01 1.02 0.98 0.99 1.01 
MCH 0.97 0.99 1.01 0.97 0.99 1.01 0.99 1.01 1.03 0.97 0.99 1.01 
MCHC 0.99 1.00 1.02 0.98 1.00 1.01 0.99 1.01 1.02 0.99 1.00 1.01 
PLT 0.94 1.02 1.11 0.87 0.94 1.02 0.85 0.93 1.01 0.89 0.96 1.04 
LYMR 0.93 0.98 1.04 0.95 1.00 1.06 0.92 0.98 1.03 0.95 1.00 1.06 
LYMA 0.87 1.07 1.32 0.82 1.01 1.25 0.85 1.05 1.29 0.79 0.98 1.20 
ClinChem NK11-/50 vs Con50 NK50- vs Con50 NK11+/50 vs Con50 NK50+ vs Con50 
Females low ratio upp low ratio upp low ratio upp low ratio upp 
ALP 0.74 0.91 1.11 0.81 0.98 1.20 0.78 0.95 1.16 0.86 1.05 1.28 
ALT 0.82 0.99 1.19 0.85 1.02 1.23 0.83 1.00 1.21 0.85 1.02 1.23 
AST 0.86 1.05 1.30 0.89 1.10 1.35 0.83 1.02 1.26 0.83 1.03 1.26 
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BIL 0.91 1.23 1.64 0.80 1.08 1.44 0.93 1.24 1.67 0.84 1.13 1.52 
ALB 0.93 0.97 1.01 0.97 1.01 1.06 0.94 0.98 1.02 0.93 0.97 1.01 
TP 0.95 0.99 1.03 0.98 1.02 1.06 0.95 0.99 1.03 0.95 0.99 1.03 
Glu 0.81 0.93 1.08 0.83 0.96 1.12 0.86 1.00 1.16 0.88 1.02 1.18 
CHOL 0.79 0.95 1.14 0.81 0.98 1.18 0.78 0.93 1.13 0.68 0.82 0.99 
TAG 0.78 0.95 1.17 0.75 0.92 1.13 0.76 0.93 1.14 0.66 0.81 0.99 
Crea 0.94 1.04 1.15 0.94 1.03 1.14 0.93 1.03 1.14 0.84 0.93 1.03 
Urea 0.98 1.08 1.20 0.89 0.99 1.09 0.97 1.07 1.19 0.89 0.98 1.09 
cHGB 0.73 1.09 1.61 0.70 1.04 1.53 0.74 1.10 1.62 0.74 1.09 1.62 
Ca 0.97 0.99 1.00 0.99 1.00 1.02 0.97 0.99 1.00 0.97 0.98 1.00 
Cl 0.98 0.99 1.01 0.98 1.00 1.01 0.98 0.99 1.01 0.98 0.99 1.01 
K 0.93 1.02 1.12 0.89 0.98 1.07 0.90 0.99 1.08 0.90 0.98 1.08 
Na 0.99 1.00 1.00 0.99 1.00 1.01 0.99 1.00 1.01 0.99 1.00 1.00 
P 0.84 1.00 1.19 0.86 1.03 1.22 0.86 1.02 1.22 0.88 1.05 1.25 
Urine NK11-/50 vs Con50 NK50- vs Con50 NK11+/50 vs Con50 NK50+ vs Con50 
Females low ratio upp low ratio upp low ratio upp low ratio upp 
uVol 0.79 1.04 1.36 0.65 0.85 1.11 0.63 0.83 1.09 0.74 0.97 1.28 
uVolW 0.77 1.03 1.39 0.63 0.85 1.14 0.58 0.78 1.05 0.73 0.98 1.32 
uLeu 0.78 1.15 1.70 0.89 1.32 1.95 0.72 1.07 1.58 0.91 1.35 2.00 
uOsmoll 0.80 1.06 1.40 0.89 1.18 1.56 0.96 1.27 1.68 0.75 0.99 1.30 
uKeton 0.66 0.89 1.20 0.78 1.05 1.42 0.69 0.93 1.26 0.70 0.95 1.28 
upH 0.76 1.00 1.31 0.76 1.00 1.31 0.84 1.10 1.44 0.86 1.13 1.49 
Organs NK11-/50 vs Con50 NK50- vs Con50 NK11+/50 vs Con50 NK50+ vs Con50 
Females low ratio upp low ratio upp low ratio upp low ratio upp 
Kidney 0.94 1.01 1.09 0.96 1.03 1.11 0.96 1.03 1.11 1.01 1.08 1.16 
Spleen 0.93 1.02 1.12 0.98 1.08 1.19 0.94 1.04 1.14 0.95 1.05 1.15 
Liver 0.95 1.00 1.06 0.97 1.02 1.08 0.93 0.98 1.03 0.94 0.99 1.04 
AdrenGl 0.89 0.98 1.07 0.96 1.05 1.15 0.95 1.04 1.14 0.93 1.01 1.11 
Heart 0.93 0.98 1.04 0.98 1.04 1.10 0.97 1.03 1.09 1.00 1.06 1.12 
Thymus 0.89 1.00 1.12 0.87 0.98 1.10 0.77 0.87 0.98 0.82 0.93 1.04 
Uterus 0.92 1.14 1.42 0.86 1.07 1.33 0.79 0.98 1.21 0.82 1.02 1.26 
Ovary 0.89 0.99 1.10 0.89 1.00 1.11 0.90 1.00 1.11 1.03 1.15 1.28 
Brain 0.94 1.00 1.06 0.94 1.00 1.07 0.91 0.96 1.02 0.95 1.01 1.08 
Immunology NK11-/50 vs Con50 NK50- vs Con50 NK11+/50 vs Con50 NK50+ vs Con50 
Females low ratio upp low ratio upp low ratio upp low ratio upp 
Monocytes 0.87 0.99 1.13 0.85 0.97 1.09 0.86 0.98 1.11 0.78 0.89 1.02 
Granulocytes 0.91 0.96 1.02 0.89 0.94 0.99 0.91 0.96 1.01 0.88 0.93 0.98 
RespirBurst 0.89 0.96 1.03 0.87 0.94 1.01 0.89 0.96 1.03 0.86 0.93 1.00 
Con 0.34 0.76 1.72 0.53 1.16 2.54 0.67 1.52 3.43 0.35 0.81 1.87 
PHA 0.63 1.42 3.21 0.86 1.89 4.12 0.90 2.04 4.62 0.48 1.09 2.52 
PWM 0.59 1.07 1.94 0.63 1.11 1.97 0.78 1.41 2.56 0.43 0.80 1.46 
Med3d 0.42 0.74 1.29 0.74 1.26 2.14 0.78 1.36 2.37 0.35 0.62 1.10 
IprConA 0.63 1.03 1.68 0.58 0.93 1.48 0.68 1.12 1.83 0.79 1.30 2.16 
IprPHA 0.97 1.93 3.81 0.78 1.50 2.88 0.76 1.50 2.98 0.87 1.75 3.52 
IprPWM 1.03 1.45 2.06 0.63 0.88 1.23 0.73 1.04 1.47 0.90 1.28 1.82 
G4c1 0.54 0.90 1.50 0.64 1.04 1.70 1.15 1.92 3.21 0.63 1.06 1.78 
G4c2 0.54 0.92 1.55 0.64 1.06 1.75 0.93 1.57 2.66 0.59 1.02 1.74 
G4c3 0.63 1.06 1.76 0.66 1.07 1.75 0.80 1.34 2.24 0.55 0.92 1.55 
NG2c1 0.63 1.03 1.69 0.63 1.02 1.64 1.05 1.73 2.84 0.62 1.03 1.72 
NG2c2 0.57 1.00 1.77 0.53 0.92 1.59 0.85 1.51 2.66 0.56 1.00 1.79 
NG2c3 0.62 1.05 1.79 0.60 0.99 1.65 0.77 1.31 2.23 0.55 0.94 1.62 
A6c1 0.70 1.12 1.79 0.71 1.11 1.74 1.02 1.62 2.59 0.51 0.81 1.31 
A6c2 0.86 1.45 2.46 0.78 1.29 2.14 0.95 1.61 2.72 0.65 1.10 1.89 
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A6c3 0.58 1.00 1.72 0.61 1.02 1.73 0.80 1.38 2.39 0.49 0.86 1.50 
Med6d 0.54 0.94 1.64 0.57 0.97 1.65 0.73 1.28 2.23 0.43 0.75 1.33 
IprG4c1 0.62 0.96 1.47 0.71 1.07 1.62 0.98 1.51 2.32 0.90 1.40 2.18 
IprG4c2 0.66 0.97 1.43 0.76 1.09 1.58 0.84 1.23 1.81 0.91 1.35 2.00 
IprG4c3 0.87 1.12 1.44 0.87 1.10 1.40 0.82 1.05 1.35 0.95 1.22 1.58 
IprNG2c1 0.76 1.09 1.57 0.74 1.05 1.49 0.94 1.36 1.95 0.95 1.37 1.99 
IprNG2c2 0.77 1.06 1.46 0.70 0.95 1.29 0.85 1.18 1.63 0.96 1.33 1.85 
IprNG2c3 0.85 1.12 1.47 0.79 1.02 1.33 0.78 1.03 1.35 0.95 1.25 1.65 
IprA6c1 0.93 1.19 1.52 0.91 1.15 1.45 1.00 1.27 1.62 0.84 1.08 1.38 
IprA6c2 1.19 1.54 2.00 1.04 1.33 1.71 0.97 1.26 1.63 1.13 1.47 1.91 
IprA6c3 0.77 1.06 1.45 0.78 1.06 1.43 0.79 1.08 1.49 0.83 1.15 1.58 
CellPhenotype NK11-/50 vs Con50 NK50- vs Con50 NK11+/50 vs Con50 NK50+ vs Con50 
Females low ratio upp low ratio upp low ratio upp low ratio upp 
sp3 0.83 0.97 1.13 0.81 0.94 1.09 0.83 0.97 1.14 0.82 0.96 1.12 
sp3-4 0.89 1.03 1.18 0.87 0.99 1.14 0.81 0.94 1.08 0.85 0.98 1.13 
sp3-8 0.89 1.08 1.31 0.87 1.04 1.25 0.90 1.09 1.32 0.79 0.96 1.16 
sp3-45 0.77 0.88 1.01 0.78 0.89 1.02 0.82 0.94 1.07 0.80 0.92 1.06 
sp3-161 0.84 0.95 1.09 0.77 0.87 0.99 0.96 1.10 1.26 0.83 0.94 1.08 
ln3 0.86 0.98 1.12 0.87 0.99 1.12 0.82 0.94 1.07 0.96 1.09 1.25 
ln3-4 0.88 0.99 1.12 0.89 1.00 1.12 0.83 0.93 1.05 1.02 1.15 1.30 
ln3-8 0.78 0.94 1.14 0.85 1.02 1.22 0.84 1.02 1.23 0.78 0.94 1.14 
ln3-45 0.70 0.92 1.21 0.69 0.89 1.16 0.86 1.13 1.48 0.56 0.74 0.97 
ty3 0.96 1.08 1.22 0.91 1.02 1.14 0.92 1.04 1.17 0.92 1.05 1.18 
ty3-4 0.99 1.10 1.23 0.91 1.01 1.12 0.95 1.06 1.18 0.93 1.04 1.16 
ty3-8 0.76 0.89 1.05 0.82 0.96 1.12 0.96 1.13 1.33 0.83 0.98 1.16 
bm3 0.73 1.12 1.69 0.71 1.06 1.58 0.71 1.07 1.63 0.77 1.18 1.80 
bm3-45 0.93 1.04 1.16 0.91 1.01 1.13 0.90 1.00 1.12 0.83 0.93 1.04 
 
Table 14 95% Confidence interval plus estimate for the ratio Δ of the feeds with 50% maize 
inclusion rate versus the corresponding 33% inclusion rate for females, and for the GM 
33% feeds versus the non-GM 33% feed. Ratios with corresponding 95/99% intervals 
that do not encompass the value 1 are coloured red/gold; this is equivalent to a 
significant difference according to a 5/1% t-test. 
Weights Con50 vs Con33 NK50- vs NK33- NK50+ vs NK33+ NK33- vs Con33 NK33+ vs Con33 
Females low ratio upp low ratio upp low ratio upp low ratio upp low ratio upp 
BodyWeight 0.91 0.96 1.02 0.92 0.98 1.04 0.93 0.99 1.04 0.94 1.00 1.06 0.92 0.98 1.04 
growthRate 0.95 0.98 1.01 0.99 1.02 1.05 0.96 0.99 1.02 0.96 0.99 1.02 0.97 1.00 1.03 
FeedMean 0.91 0.96 1.02 0.91 0.97 1.02 0.96 1.01 1.07 0.95 1.01 1.07 0.93 0.98 1.04 
Haematology Con50 vs Con33 NK50- vs NK33- NK50+ vs NK33+ NK33- vs Con33 NK33+ vs Con33 
Females low ratio upp low ratio upp low ratio upp low ratio upp low ratio upp 
WBC 0.82 0.99 1.19 0.80 0.97 1.18 0.83 1.00 1.21 0.84 1.02 1.23 0.79 0.96 1.16 
RBC 0.98 1.00 1.02 0.99 1.01 1.04 0.96 0.98 1.01 0.98 1.01 1.03 1.00 1.03 1.05 
HGB 0.98 1.01 1.03 0.99 1.02 1.05 0.97 0.99 1.02 0.97 0.99 1.02 0.98 1.01 1.04 
HCT 0.98 1.00 1.03 0.98 1.01 1.04 0.97 0.99 1.02 0.98 1.00 1.03 0.98 1.01 1.03 
MCV 0.99 1.00 1.02 0.98 1.00 1.01 0.99 1.01 1.03 0.98 1.00 1.01 0.97 0.98 1.00 
MCH 0.99 1.01 1.03 0.98 1.00 1.02 0.99 1.01 1.03 0.98 1.00 1.02 0.96 0.98 1.00 
MCHC 0.99 1.00 1.02 0.98 1.00 1.01 0.99 1.00 1.02 0.99 1.00 1.02 0.99 1.00 1.02 
PLT 0.93 1.00 1.09 0.89 0.97 1.05 0.84 0.92 1.00 0.90 0.98 1.06 0.97 1.05 1.15 
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LYMR 0.97 1.02 1.08 0.95 1.00 1.06 0.97 1.02 1.08 0.96 1.02 1.07 0.95 1.00 1.06 
LYMA 0.81 1.00 1.23 0.79 0.98 1.21 0.83 1.02 1.26 0.84 1.04 1.28 0.78 0.96 1.18 
ClinChem Con50 vs Con33 NK50- vs NK33- NK50+ vs NK33+ NK33- vs Con33 NK33+ vs Con33 
Females low ratio upp low ratio upp low ratio upp low ratio upp low ratio upp 
ALP 0.82 1.00 1.23 0.73 0.89 1.08 0.92 1.12 1.37 0.91 1.11 1.36 0.77 0.94 1.15 
ALT 0.80 0.97 1.16 0.87 1.04 1.26 1.03 1.24 1.50 0.79 0.95 1.14 0.66 0.79 0.96 
AST 0.75 0.92 1.13 0.89 1.10 1.35 0.75 0.93 1.14 0.75 0.92 1.13 0.83 1.02 1.25 
BIL 0.70 0.94 1.27 0.69 0.93 1.25 0.64 0.86 1.15 0.81 1.09 1.47 0.93 1.24 1.67 
ALB 0.95 0.99 1.04 0.93 0.97 1.01 0.91 0.96 1.00 0.99 1.04 1.09 0.96 1.01 1.05 
TP 0.94 0.98 1.02 0.94 0.98 1.02 0.94 0.98 1.02 0.98 1.02 1.07 0.96 1.00 1.04 
Glu 0.92 1.07 1.24 0.84 0.97 1.13 0.92 1.06 1.24 0.91 1.06 1.23 0.88 1.02 1.19 
CHOL 0.75 0.90 1.09 0.68 0.82 0.99 0.68 0.82 0.99 0.89 1.07 1.29 0.75 0.90 1.09 
TAG 0.77 0.94 1.15 0.70 0.86 1.05 0.67 0.81 1.00 0.82 1.01 1.23 0.76 0.94 1.15 
Crea 0.94 1.03 1.14 0.97 1.07 1.18 0.82 0.91 1.00 0.91 1.00 1.10 0.96 1.06 1.17 
Urea 0.98 1.08 1.19 0.89 0.99 1.09 0.90 0.99 1.10 0.98 1.08 1.19 0.97 1.07 1.19 
cHGB 0.72 1.06 1.57 0.79 1.16 1.72 0.67 1.01 1.52 0.64 0.94 1.40 0.76 1.14 1.72 
Ca 0.98 1.00 1.02 0.97 0.99 1.01 0.99 1.00 1.02 1.00 1.01 1.03 0.96 0.98 1.00 
Cl 1.01 1.02 1.04 0.99 1.00 1.02 0.99 1.01 1.02 1.00 1.02 1.03 0.99 1.01 1.02 
K 0.93 1.02 1.12 0.89 0.97 1.06 0.88 0.97 1.06 0.94 1.03 1.13 0.95 1.04 1.14 
Na 0.99 1.00 1.01 0.99 1.00 1.01 0.99 1.00 1.01 1.00 1.01 1.01 0.99 1.00 1.01 
P 0.85 1.01 1.20 0.76 0.90 1.07 0.76 0.91 1.08 0.96 1.15 1.36 0.98 1.17 1.39 
Urine Con50 vs Con33 NK50- vs NK33- NK50+ vs NK33+ NK33- vs Con33 NK33+ vs Con33 
Females low ratio upp low ratio upp low ratio upp low ratio upp low ratio upp 
uVol 0.98 1.28 1.68 0.56 0.73 0.96 0.75 0.99 1.29 1.13 1.49 1.95 0.97 1.27 1.66 
uVolW 0.99 1.33 1.79 0.56 0.76 1.02 0.75 1.00 1.35 1.11 1.49 2.00 0.96 1.30 1.74 
uLeu 0.59 0.87 1.29 0.83 1.23 1.82 0.91 1.35 2.00 0.63 0.93 1.38 0.59 0.87 1.29 
uOsmoll 0.60 0.80 1.05 0.95 1.25 1.66 0.75 0.99 1.30 0.57 0.75 0.99 0.60 0.80 1.05 
uKeton 0.84 1.13 1.53 0.82 1.11 1.50 0.85 1.15 1.55 0.79 1.07 1.45 0.69 0.93 1.26 
upH 0.69 0.91 1.20 0.54 0.71 0.93 0.63 0.83 1.09 0.98 1.28 1.69 0.95 1.24 1.63 
Organs Con50 vs Con33 NK50- vs NK33- NK50+ vs NK33+ NK33- vs Con33 NK33+ vs Con33 
Females low ratio upp low ratio upp low ratio upp low ratio upp low ratio upp 
Kidney 0.94 1.01 1.08 0.97 1.04 1.12 0.99 1.07 1.14 0.93 1.00 1.07 0.95 1.02 1.09 
Spleen 0.91 1.00 1.11 0.95 1.04 1.15 0.98 1.08 1.18 0.95 1.04 1.15 0.89 0.98 1.08 
Liver 0.93 0.98 1.04 0.93 0.98 1.03 0.96 1.01 1.06 0.98 1.03 1.09 0.92 0.97 1.02 
AdrenGl 0.88 0.97 1.06 0.97 1.06 1.16 0.91 1.00 1.09 0.87 0.95 1.04 0.89 0.98 1.07 
Heart 0.92 0.97 1.03 0.98 1.04 1.10 1.01 1.07 1.13 0.91 0.97 1.02 0.90 0.96 1.01 
Thymus 0.91 1.02 1.15 0.93 1.05 1.18 0.87 0.98 1.10 0.85 0.95 1.07 0.86 0.97 1.09 
Uterus 0.80 1.00 1.24 0.82 1.02 1.26 0.80 0.99 1.23 0.84 1.05 1.30 0.82 1.02 1.27 
Ovary 0.88 0.98 1.09 0.97 1.07 1.19 1.08 1.20 1.33 0.82 0.91 1.01 0.84 0.94 1.04 
Brain 1.00 1.06 1.12 0.97 1.03 1.10 0.98 1.04 1.11 0.97 1.03 1.09 0.97 1.03 1.10 
Immunology Con50 vs Con33 NK33- vs Con33 NK33+ vs Con33 NK50- vs NK33- NK50+ vs NK33+ 
Females low ratio upp low ratio upp low ratio upp low ratio upp low ratio upp 
Monocytes 0.86 0.98 1.11 0.83 0.95 1.08 0.80 0.91 1.04 0.87 0.99 1.14 0.85 0.96 1.09 
Granulocytes 0.96 1.01 1.06 0.92 0.97 1.03 0.91 0.97 1.02 0.92 0.98 1.03 0.93 0.97 1.03 
RespirBurst 0.97 1.04 1.11 0.93 1.00 1.08 0.95 1.02 1.10 0.90 0.97 1.05 0.88 0.94 1.01 
Con 0.38 0.84 1.84 0.71 1.60 3.60 0.50 1.15 2.63 0.27 0.61 1.41 0.27 0.60 1.31 
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PHA 0.26 0.56 1.23 0.80 1.81 4.07 0.57 1.32 3.04 0.25 0.58 1.34 0.21 0.46 1.01 
PWM 0.47 0.83 1.47 0.73 1.31 2.38 0.58 1.07 1.96 0.38 0.70 1.29 0.35 0.62 1.09 
Med3d 0.76 1.30 2.22 0.97 1.69 2.95 0.52 0.92 1.62 0.55 0.96 1.70 0.52 0.88 1.51 
IprConA 0.40 0.65 1.04 0.58 0.95 1.55 0.76 1.25 2.07 0.38 0.64 1.05 0.42 0.68 1.08 
IprPHA 0.22 0.43 0.83 0.54 1.07 2.11 0.72 1.44 2.90 0.30 0.61 1.22 0.27 0.52 1.01 
IprPWM 0.46 0.64 0.89 0.55 0.78 1.10 0.82 1.17 1.67 0.51 0.73 1.04 0.50 0.70 0.98 
G4c1 0.68 1.12 1.82 0.76 1.26 2.10 0.68 1.14 1.92 0.55 0.92 1.55 0.63 1.03 1.68 
G4c2 0.68 1.12 1.87 0.68 1.15 1.94 0.65 1.12 1.92 0.61 1.04 1.77 0.62 1.02 1.69 
G4c3 0.66 1.08 1.76 0.69 1.14 1.90 0.56 0.94 1.59 0.60 1.01 1.70 0.64 1.05 1.72 
NG2c1 0.64 1.03 1.66 0.68 1.11 1.82 0.66 1.10 1.83 0.57 0.94 1.57 0.60 0.96 1.55 
NG2c2 0.66 1.15 1.98 0.54 0.95 1.68 0.58 1.04 1.86 0.62 1.11 1.98 0.64 1.10 1.91 
NG2c3 0.67 1.11 1.85 0.56 0.96 1.63 0.53 0.91 1.57 0.67 1.15 1.98 0.69 1.15 1.92 
A6c1 0.68 1.07 1.67 0.60 0.96 1.53 0.43 0.69 1.11 0.77 1.23 1.99 0.80 1.26 1.97 
A6c2 0.62 1.03 1.70 0.54 0.92 1.55 0.48 0.82 1.40 0.84 1.44 2.47 0.84 1.39 2.31 
A6c3 0.71 1.20 2.02 0.56 0.97 1.67 0.52 0.91 1.59 0.72 1.26 2.20 0.67 1.13 1.91 
Med6d 0.70 1.20 2.05 0.60 1.05 1.83 0.48 0.85 1.50 0.63 1.11 1.96 0.63 1.07 1.82 
IprG4c1 0.61 0.93 1.40 0.78 1.20 1.85 0.87 1.35 2.09 0.53 0.83 1.29 0.64 0.97 1.46 
IprG4c2 0.65 0.93 1.35 0.74 1.09 1.60 0.89 1.32 1.96 0.63 0.93 1.38 0.66 0.96 1.38 
IprG4c3 0.70 0.89 1.14 0.85 1.09 1.39 0.86 1.11 1.44 0.70 0.91 1.17 0.77 0.98 1.25 
IprNG2c1 0.60 0.85 1.21 0.74 1.06 1.52 0.90 1.30 1.88 0.59 0.85 1.23 0.64 0.90 1.28 
IprNG2c2 0.70 0.95 1.30 0.66 0.91 1.25 0.88 1.23 1.71 0.72 1.00 1.39 0.76 1.03 1.41 
IprNG2c3 0.71 0.92 1.20 0.70 0.91 1.20 0.81 1.07 1.42 0.78 1.03 1.37 0.83 1.08 1.40 
IprA6c1 0.70 0.89 1.12 0.72 0.91 1.16 0.63 0.81 1.04 0.87 1.11 1.43 0.93 1.18 1.49 
IprA6c2 0.67 0.85 1.09 0.68 0.88 1.13 0.74 0.96 1.25 1.00 1.30 1.69 1.02 1.30 1.67 
IprA6c3 0.74 1.00 1.35 0.68 0.92 1.26 0.78 1.08 1.48 0.83 1.14 1.57 0.78 1.06 1.44 
CellPhenotype Con50 vs Con33 NK50- vs NK33- NK50+ vs NK33+ NK33- vs Con33 NK33+ vs Con33 
Females low ratio upp low ratio upp low ratio upp low ratio upp low ratio upp 
sp3 0.91 1.06 1.23 0.98 1.15 1.34 0.88 1.03 1.21 0.74 0.87 1.02 0.85 0.99 1.15 
sp3-4 0.85 0.97 1.11 0.96 1.11 1.27 0.88 1.02 1.18 0.76 0.87 1.01 0.81 0.93 1.07 
sp3-8 0.78 0.94 1.14 0.91 1.10 1.33 0.83 1.01 1.23 0.74 0.90 1.09 0.74 0.89 1.07 
sp3-45 0.99 1.13 1.29 0.86 0.99 1.13 0.90 1.04 1.19 0.89 1.02 1.17 0.89 1.01 1.15 
sp3-161 0.89 1.01 1.15 0.77 0.88 1.00 0.85 0.97 1.11 0.88 1.01 1.15 0.87 0.98 1.12 
ln3 0.86 0.98 1.11 0.92 1.04 1.19 0.99 1.13 1.29 0.81 0.92 1.06 0.83 0.95 1.07 
ln3-4 0.87 0.97 1.09 0.90 1.01 1.14 1.06 1.20 1.35 0.85 0.96 1.08 0.83 0.93 1.04 
ln3-8 0.81 0.97 1.17 0.97 1.17 1.41 0.80 0.97 1.17 0.70 0.85 1.02 0.79 0.95 1.14 
ln3-45 1.01 1.31 1.70 0.65 0.85 1.12 0.50 0.66 0.87 1.04 1.37 1.82 1.13 1.47 1.91 
ty3 0.79 0.89 1.00 0.81 0.91 1.02 0.85 0.96 1.08 0.89 1.00 1.13 0.87 0.97 1.09 
ty3-4 0.81 0.90 1.00 0.84 0.94 1.05 0.84 0.94 1.05 0.86 0.96 1.08 0.89 0.99 1.10 
ty3-8 0.89 1.04 1.21 0.75 0.88 1.03 0.85 1.00 1.18 0.96 1.13 1.33 0.87 1.02 1.19 
bm3 0.53 0.79 1.19 0.89 1.35 2.05 0.58 0.88 1.35 0.40 0.62 0.95 0.71 1.06 1.58 
bm3-45 0.96 1.07 1.19 0.88 0.98 1.10 0.91 1.01 1.13 0.83 0.93 1.04 0.95 1.06 1.18 
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Figure 10 Confidence intervals for the ratio of NK11-/50 and NK50- vs the Con50 feed for males with intervals for equivalence limits (see text). 
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Figure 11 Confidence intervals for the ratio of NK11+/50 and NK50+ vs the Con50 feed for males with intervals for equivalence limits (see text). 
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Figure 12 Confidence intervals for the ratio of NK50- and NK50+ vs the corresponding 33% feed for males with intervals for equivalence limits (see text). 
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Figure 13 Confidence intervals for the ratio of NK33- and NK33+ vs the Con33 feed for males with intervals for equivalence limits (see text). 
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Figure 14 Confidence intervals for the ratio of NK11-/50 and NK50- vs the Con50 feed for females with intervals for equivalence limits (see text). 
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Figure 15 Confidence intervals for the ratio of NK11+/50 and NK50+ vs the Con50 feed for females with intervals for equivalence limits (see text). 
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Figure 16 Confidence intervals for the ratio of NK50- and NK50+ vs corresponding 33% feed for females with intervals for equivalence limits (see text). 
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Figure 17 Confidence intervals for the ratio of NK33- and NK33+ vs the Con33 feed for females with intervals for equivalence limits (see text). 
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Figure 18 Confidence intervals for the ratio of the two control feeds for males and females with intervals for the equivalence limits (see text). 
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Figure 19 Residual variance (sig2F or 𝝈𝝈𝑭𝑭𝟐𝟐) in the current G-TwYST B study as a percentage of the 
residual variance (sig2E or 𝝈𝝈𝑬𝑬𝟐𝟐) in the historical GRACE studies for males (top panel) and 
females (bottom panel). 
4.2 Equivalence testing using target effect sizes 
4.2.1 Method 
For a limited number of variables Hong et al (2017) use what they call targeted effect sizes for the 
purpose of statistical power analysis for a rat sub-chronic feeding study. Although they warn that 
these effect sizes should not be considered synonymous with biologically or toxicologically relevant 
effects, these targeted effect sizes were used for equivalence testing. The targeted effect sizes for 
nine variables that are also relevant in G-TwYST are given in Table 15 along with the implied limits on 
the log-ratio scale which are used in the equivalence test. Note the asymmetry in these limits: for a 
targeted effect size of +/- 30%, +30% corresponds to a factor 1.3 which is 0.262 on the log scale, 
while -30% corresponds to a factor 0.7 which equals -0.357 on the log scale. Denoting the limits on 
the log-ratio scale as 𝛿𝛿𝑙𝑙𝑙𝑙𝑙𝑙 and 𝛿𝛿𝑢𝑢𝑢𝑢𝑢𝑢, the two-sided non-equivalence null hypothesis reads, with Δ the 
ratio of the mean of a GMO feed and the mean of the control feed: 
 𝐻𝐻0: log(𝛥𝛥) <  𝛿𝛿𝑙𝑙𝑙𝑙𝑙𝑙 or log(𝛥𝛥) >  𝛿𝛿𝑢𝑢𝑢𝑢𝑢𝑢  
 𝐻𝐻1:  𝛿𝛿𝑙𝑙𝑙𝑙𝑙𝑙 ≤  log(𝛥𝛥) ≤  𝛿𝛿𝑢𝑢𝑢𝑢𝑢𝑢 
This was tested by means of the TOST approach of Schuirmann (1987) at the 5% level which is 
equivalent to checking whether the 10% confidence interval for log(𝛥𝛥) lies completely within the 
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interval �𝛿𝛿𝑙𝑙𝑙𝑙𝑙𝑙 ,𝛿𝛿𝑢𝑢𝑢𝑢𝑢𝑢� composed of the equivalence limits. For one-sided tests the same confidence 
interval can be used where only one of the confidence bounds is relevant. 
Table 15 Targeted effect sizes from Table 1 in Hong et al (2017) along with their implied lower 
and upper limits on the ratio scale and on the log-ratio scale. 
Name in Hong et al (2017) G-TwYST 
Name 
Targeted 
effect 
size 
Ratio scale Log-ratio scale 
Lower Upper Lower Upper 
Body weight; final non-fasted BodyWeight -  10% 0.90 - -0.105 - 
Leukocyte (WBC) count WBC +/-  30% 0.70 1.30 -0.357 0.262 
Lymphocyte (ALYM) count LYMA +/-  30% 0.70 1.30 -0.357 0.262 
Alkaline phosphatase (ALKP) ALP +  100% - 2.00 - 0.693 
Creatinine (CREA) Krea +  50% - 1.50 - 0.405 
Blood urea nitrogen (BUN) Urea +  50% - 1.50 - 0.405 
Cholesterol (CHOL)  CHOL +  200% - 3.00 - 1.099 
Kidney, % body weight Kidney +  25% - 1.25 - 0.223 
Liver, % body weight Liver +  25% - 1.25 - 0.223 
 
4.2.2 Results 
The confidence intervals for the 9 variables in Table 15, as well as the equivalence limits are given in 
Figure 20 for males and in Figure 21 for females. In all cases the null hypothesis of non-equivalence is 
rejected in favour of equivalence with generally small p-values (Table 16).  
Table 16 P-values of equivalence tests for the ratio of two means using targeted effect sizes of 
Hong et al (2017), see Table 15, as equivalence limits. P-values smaller than 0.01/0.05 
have a gold/yellow background. 
Males 
Variable 
NK11-/50 
Con50 
NK50- 
Con50 
NK11+/50 
Con50 
NK50+ 
Con50 
Con50 
Con33 
NK50- 
NK33- 
NK50+ 
NK33+ 
NK33- 
Con33 
NK33+ 
Con33 
BodyWeight 0.010 0.027 0.000 0.001 0.000 0.000 0.000 0.000 0.000 
WBC 0.002 0.014 0.001 0.010 0.000 0.004 0.005 0.002 0.001 
LYMA 0.001 0.025 0.000 0.015 0.001 0.002 0.013 0.017 0.001 
ALP 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Krea 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Urea 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CHOL 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Kidney 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Liver 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Females 
Variable 
NK11-/50 
Con50 
NK50- 
Con50 
NK11+/50 
Con50 
NK50+ 
Con50 
Con50 
Con33 
NK50- 
NK33- 
NK50+ 
NK33+ 
NK33- 
Con33 
NK33+ 
Con33 
BodyWeight 0.000 0.000 0.000 0.000 0.011 0.003 0.001 0.000 0.003 
WBC 0.034 0.005 0.021 0.002 0.003 0.002 0.004 0.007 0.001 
LYMA 0.037 0.010 0.021 0.004 0.008 0.004 0.013 0.018 0.002 
ALP 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Krea 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Urea 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CHOL 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Kidney 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Liver 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
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Figure 20 90% confidence intervals for the ratio of two means for selected variables for males 
along with equivalence intervals defined by targeted effect sizes of Hong et al (2017). 
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Figure 21 90% confidence intervals for the ratio of two means for selected variables for females 
along with equivalence intervals defined by targeted effect sizes of Hong et al (2017). 
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4.3 Classical statistical analysis 
4.3.1 Method 
G-TwYST study C is based on OECD guidance 408 on repeated dose 90-day oral toxicity studies in 
rodents (OECD 1998), EFSA guidance complementing the OECD guidance for whole food/feed studies 
(EFSA 2011b), and additional EFSA clarifications (EFSA 2013, 2014). OECD guidance 408 (OECD 1998) 
requires numerical results to be evaluated by an appropriate and acceptable statistical method, but 
gives no further guidance on statistical analysis. More detailed guidance, although strictly meant for 
chronic and carcinogenicity studies, is provided in chapter 4 of OECD guidance document 116 (OECD 
2012), which describes a flowchart for statistical analysis methods (reproduced in Figure 22).  
 
Figure 22 Classical approach to statistical analysis of data in long-term toxicity studies (copied 
from OECD 2012). 
EFSA (2011b) gives further guidance, such as considering cage as the experimental unit, and including 
block in the model for data from a randomised block design (as is the case for the G-TwYST study). 
In the current section we apply classical statistical methods for continuous data in line with these 
OECD and EFSA approaches, and very similar to the approaches followed in the GRACE project 
(Schmidt and Schmidtke 2014, Schmidt et al 2015ab). 
A classical analysis of variance was performed on the cage means after log transforming the data. 
This was done in the statistical program R. The R-script which analyses a single response variable is 
given in Appendix 10; Appendix 11 contains an example dataset for the R-script. The classical analysis 
involves: 
• Analysis of variance according to the randomized block design employing the model “Block + 
Treatment” where Treatment defines the eight feeding groups. The model was fitted by 
means of linear regression, using the lm() function in R, because this takes proper account of 
any missing values. The usual summary statistics are saved as well as estimates for the nine 
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primary comparisons. Standard errors, t-values and p-values of the differences were also 
saved. These are all calculated using the pooled ANOVA residual standard error which has 49 
degrees of freedom whenever measurements are available for 8 cages per feeding group 
(Table 3). 
• The ANOVA p-values do not take account of multiple comparisons between the feeds. Therefore 
Dunnett’s test was performed separately for two sets of comparisons. The first set compared 
the four GM feeds with maize inclusion rate 33% with the non-GM control feed Con33, and the 
second set compared the two GM feeds NK50- and NK50+ to the corresponding non-GM control 
feed Con50. The first set thus contains four simultaneous comparisons, while the second set 
contains two simultaneous comparisons.  Dunnett’s test is performed by means of the glht() 
function in the multcomp R-package. 
• The residuals of the analysis of variance are checked for normality using the Kolmogorov-
Smirnov test as well as the Shapiro-Wilk test for normality. These tests are only approximate 
since the residuals are not independent. The p-value of the Kolmogorov-Smirnov test is not 
reported since it is almost always larger that the p-value of the Shapiro-Wilk test, moreover for 
variables where it is smaller, the p-value is far from significant. Note that the ANOVA residuals 
were already assessed by means of a normal probability plot (Appendix 5) and a plot of residuals 
versus fitted values (Appendix 6). 
• The non-parametric Wilcoxon signed rank test is used to test for a difference for each of the 
nine comparisons. Note that this test only uses data of two feeds and that the test employs the 
within block difference between the two feeds. This test is nor useful for the endpoints in the 
Immunology and CellPhenotype groups because these consist of non-aligned missing values. The 
exact p-value of the test is calculated by means of the wilcox.test() function in R. 
• The non-parametric Friedman test, which is applicable to a randomized block design, is used to 
test for overall differences between the eight feeds. Results of this test are not reported. 
• Homogeneity of variance is assessed by means of Bartlett’s test and by means of Levene’s test 
both using the mean and the median. These test do not take blocking into account and basically 
compare the within feed variances. Note that homogeneity of variance was already assessed by 
means of a plot of residuals versus fitted values (Appendix 6). The p-value of the Levene test 
with the median is not reported since it is almost always larger that the p-value of the Levene 
test with the mean, and for variables where it is smaller the p-value is far from significant. Note 
that both analysis of variance and non-parametric tests require homogeneity of variance. 
• Finally, for each feeding group separately, normality was assessed by means of the Kolmogorov-
Smirnov test and the Shapiro-Wilk test. The p-value of the Kolmogorov-Smirnov test is always 
larger than 5% and is thus not reported. 
4.3.2 Results 
Table 17 (males) and Table 18 (females) present the results of t-tests, of Dunnett’s tests and of 
Wilcoxon tests for the 88 variables divided in seven groups. Note that Dunnett’s test is only 
performed for comparisons between GM 50% feeds and Con 50, and between GM 33% feeds and 
Con33. Ordinary letters indicate a significant difference at the 5% level, while a capital letter 
indicates significance at the 1% level. Exact p-values for all tests are given in Appendix 12. For ease of 
interpretation means on the original scale are given, rather than means on the log-transformed scale. 
Note however that 95% confidence intervals on the ratio scale are given in Table 11 to Table 14. The 
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colouring in these latter tables corresponds to the letters t/d and T/D in Table 17 and Table 18, since 
both are based on significance of t-tests at the 5% and 1%  level. 
For males a difference was significant by at least one of the tests at the 5% level in 48 cases (6.1% of 
the 792 tests). On their own Dunnett’s test resulted in 5 significant differences (0.6%), the t-test 
resulted in 38 significant differences (4.8%), and Wilcoxon’s test resulted in 25 significant differences 
(6.2% of 405 tests, since Wilcoxon is not performed for Immunology and CellPhenotype endpoints). 
For females a difference was significant by at least one of the tests at the 5% level in 62 cases (7.8%). 
On their own Dunnett’s test resulted in 12 significant differences (1.5%), the t-test resulted in 52 
significant differences (6.6%), and Wilcoxon’s test resulted in 20 significant differences (4.9%). 
Results of the Shapiro-Wilks test for normality and Bartlett’s and Levene’s test for homogeneity of 
variance are given in Appendix 13. The non-normality as indicated by the Shapiro-Wilks test for 
separate feeding groups is frequently significant. The graphs of cage means on the log scale in 
Appendix 4 indicate that significance of non-normality is mostly due to one outlying observation in a 
feeding group. 
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Table 17 Means per feeding group and results of statistical tests for nine comparisons for male rats. Significant difference are marked, with red 
background colouring, as follows: D: P<0.01 by Dunnett-test, d: P<0.05 by Dunnett-test, T: P<0.01 by t-test but not by Dunnett-test, t: P<0.05 
by t-test but not by Dunnett-test, W: P<0.01 by Wilcoxon signed rank test, w: P<0.05 by Wilcoxon signed rank test. See text. 
Males Means NK11- 
Con50 
NK50- 
Con50 
NK11+ 
Con50 
NK50+ 
Con50 
Con50 
Con33 
NK50- 
NK33- 
NK50+ 
NK33+ 
NK33- 
Con33 
NK33+ 
Con33 Weights Con50 NK11- NK50- NK11+ NK50+ Con33 NK33- NK33+ 
BodyWeight 462.0 443.0 437.5 459.0 452.9 441.2 444.3 444.2  tw   w     
growthRate 0.166 0.172 0.159 0.168 0.156 0.167 0.154 0.171          
FeedMean 2.769 2.655 2.633 2.833 2.745 2.648 2.615 2.683  tw        
Males Means NK11- 
Con50 
NK50- 
Con50 
NK11+ 
Con50 
NK50+ 
Con50 
Con50 
Con33 
NK50- 
NK33- 
NK50+ 
NK33+ 
NK33- 
Con33 
NK33+ 
Con33 Haematology Con50 NK11- NK50- NK11+ NK50+ Con33 NK33- NK33+ 
WBC 7.981 8.012 8.562 7.406 8.462 8.363 8.238 8.219          
RBC 8.630 8.673 8.539 8.707 8.538 8.631 8.636 8.793       Tw  w 
HGB 15.72 16.14 15.71 16.19 15.89 15.95 15.97 15.78 t  dTW       
HCT 46.84 47.31 46.46 47.79 46.89 46.91 47.16 47.02   tw       
MCV 54.28 54.58 54.42 54.92 54.95 54.37 54.62 53.48       Tw  t 
MCH 18.22 18.62 18.42 18.62 18.61 18.50 18.51 17.96       Tw  d 
MCHC 33.58 34.13 33.82 33.88 33.89 33.99 33.87 33.57 t         
PLT 736.7 792.2 858.8 776.2 828.9 770.2 762.6 843.1  tw  tw      
LYMR 74.46 74.49 76.30 75.71 75.79 75.25 77.89 72.99       t   
LYMA 5.919 5.975 6.525 5.612 6.400 5.944 6.406 5.994          
Males Means NK11- 
Con50 
NK50- 
Con50 
NK11+ 
Con50 
NK50+ 
Con50 
Con50 
Con33 
NK50- 
NK33- 
NK50+ 
NK33+ 
NK33- 
Con33 
NK33+ 
Con33 ClinChem Con50 NK11- NK50- NK11+ NK50+ Con33 NK33- NK33+ 
ALP 1.283 1.471 1.193 1.201 1.333 1.386 1.294 1.349          
ALT 0.536 0.658 0.533 0.639 0.574 0.533 0.524 0.546          
AST 2.366 2.916 2.456 2.665 2.571 2.424 2.276 2.392          
BIL 7.469 8.919 7.856 8.044 8.206 7.500 7.587 7.719 t         
ALB 37.46 39.29 38.27 38.99 38.36 38.38 38.19 38.29 t         
TP 64.17 65.49 65.39 64.63 65.64 66.17 65.36 65.66  W  w t     
Glu 5.578 5.449 5.224 5.699 5.027 5.743 5.395 5.292          
CHOL 2.133 2.110 2.234 2.252 2.262 2.151 2.079 2.114          
TAG 1.132 1.118 1.178 1.184 1.201 1.068 1.275 1.122          
Crea 33.41 32.31 34.90 32.23 33.32 36.18 34.38 33.28          
Urea 4.958 4.912 4.691 5.501 4.859 5.455 4.838 5.307   tw     d  
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cHGB 66.4 138.2 88.9 106.1 107.1 87.0 73.9 88.7 d   tW      
Ca 2.388 2.371 2.403 2.386 2.391 2.391 2.396 2.393          
Cl 100.1 99.6 100.8 100.3 99.0 99.4 99.8 100.4       w  w 
K 4.438 4.888 4.662 4.500 4.556 4.556 4.512 4.431 t         
Na 143.6 143.2 144.6 143.2 143.2 144.1 143.4 144.7  w        
P 1.999 2.114 1.993 2.025 2.043 2.192 2.224 2.216       w   
Males Means NK11- 
Con50 
NK50- 
Con50 
NK11+ 
Con50 
NK50+ 
Con50 
Con50 
Con33 
NK50- 
NK33- 
NK50+ 
NK33+ 
NK33- 
Con33 
NK33+ 
Con33 Urine Con50 NK11- NK50- NK11+ NK50+ Con33 NK33- NK33+ 
uVol 23.75 23.00 25.19 25.31 25.50 18.88 21.12 20.75          
uVolW 5.306 5.476 6.141 5.747 5.801 4.533 4.941 4.842          
uLeu 12.50 9.38 4.69 7.81 6.25 12.50 9.38 20.31          
uOsmoll 457.7 417.2 395.1 405.2 432.7 432.0 421.5 515.9          
uKeton 0.500 0.344 0.375 0.219 0.469 0.312 0.625 0.438          
upH 6.938 6.906 6.938 7.125 6.719 7.094 7.031 7.250       Tw   
Males Means NK11- 
Con50 
NK50- 
Con50 
NK11+ 
Con50 
NK50+ 
Con50 
Con50 
Con33 
NK50- 
NK33- 
NK50+ 
NK33+ 
NK33- 
Con33 
NK33+ 
Con33 Organs Con50 NK11- NK50- NK11+ NK50+ Con33 NK33- NK33+ 
Kidney 0.535 0.555 0.547 0.561 0.554 0.543 0.533 0.579          
Spleen 0.163 0.162 0.170 0.168 0.170 0.167 0.167 0.168          
Liver 2.272 2.219 2.342 2.345 2.296 2.352 2.289 2.293          
AdrenGl 0.0138 0.0140 0.0138 0.0135 0.0138 0.0136 0.0135 0.0133          
Heart 0.250 0.248 0.258 0.256 0.255 0.256 0.242 0.261      tw  tw  
Thymus 0.095 0.090 0.097 0.101 0.092 0.096 0.087 0.096      t    
Testis 0.819 0.830 0.883 0.863 0.855 0.864 0.846 0.833  tW w       
Epididymis 0.280 0.280 0.298 0.296 0.291 0.293 0.280 0.290          
Brain 0.493 0.506 0.522 0.502 0.500 0.511 0.509 0.510  t   w     
Males Means NK11- 
Con50 
NK50- 
Con50 
NK11+ 
Con50 
NK50+ 
Con50 
Con50 
Con33 
NK50- 
NK33- 
NK50+ 
NK33+ 
NK33- 
Con33 
NK33+ 
Con33 Immunology Con50 NK11- NK50- NK11+ NK50+ Con33 NK33- NK33+ 
Monocytes 62.55 65.42 66.20 61.45 67.63 63.35 66.73 68.80         d 
Granulocytes 82.43 80.28 82.76 81.91 81.46 82.73 83.88 84.03          
RespirBurst 76.01 79.79 72.31 76.65 76.74 74.16 73.03 74.99          
Con 87808 105440 135550 128899 98139 154631 175636 134747          
PHA 45620 50308 51155 68895 38421 59322 77656 51970          
PWM 31814 40579 54890 41618 31232 38623 52515 51542          
Med3d 1834 2281 3155 2156 1469 2628 3649 3175          
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IprConA 49.24 52.23 47.33 63.45 62.08 62.09 50.34 63.17   t  t     
IprPHA 29.93 30.27 21.59 34.62 27.36 26.36 24.66 31.37          
IprPWM 23.87 22.27 24.25 24.66 23.89 17.33 16.88 24.34          
G4c1 1991 1855 2227 2233 1493 2210 3181 1694          
G4c2 2341 2218 2231 2435 2209 2666 3947 1729          
G4c3 2630 2171 2628 3259 3534 3266 4055 2119          
NG2c1 1979 2047 2445 2262 2116 2199 3649 1970          
NG2c2 2442 2130 2378 2545 2437 3043 4124 1959          
NG2c3 2417 2259 2450 2968 3948 3446 4620 2189      t    
A6c1 2330 2467 2300 2620 2161 3123 4264 2137          
A6c2 2449 2726 2195 2603 3049 3204 4156 2240          
A6c3 2316 2118 2197 2601 3881 3192 3517 2062          
Med6d 2287 1818 1950 1988 1941 2498 3493 1742          
IprG4c1 1.336 1.397 2.004 1.211 1.132 1.119 0.920 1.076      t    
IprG4c2 1.330 1.372 1.704 1.188 1.152 1.128 1.355 1.061          
IprG4c3 1.733 2.051 1.701 1.914 1.730 1.690 1.448 1.578          
IprNG2c1 1.287 1.423 1.903 1.469 1.331 1.100 1.080 1.239          
IprNG2c2 1.663 1.416 1.729 1.210 1.264 1.283 1.258 1.282          
IprNG2c3 1.774 1.821 1.637 1.787 1.811 1.682 1.581 1.693          
IprA6c1 1.356 1.701 1.601 1.571 1.361 1.458 1.288 1.231          
IprA6c2 1.560 1.486 1.565 1.293 1.904 1.398 1.253 1.402          
IprA6c3 1.527 1.841 1.378 1.568 1.775 1.652 1.303 1.535          
Males Means NK11- 
Con50 
NK50- 
Con50 
NK11+ 
Con50 
NK50+ 
Con50 
Con50 
Con33 
NK50- 
NK33- 
NK50+ 
NK33+ 
NK33- 
Con33 
NK33+ 
Con33 CellPhenotype Con50 NK11- NK50- NK11+ NK50+ Con33 NK33- NK33+ 
sp3 45.88 42.09 46.60 44.42 46.16 44.70 44.96 41.80          
sp3-4 31.49 28.64 32.55 29.92 31.78 31.84 31.17 28.94          
sp3-8 12.84 12.93 13.43 13.35 14.35 14.17 14.99 14.21          
sp3-45 24.93 28.51 26.20 23.92 24.88 23.38 25.26 24.98          
sp3-161 7.871 8.196 7.379 7.983 7.915 7.896 7.125 8.088          
ln3 47.38 46.02 47.71 46.78 48.39 48.98 45.18 45.20          
ln3-4 34.55 35.13 36.20 34.74 36.30 36.89 32.20 33.63          
ln3-8 10.95 10.84 11.02 11.70 11.82 12.15 13.23 11.16          
ln3-45 29.68 33.54 27.75 31.48 32.60 35.33 31.30 31.64          
ty3 21.13 18.45 19.83 19.84 19.71 18.16 20.06 19.65          
ty3-4 17.54 15.45 17.10 16.77 16.37 15.41 17.69 16.96          
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ty3-8 11.28 9.45 9.70 11.30 9.48 9.44 9.11 10.27          
bm3 7.67 9.23 7.23 5.89 6.31 12.46 5.74 13.74     T  t t  
bm3-45 53.94 57.23 60.15 57.86 59.27 57.75 66.49 60.77   t    t   
 
Table 18 Means per feeding group and results of statistical tests for nine comparisons for female rats. Significant difference are marked, with red 
background colouring, as follows: D: P<0.01 by Dunnett-test, d: P<0.05 by Dunnett-test, T: P<0.01 by t-test but not by Dunnett-test, t: P<0.05 
by t-test but not by Dunnett-test, W: P<0.01 by Wilcoxon signed rank test, w: P<0.05 by Wilcoxon signed rank test. See text. 
Females Means NK11- 
Con50 
NK50- 
Con50 
NK11+ 
Con50 
NK50+ 
Con50 
Con50 
Con33 
NK50- 
NK33- 
NK50+ 
NK33+ 
NK33- 
Con33 
NK33+ 
Con33 Weights Con50 NK11- NK50- NK11+ NK50+ Con33 NK33- NK33+ 
BodyWeight 246.7 249.4 249.2 261.5 246.2 255.7 254.6 250.2   t       
growthRate 0.128 0.155 0.160 0.135 0.140 0.152 0.137 0.151  t        
FeedMean 1.829 1.864 1.857 2.030 1.893 1.901 1.919 1.863   Dw       
Females Means NK11- 
Con50 
NK50- 
Con50 
NK11+ 
Con50 
NK50+ 
Con50 
Con50 
Con33 
NK50- 
NK33- 
NK50+ 
NK33+ 
NK33- 
Con33 
NK33+ 
Con33 Haematology Con50 NK11- NK50- NK11+ NK50+ Con33 NK33- NK33+ 
WBC 5.006 5.344 4.950 5.250 4.906 4.994 5.169 4.812          
RBC 7.636 7.684 7.781 7.689 7.702 7.636 7.699 7.836         tw 
HGB 15.11 15.10 15.22 15.40 15.10 15.02 14.97 15.17          
HCT 43.96 43.73 44.44 44.51 43.92 43.87 44.04 44.22          
MCV 57.59 56.93 57.13 57.91 57.04 57.46 57.21 56.46         t 
MCH 19.80 19.68 19.57 20.04 19.61 19.69 19.66 19.38          
MCHC 34.38 34.53 34.29 34.60 34.42 34.27 34.36 34.33          
PLT 787.4 807.2 745.3 733.9 760.4 784.6 773.0 823.7       tw   
LYMR 79.38 78.14 79.82 77.47 79.59 77.89 79.24 77.96          
LYMA 3.969 4.156 3.956 4.050 3.919 3.913 4.094 3.788          
Females Means NK11- 
Con50 
NK50- 
Con50 
NK11+ 
Con50 
NK50+ 
Con50 
Con50 
Con33 
NK50- 
NK33- 
NK50+ 
NK33+ 
NK33- 
Con33 
NK33+ 
Con33 ClinChem Con50 NK11- NK50- NK11+ NK50+ Con33 NK33- NK33+ 
ALP 0.656 0.591 0.644 0.626 0.676 0.643 0.716 0.625          
ALT 0.481 0.484 0.494 0.484 0.497 0.499 0.475 0.431       t  d 
AST 2.223 2.362 2.439 2.288 2.286 2.397 2.207 2.481          
BIL 6.24 8.65 6.61 8.97 8.05 6.50 8.01 10.42          
ALB 44.05 42.67 44.69 43.11 42.71 44.39 46.15 44.67       t   
TP 69.16 68.57 70.42 68.41 68.56 70.41 72.11 70.14          
G-TwYST Study C  Statistical report 
60 
 
Glu 5.237 4.948 5.010 5.248 5.356 4.869 5.156 5.051          
CHOL 1.627 1.574 1.647 1.538 1.336 1.834 1.954 1.681    t  t tw   
TAG 0.521 0.511 0.479 0.484 0.427 0.561 0.558 0.540    t  w t   
Crea 36.54 38.46 37.68 37.65 34.01 35.37 35.33 37.59       w   
Urea 5.925 6.471 5.866 6.364 5.851 5.485 5.959 5.899          
cHGB 73.2 97.9 77.5 109.6 100.7 67.2 65.4 100.5          
Ca 2.459 2.429 2.465 2.428 2.416 2.456 2.492 2.408   w tW     d 
Cl 102.7 102.0 102.4 101.9 101.9 100.6 102.2 101.2     T   t  
K 4.188 4.306 4.094 4.175 4.150 4.087 4.244 4.319          
Na 143.8 143.2 144.2 143.4 143.3 143.4 144.2 143.6          
P 1.647 1.634 1.637 1.660 1.709 1.622 1.841 1.874          
Females Means NK11- 
Con50 
NK50- 
Con50 
NK11+ 
Con50 
NK50+ 
Con50 
Con50 
Con33 
NK50- 
NK33- 
NK50+ 
NK33+ 
NK33- 
Con33 
NK33+ 
Con33 Urine Con50 NK11- NK50- NK11+ NK50+ Con33 NK33- NK33+ 
uVol 19.94 21.06 18.12 16.50 19.94 15.31 22.56 20.06     w t  DW w 
uVolW 8.494 9.110 7.731 6.728 8.588 6.380 9.381 8.494     w   dTW w 
uLeu 0.00 3.12 9.38 1.56 32.81 3.12 1.56 0.00          
uOsmoll 340.2 383.5 434.8 429.0 340.5 422.6 321.6 347.2   w     tw  
uKeton 0.125 0.031 0.188 0.094 0.063 0.031 0.063 0.000          
upH 6.438 6.438 6.437 6.531 6.563 6.531 6.781 6.750      t    
Females Means NK11- 
Con50 
NK50- 
Con50 
NK11+ 
Con50 
NK50+ 
Con50 
Con50 
Con33 
NK50- 
NK33- 
NK50+ 
NK33+ 
NK33- 
Con33 
NK33+ 
Con33 Organs Con50 NK11- NK50- NK11+ NK50+ Con33 NK33- NK33+ 
Kidney 0.581 0.589 0.600 0.601 0.628 0.577 0.579 0.588    t      
Spleen 0.214 0.220 0.233 0.222 0.226 0.213 0.223 0.209          
Liver 2.400 2.413 2.461 2.346 2.377 2.437 2.514 2.354          
AdrenGl 0.0300 0.0293 0.0315 0.0312 0.0305 0.0312 0.0298 0.0304          
Heart 0.302 0.297 0.313 0.312 0.320 0.313 0.301 0.298       t   
Thymus 0.134 0.134 0.131 0.116 0.124 0.131 0.126 0.127   t w      
Uterus 0.259 0.298 0.273 0.249 0.257 0.253 0.270 0.262          
Ovary 0.0398 0.0391 0.0396 0.0399 0.0458 0.0403 0.0371 0.0389    dw   TW   
Brain 0.855 0.853 0.858 0.823 0.868 0.807 0.832 0.833     w     
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Females Means NK11- 
Con50 
NK50- 
Con50 
NK11+ 
Con50 
NK50+ 
Con50 
Con50 
Con33 
NK50- 
NK33- 
NK50+ 
NK33+ 
NK33- 
Con33 
NK33+ 
Con33 Immunology Con50 NK11- NK50- NK11+ NK50+ Con33 NK33- NK33+ 
Monocytes 63.81 65.83 59.79 62.54 56.88 64.35 63.04 61.33          
Granulocytes 80.73 78.87 73.77 76.39 74.40 78.88 76.98 76.86  t  d      
RespirBurst 81.03 79.61 73.12 77.10 74.88 76.76 74.44 73.35          
Con 75692 68670 81048 117206 54584 78625 62550 60367          
PHA 26868 30960 34023 53806 15683 32723 26036 22252          
PWM 20924 26486 25090 36709 14985 24881 18383 20029          
Med3d 1975 1923 3125 3244 1654 1768 1558 1652          
IprConA 34.23 31.90 28.30 32.90 36.59 42.50 34.95 34.83          
IprPHA 12.74 17.58 15.47 15.90 15.18 23.62 14.43 14.41     t     
IprPWM 11.06 15.10 9.47 10.60 12.97 15.92 12.48 12.81 t    t    t 
G4c1 2319 2175 2536 3478 1990 1886 1894 2242   d       
G4c2 2535 2535 2826 3409 2435 2165 2371 2591          
G4c3 2775 2586 2779 3122 2334 2170 2474 2798          
NG2c1 2299 2158 2465 3432 1931 1956 2216 2385   t       
NG2c2 2559 2577 2882 3309 2357 2182 2643 2811          
NG2c3 2674 2593 2939 3274 2499 2151 2691 2795          
A6c1 2444 2544 2862 3288 1858 2182 2657 2905   t       
A6c2 1980 2729 2699 3204 2596 1967 2722 2808          
A6c3 2417 2337 2724 3162 2161 1945 2439 2488          
Med6d 2572 2451 2480 2663 1697 1910 2177 2307          
IprG4c1 0.953 0.927 1.076 1.431 1.317 1.001 0.993 1.016          
IprG4c2 1.100 1.130 1.319 1.343 1.502 1.182 1.302 1.225          
IprG4c3 1.169 1.264 1.383 1.206 1.416 1.265 1.240 1.290          
IprNG2c1 1.001 0.976 1.112 1.374 1.309 1.101 1.074 1.107          
IprNG2c2 1.193 1.205 1.223 1.353 1.630 1.273 1.306 1.484          
IprNG2c3 1.354 1.261 1.326 1.275 1.729 1.390 1.421 1.475          
IprA6c1 1.076 1.228 1.262 1.421 1.225 1.235 1.341 1.486          
IprA6c2 0.995 1.384 1.420 1.267 1.668 1.296 1.484 1.564 D t  dT    t t 
IprA6c3 1.084 1.119 1.241 1.256 1.487 1.268 1.322 1.238          
Females Means NK11- 
Con50 
NK50- 
Con50 
NK11+ 
Con50 
NK50+ 
Con50 
Con50 
Con33 
NK50- 
NK33- 
NK50+ 
NK33+ 
NK33- 
Con33 
NK33+ 
Con33 CellPhenotype Con50 NK11- NK50- NK11+ NK50+ Con33 NK33- NK33+ 
sp3 50.67 52.00 50.95 52.82 58.57 52.68 44.47 46.88          
sp3-4 25.56 26.71 26.21 24.80 26.51 27.22 22.61 24.82          
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sp3-8 10.90 12.31 12.83 12.17 12.07 12.82 11.25 11.08          
sp3-45 32.09 28.32 27.89 31.03 29.75 28.18 28.59 28.04          
sp3-161 7.300 6.685 6.296 7.625 6.415 6.917 7.290 7.158  t        
ln3 53.23 50.50 55.07 49.37 56.36 53.07 51.70 52.01          
ln3-4 38.12 36.77 39.83 35.59 43.17 38.55 38.98 36.75    t   T   
ln3-8 14.12 13.11 15.19 14.09 12.66 14.02 12.98 14.21          
ln3-45 27.80 23.97 24.66 33.53 20.23 21.04 28.28 31.38    t t  T d dT 
ty3 17.22 18.05 18.35 18.84 18.49 18.77 19.44 19.43          
ty3-4 15.48 16.88 16.47 17.31 16.78 17.09 16.92 17.71     t     
ty3-8 8.596 7.970 7.900 9.950 8.660 8.333 8.900 8.783          
bm3 11.20 13.93 16.30 15.78 16.72 18.03 7.93 16.07        t  
bm3-45 62.30 62.56 60.67 59.74 53.90 55.61 62.79 55.79          
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4.4 Standardised effect sizes 
4.4.1 Method 
EFSA (2011b) defines the standardised effect size (SES) as the effect size measured in SD units, where 
SD is the standard deviation among experimental units. We will assume that in a randomised block, 
experiment like the current G-TwYST study, SD refers to the pooled residual variation. The use of SES 
in EFSA (2011b) was in the context of determination of sample size and power: ‘If experience from 
previous toxicity tests shows an effect size of, say, one SD or less is of little toxicological relevance 
then this can be used to determine sample size in new situations’ (EFSA 2011b). Zeljenková et al 
(2014) followed this example and, without further toxicological motivation, ‘assumed that an SES of 
1.0 SD or less is unlikely to be of toxicological importance’. Consequently, all results of the GRACE 
studies have been reported as confidence intervals on the SES scale (Zeljenková et al, 2014, 2016, 
Schmidt et al 2015, 2017). In this section the same SES graphs are calculated for comparability 
between GRACE and G-TwYST. 
Standardized effect sizes (SES), again using the residual standard error with 49 degrees of freedom 
whenever 8 cages are available for an endpoint, and their exact 95% confidence intervals were 
calculated. This employed the conf.limits.nct() function in the MBESS R-package, see section 3 in 
Kelley (2007). Note that, since the calculated SES confidence interval is exact, the SES interval does 
not contain zero if and only if the p-value of the t-test is smaller than 5%. 
4.4.2 Results 
SES intervals were calculated for all 88 variables, and these are given in Figure 23 to Figure 31. Only 
very few intervals (26 out of 1584, or 1.6%) are within the (-1,1) SD interval. Intervals are only inside 
the (-1,1) SD interval for those endpoints which are measured in all 8 cages per feeding group, and 
for which the difference on the log-scale is almost zero. Examples of endpoints for males in Figure 23 
which are (just) inside the SD limits are uVol when comparing NK11-/50 versus Con50, and HGB, ALT 
and upH when comparing NK50- versus Con50. 
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Figure 23 Confidence intervals for Standardized Effect Sized (SES) for male rats for GMO feeds 
NK11-/50 and NK50- versus the non-GM control feed Con50. 
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Figure 24 Confidence intervals for Standardized Effect Sized (SES) for male rats for GMO feeds 
NK11+/50 and NK50+ versus the non-GM control feed Con50. 
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Figure 25 Confidence intervals for Standardized Effect Sized (SES) for male rats for GMO feeds 
NK50- versus NK33- and for NK50+ versus NK33+. 
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Figure 26 Confidence intervals for Standardized Effect Sized (SES) for male rats for GMO feeds 
NK33- and NK33+ versus the non-GM control feed Con33. 
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Figure 27 Confidence intervals for Standardized Effect Sized (SES) for female rats for GMO feeds 
NK11-/50 and NK50- versus the non-GM control feed Con50. 
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Figure 28 Confidence intervals for Standardized Effect Sized (SES) for female rats for GMO feeds 
NK11+/50 and NK50+ versus the non-GM control feed Con50. 
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Figure 29 Confidence intervals for Standardized Effect Sized (SES) for female rats for GMO feeds 
NK50- versus NK33- and for NK50+ versus NK33+. 
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Figure 30 Confidence intervals for Standardized Effect Sized (SES) for female rats for GMO feeds 
NK33- and NK33+ versus the non-GM control feed Con33. 
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Figure 31 Confidence intervals for Standardized Effect Sized (SES) for male and female rats for the 
non-GM control feed Con50 versus the non-GM control feed Con33. 
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4.5 Factorial analysis 
4.5.1 Method 
The treatment structure of Study C can be considered as a 2 × 3 factorial with additional treatments 
NK11-/50 and NK11+/50 as in Table 19. 
Table 19  Diets organized as a 2 × 3 factorial with treatments MaizeRate with 2 levels (33% and 
50%) and MaizeType with three levels (Control, NK- and NK+), with additional 
treatments NK11-/50 and NK11+/50. 
MaizeRate / MaizeType Control NK- NK+ Additional treatments 
33% Maize Con33 NK33- NK33+ - - 
50% Maize Con50 NK50- NK50+ NK11-/50 NK11+/50 
 
The factorial setup enables testing whether there is a significant interaction between MaizeRate and 
MaizeType, and , if not, whether there are significant main effects for MaizeRate and MaizeType. Of 
special interest is the main MaizeRate effect because this study was specifically setup to see whether 
an inclusion rate of 50% is different from an inclusion rate of 33%. The main effect MaizeType has 
two degrees of freedom which can be split up in one degree of freedom for the difference between 
NK- and NK+ (this comparison will be called MaizeType.RoundUp), and one degree of freedom for 
the difference between the mean of NK- and NK+ and the control feed (which will be called 
MaizeType.GM). The latter comparison is only relevant when the first comparison is not significant. 
Similarly, the interaction between MaizeRate and MaizeType can be split up in the same way. This 
gives rise to the independent contrasts for the 2 × 3 factorial part in Table 20. 
Table 20  Contrasts for the 2 × 3 factorial defined in Table 19. 
Contrast (abbreviation in Results tables) Con50 NK50- NK50+ Con33 NK33- NK33+ 
MaizeRate (Rate) 1 1 1 -1 -1 -1 
MaizeType.GM (Type1) 2 -1 -1 2 -1 -1 
MaizeType.RoundUp (Type2) 0 -1 1 0 -1 1 
MaizeRate.MaizeType.GM (Int1) 2 -1 -1 -2 1 1 
MaizeRate.MaizeType.RoundUp (Int2) 0 -1 1 0 1 -1 
 
The following sequence of testing is followed: 
1. In case MaizeRate.MaizeType.RoundUp is significant the ratio of NK50+ versus NK50- is 
significantly different from the ratio of NK33+ versus NK33-, and therefore both ratios, 
denoted as 50.RoundUp and 33.RoundUp, are reported. Results for all other comparisons are 
not reported. 
2. In case the MaizeRate.MaizeType.RoundUp is not significant, then the ratios 50.RoundUp 
and 33.RoundUp are set to missing. Furthermore 
a. if also MaizeRate.MaizeType.GM is significant, then the ratio of the mean of NK50- 
and NK50+ versus Con50 is reported, as well as the ratio of the mean of NK33- and 
NK33+ versus Con30. These are denoted as 50.GM and 30.GM. Results for the ratios 
MaizeRate and MaizeType.GM are set to missing. 
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b. if also MaizeType.RoundUp is significant the ratio NK+ versus NK- is reported, where 
NK+ is the mean of NK50+ and NK33+, and similarly NK-. Results for the ratio 
MaizeType.GM are set to missing. 
3.  In case both interactions MaizeRate.MaizeType.RoundUp and MaizeRate.MaizeType.GM are 
not significant, the main effect MaizeRate is reported whenever it is significant. Moreover 
MaizeType.RoundUp is reported (as in 2b) whenever it is significant, and MaizeType.GM is 
reported when it is significant and MaizeType.RoundUp is not significant. 
Due to missing values and unbalance for the endpoints in the Immunology and CellPhenotype group, 
the contrast given in Table 20 are not independent and therefore this factorial approach is not 
followed for those endpoints.  
4.5.2 Results 
P-values for testing the five contrasts are given in Table 21, while significant effects according to the 
testing sequence are given in Table 22 
Table 21  P values for significance of contrasts obtained for the factorial model. Type1 / Type2 
denote contrasts  MaizeType.GM / MaizeType.RoundUp, while Int1 / Int2 denote the 
interaction contrasts MaizeRate.MaizeType.GM / MaizeRate.MaizeType.RoundUp. 
P-values smaller than 0.01/0.05 have a gold/yellow background. 
Variable Males Females 
Weights Rate Type1 Type2 Int1 Int2 Rate Type1 Type2 Int1 Int2 
BodyWeight 0.277 0.328 0.371 0.147 0.380 0.140 0.825 0.452 0.607 0.854 
growthRate 0.467 0.225 0.296 0.764 0.126 0.638 0.472 0.788 0.117 0.127 
FeedMean 0.083 0.323 0.057 0.318 0.670 0.238 0.563 0.775 0.378 0.246 
Variable Males Females 
Haematology Rate Type1 Type2 Int1 Int2 Rate Type1 Type2 Int1 Int2 
WBC 0.807 0.509 0.817 0.486 0.955 0.821 0.861 0.475 0.980 0.813 
RBC 0.030 0.945 0.243 0.127 0.232 0.720 0.050 0.673 0.827 0.121 
HGB 0.214 0.934 0.952 0.459 0.149 0.447 0.748 0.728 0.951 0.244 
HCT 0.265 0.964 0.680 0.591 0.373 0.874 0.524 0.689 0.948 0.389 
MCV 0.128 0.873 0.306 0.182 0.010 0.411 0.044 0.191 0.811 0.295 
MCH 0.411 0.890 0.220 0.029 0.013 0.456 0.113 0.389 0.892 0.266 
MCHC 0.735 0.953 0.468 0.051 0.261 0.746 0.890 0.765 0.699 0.644 
PLT 0.693 0.013 0.309 0.253 0.169 0.111 0.479 0.094 0.203 0.360 
LYMR 0.724 0.293 0.008 0.362 0.027 0.346 0.732 0.634 0.853 0.657 
LYMA 0.513 0.163 0.380 0.646 0.576 1.000 0.949 0.424 0.988 0.765 
Variable Males Females 
ClinChem Rate Type1 Type2 Int1 Int2 Rate Type1 Type2 Int1 Int2 
ALP 0.360 0.586 0.252 0.907 0.699 0.976 0.738 0.482 0.950 0.107 
ALT 0.687 0.703 0.306 0.686 0.773 0.166 0.287 0.184 0.153 0.185 
AST 0.585 0.902 0.554 0.540 0.901 0.694 0.835 0.795 0.465 0.249 
BIL 0.508 0.277 0.402 0.519 0.673 0.271 0.168 0.391 0.760 0.699 
ALB 0.610 0.474 0.891 0.324 0.981 0.035 0.616 0.016 0.237 0.628 
TP 0.138 0.452 0.640 0.036 0.962 0.081 0.601 0.058 0.807 0.942 
Glu 0.202 0.027 0.487 0.857 0.790 0.425 0.740 0.821 0.579 0.388 
CHOL 0.131 0.658 0.799 0.204 0.957 0.003 0.261 0.011 0.423 0.975 
TAG 0.625 0.128 0.535 0.668 0.460 0.021 0.157 0.164 0.350 0.701 
Crea 0.566 0.479 0.257 0.222 0.952 0.989 0.864 0.528 0.406 0.022 
Urea 0.035 0.109 0.088 0.559 0.367 0.535 0.342 0.887 0.155 0.940 
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cHGB 0.977 0.397 0.114 0.055 0.548 0.512 0.675 0.381 0.919 0.621 
Ca 0.967 0.599 0.552 0.804 0.702 0.658 0.311 0.000 0.629 0.243 
Cl 0.826 0.621 0.261 0.311 0.024 0.026 0.556 0.187 0.096 0.608 
K 0.618 0.691 0.472 0.215 0.914 0.593 0.759 0.734 0.313 0.936 
Na 0.589 0.781 0.982 0.735 0.013 0.965 0.592 0.085 0.441 0.727 
P 0.009 0.631 0.790 0.808 0.759 0.204 0.095 0.751 0.307 0.987 
Variable Males Females 
Urine Rate Type1 Type2 Int1 Int2 Rate Type1 Type2 Int1 Int2 
uVol 0.064 0.406 0.512 0.863 0.933 0.756 0.186 0.915 0.016 0.125 
uVolW 0.089 0.302 0.387 0.643 0.901 0.961 0.202 0.972 0.024 0.181 
uLeu 0.128 0.177 0.348 0.279 0.638 0.279 0.443 0.878 0.108 0.733 
uOsmoll 0.163 0.572 0.245 0.357 0.780 0.943 0.290 0.549 0.055 0.224 
uKeton 0.836 0.437 0.463 0.201 0.358 0.166 1.000 0.256 1.000 0.883 
upH 0.011 0.766 1.000 0.458 0.076 0.010 0.080 0.627 0.305 0.419 
Variable Males Females 
Organs Rate Type1 Type2 Int1 Int2 Rate Type1 Type2 Int1 Int2 
Kidney 0.637 0.219 0.038 0.817 0.132 0.080 0.133 0.224 0.299 0.602 
Spleen 0.849 0.536 0.943 0.525 0.872 0.157 0.200 0.167 0.374 0.627 
Liver 0.756 0.799 0.495 0.057 0.438 0.531 0.907 0.010 0.793 0.453 
AdrenGl 0.432 0.843 0.871 0.736 0.817 0.766 0.946 0.900 0.245 0.327 
Heart 0.681 0.788 0.127 0.168 0.034 0.127 0.866 0.805 0.018 0.474 
Thymus 0.309 0.423 0.651 0.558 0.087 0.614 0.216 0.613 0.897 0.394 
Testis 0.715 0.479 0.282 0.022 0.691 - - - - - 
Epididymis 0.747 0.574 0.856 0.086 0.292 - - - - - 
Uterus - - - - - 0.955 0.576 0.623 0.950 0.878 
Ovary - - - - - 0.015 0.837 0.024 0.028 0.147 
Brain 0.474 0.326 0.258 0.248 0.203 0.021 0.301 0.814 0.566 0.829 
 
Table 22 Ratios for significant contrasts for males and females according to the testing sequence 
for the factorial model (see text). 
Male Interaction effects Main effects 
Variable 50.Roundup 33.Roundup 50.GM 33.GM Roundup GM Rate 
RBC - - - - - - 0.99 
MCV 1.01 0.98 - - - - - 
MCH 1.01 0.97 - - - - - 
PLT - - - - - 1.10 - 
LYMR 0.99 0.94 - - - - - 
TP - - 1.02 0.99 - - - 
Glu - - - - - 0.92 - 
Urea - - - - - - 0.94 
Cl 0.98 1.01 - - - - - 
Na 0.99 1.01 - - - - - 
P - - - - - - 0.91 
upH - - - - - - 0.77 
Kidney - - - - 1.05 - - 
Heart 0.99 1.08 - - - - - 
Testis - - 1.06 0.97 - - - 
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Female Interaction effects Main effects 
Variable 50.Roundup 33.Roundup 50.GM 33.GM Roundup GM Rate 
MCV - - - - - 0.99 - 
ALB - - - - 0.96 - 0.97 
CHOL - - - - 0.84 - 0.85 
TAG - - - - - - 0.87 
Crea 0.90 1.06 - - - - - 
Ca - - - - 0.97 - - 
Cl - - - - - - 1.01 
uVol - - 0.91 1.37 - - - 
uVolW - - 0.91 1.39 - - - 
upH - - - - - - 0.81 
Liver - - - - 0.95 - - 
Heart - - 1.05 0.96 - - - 
Ovary - - 1.07 0.92 1.09 - - 
Brain - - - - - - 1.04 
 
4.6 Correlation analysis 
4.6.1 Method 
For single variables the difference between two feeding groups is quantified by the ratio of the 
responses. These can then be compared to given limits (as in Figure 20 and Figure 21) or to limits 
calculated from historical data (as in Figure 10 - Figure 18), or rescaled, as in Figure 6 -Figure 9). 
For a toxicological interpretation it may be helpful to see results for variables that simultaneously 
relate to the same pathological endpoint. Bivariate plots were prepared showing the patterns for 
each pair for three variables related to liver disorder (relative liver weight, ALP, CHOL) and three 
variables related to kidney disorder (relative kidney weight, Urea, Crea). The eight points in each 
graph are based on the cage means in the eight blocks of the study. 
For comparison, the proposed target effect sizes of Hong et al (2017), see Table 15, are included in 
the plots as horizontal and vertical lines (together with lines at ratio 1 for reference). It can be noted 
that similar plots could have been made using the equivalence limit scaled differences (ELSDs) as 
presented in Figure 6 - Figure 9. 
4.6.2 Results 
The correlation plots for three liver-related and three kidney-related variables in males and females 
are shown in Figure 32 - Figure 39. In most cases there appears to be no clear correlation with liver or 
kidney weights. The following four correlation are significant: (1) A significant positive correlation for 
liver weight versus CHOL for NK33+ versus Con33 in males (corr = 0.74, p-value = 0.03, Figure 33); 
(2) A significant negative correlation between liver weight and CHOL for NK50+ versus Con50 in 
females (corr=-0.81, p-value=0.01, Figure 36); (3) A significant positive correlation for kidney weight 
versus Urea for NK50+ versus NK33+ in females (corr = 0.77, p-value = 0.02, Figure 39). In this case 
there are also significant correlations between Kidney and Crea, and between Urea and Crea; 
(4) A significant negative correlation for kidney weight versus Crea for NK33- versus Con33 in females 
(corr = 0.-71, p-value = 0.05, Figure 39).  
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Figure 32 Pairwise results for variables with set target effect sizes related to liver damage in 
males. Points represent the ratio of the cage means for the comparison given at the top 
of each column. Horizontal and vertical lines represent a ratio of 1 and the target effect 
sizes from Hong et al (2017). 
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Figure 33 Pairwise results for variables with set target effect sizes related to liver damage in 
males. Points represent the ratio of the cage means for the comparison given at the top 
of each column. Horizontal and vertical lines represent a ratio of 1 and the target effect 
sizes from Hong et al (2017). 
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Figure 34 Pairwise results for variables with set target effect sizes related to kidney damage in 
males. Points represent the ratio of the cage means for the comparison given at the top 
of each column. Horizontal and vertical lines represent a ratio of 1 and the target effect 
sizes from Hong et al (2017). 
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Figure 35 Pairwise results for variables with set target effect sizes related to kidney damage in 
males. Points represent the ratio of the cage means for the comparison given at the top 
of each column. Horizontal and vertical lines represent a ratio of 1 and the target effect 
sizes from Hong et al (2017). 
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Figure 36 Pairwise results for variables with set target effect sizes related to liver damage in 
females. Points represent the ratio of the cage means for the comparison given at the 
top of each column. Horizontal and vertical lines represent a ratio of 1 and the target 
effect sizes from Hong et al (2017). 
  
G-TwYST Study C  Statistical report 
82 
 
 
Figure 37 Pairwise results for variables with set target effect sizes related to liver damage in 
females. Points represent the ratio of the cage means for the comparison given at the 
top of each column. Horizontal and vertical lines represent a ratio of 1 and the target 
effect sizes from Hong et al (2017). 
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Figure 38 Pairwise results for variables with set target effect sizes related to kidney damage in 
females. Points represent the ratio of the cage means for the comparison given at the 
top of each column. Horizontal and vertical lines represent a ratio of 1 and the target 
effect sizes from Hong et al (2017). 
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Figure 39 Pairwise results for variables with set target effect sizes related to kidney damage in 
females. Points represent the ratio of the cage means for the comparison given at the 
top of each column. Horizontal and vertical lines represent a ratio of 1 and the target 
effect sizes from Hong et al (2017). 
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4.7 Post-hoc power analysis comparing the 33% and 50% inclusion rates 
One of the main question of this study was whether a trial with 50% maize inclusion rate has a larger 
power for finding differences between GM feeds and the corresponding non-GM feed, than a trial 
with 33% maize inclusion rate. Given the design of the experiment and the number of replications, 
the power of any trial is dependent on (1) the difference that is relevant, and (2) the residual 
standard error.  
With respect to the difference, when there would indeed be a difference between the GM and non-
GM feeding groups, higher inclusion rates might give rise to larger differences between groups. In 
Figure 40 the ratio of the mean of the two NK50 feeds (i.e. NK50- and NK50+) and the Con50 feed is 
expressed as a percentage of the ratio of the mean of the two NK33 feeds (i.e. NK33- and NK33+) and 
the Con30 feed, using the ratios in Table 11 to Table 14. For endpoints with a significant difference 
between the NK50 feeds or between the NK33 feeds, the mean of the NK50 feeds or the mean of the 
NK33 feeds might be uninformative, and therefore such ratios are denoted by a red circle. In general 
the observed effect for the NK50 feeds is similar to the observed effect for the NK33 feeds with 
notable exceptions for variables in the Urine, Immunology and CellPhenotype groups.   
in Figure 41 the residual standard error of an ANOVA on the five 50% feeds only is compared to the 
residual standard error of an ANOVA on the three 33% feeds only. This reveals that the residual 
standard error for the 50% feeds is larger for almost all Immunology variables and also for the 
CellPhenotype variables in females. For the other categories the pattern is somewhat mixed, 
although all-in-all the residual standard error for the 50% feeds seems somewhat larger than for the 
33% feeds.  
Since the power of a statistical test depends on the ratio of the true difference and the residual 
standard error, the ratio of the values in Figure 40 (which displays the differences) and the values in 
Figure 41 (which displays the residual standard error) is displayed in Figure 42. Positive values would 
then imply a larger power of the statistical test for the 50% feeds as compared to the 33% feeds, and 
negative values would indicate smaller power. Again the pattern of positive and negative values is 
mixed and can be different for males and females (see e.g. the CellPhenotype variables). Only for the 
Immunology variables it is clear that a trial with 50% feeds will have lower power than a trial with 
33% feeds.  
Conclusion: There is no evidence that a trial with 50% maize inclusion rates has generally larger 
power, as compared to a trial with 33% inclusion rates, in finding differences between a GM feed and 
a control non-GM feed. For the Immunology endpoints the power of a 50% trial is likely to be lower 
due to the increased residual standard error. 
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Figure 40 Observed ratio between NK50 feeds and the Con50 feed compared to the ratio between 
NK33 feeds and the Con33 feed. The red dots are for endpoints with a significant 
difference between NK50+ and NK50- and/or between NK33+ and NK33-.  
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Figure 41 Residual standard error of an ANOVA for the five 50% feeds compared to the residual 
standard error of an ANOVA for the three 33% feeds. 
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Figure 42 Observed ratio divided by the residual standard error for the 50% feeds as compared to 
the observed ratio divided by the residual standard error for the 33% feeds. 
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5 Summary and discussion 
In this report the data from G-TwYST study C have been analysed following six approaches. For 
comparisons between a GM feeding group and the control feed, or between the two control groups 
with 33% or 50% maize inclusion rate, for a single variable, these approaches were two forms of 
equivalence analysis (4.1, 4.2), the traditional approach focusing on significant differences (4.3), and 
the standardised effect size (SES) approach (4.4). In addition, a factorial analysis (0) and a correlation 
analysis (4.6) allowed some limited forms of integration over dose groups or variables, respectively. 
Among the two forms of equivalence analysis, the approach with given external equivalence limits 
(4.2) is the most simple one. It could be preferred if toxicologists were able to set external 
equivalence limits for all relevant variables based on their expert knowledge. In the current report it 
was applied to nine variables, for which Hong et al (2017) recently proposed targeted effect sizes. 
Obviously, the uncertainty in setting these targeted effect sizes is not accounted for in the 
equivalence analysis using these fixed limits. 
However, external equivalence limits are often not available, and toxicologists notice many 
uncertainties about the impact of toxicological effects. Moreover, they find it often difficult to come 
to a conclusion on such equivalence limits. For such cases, the equivalence analysis which bases 
equivalence on historical non-GM data (4.1) may be an attractive alternative. This approach assumes 
that test facilities perform whole-food studies with rodents on a routine basis, such that variations 
between non-GM foods and between experimental units which are seen in historical studies have a 
relevance for the current study. In the current report, the approach could be applied to 36 variables, 
which were also observed in five preceding studies in the same test facility in the GRACE project. Van 
der Voet et al (2017) discusses this new method which was developed in the G-TwYST project. 
Given tentative settings for regulatory parameters, equivalence was established in 100% of cases 
(162/162) for the approach with external equivalence limits and for 99% of cases (643/648) for the 
approach based on the historical GRACE data. The regulatory parameters are the testing level (set at 
5%) for all approaches, and two parameters for the new G-TwYST equivalence approach: the desired 
power (set at 95%) and the minimum sample size per group (set at 8 experimental units). Note that 
test results could be different if these parameters were chosen differently. 
In the five cases where equivalence was not established by means of the statistical test, the median 
estimate was still in the equivalence region. Therefore, in the terminology of EFSA (2011a), these 
cases are still classified as ‘equivalence more likely than lack of equivalence’.  
As noted by EFSA (2011b), separate analysis of many endpoints, most of which are not expected to 
differ between treatment groups, results in a large number of statistical tests. This will lead to the 
issue of multiple testing (multiplicity). The proportion of non-significant equivalence tests (0% or 1%) 
was lower than the nominal level of the tests (which was set at 5%). In this report, we have not tried 
to adapt equivalence tests for multiplicity. However, it should be pointed out that a recently 
proposed approach to adjusting for multiplicity based on the False Discovery Rate (FDR) is not 
appropriate. Hong et al (2017) used adjusted p values using the FDR method for multiplicity 
adjustment. This means that effectively most p values are much larger (indicating less significant 
differences) than in a standard unadjusted analysis. This may explain why they report that ‘no 
treatment-related differences were observed’, although there were some 150 continuous endpoints 
in total. This complete absence of statistically significant differences is very much at odds with what 
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is commonly found (e.g. in the GRACE, G-TwYST, and GMO90+ studies). Indeed, the absence of 
significant differences in Hong et al (2017) could be a direct consequence of using the FDR 
adjustment. It is doubtful whether the use of the FDR-correction makes sense in food safety testing 
(EFSA 2010). It controls false discoveries, and is therefore connected to difference testing, where 
false positives are considered as error of the first kind. i.e. one wants to have a small probability of 
erroneously reporting a difference. In the context of equivalence testing the statistical hypotheses 
are reversed, and false negatives are the error of the first kind, i.e. one wants to have a small 
probability of erroneously reporting equivalence. Consequently, the FDR concept is addressing the 
wrong type of error. 
Classical analysis following OECD guidance is only focusing on finding differences, not equivalences. If 
performed using t-tests after applying an ANOVA model, there were 90 significant differences at the 
5% significance level. This is 6% of the total number of comparisons (1584), and slightly higher than 
the nominal 5% level that could be expected. The scheme advocated by OECD contains several 
adaptations. First, a multiplicity correction by using Dunnett’s test rather than the straight-forward 
t-test is proposed for the fact that four groups are compared at the same time to the control group. 
Thus, applying Dunnett’s test the number of significant cases at the 5% significance level was 
reduced to 17 (1% of all comparisons, i.e. similar to the nominal error level). However, a multiplicity 
correction may be wrong for the same reason why the FDR method was wrong: if we are primarily 
interested in safety and equivalence, then the roles of the statistical hypotheses are reversed, and 
corrections as used in Dunnett’s test address the wrong type of error. 
OECD (2012) also proposes non-parametric tests in case of non-normality or heterogeneity of 
variance. For the current set of variables (176, i.e. 88 for males and 88 for females) 18 variables 
(10%) showed non-normality of ANOVA residuals in a Shapiro-Wilks test at the 5% level, while in a 
Shapiro-Wilks test at the 1% level 10 variables were significant (Appendix 13). 23 variables (13%) 
showed variance heterogeneity in a Bartlett’s or Levene’s test at the 5% level. Among all 1584 
comparisons the non-parametric Wilcoxon’s test resulted in 45 significant differences (3%); note that 
this tests also requires homogeneity of variance. Despite these findings, i.e. non-normality or 
variance heterogeneity, the normal probability plots (Appendix 5) and the plots of residuals versus 
fitted values (Appendix 6) were generally satisfactory. This suggests that parametric t-tests and 
Dunnett tests can safely be applied. 
In this report confidence intervals were also expressed and plotted as Standardised Effect Size (SES), 
see EFSA (2011b), in order to allow a comparison with SES results for the preceding GRACE project 
(Schmidt and Schmidtke 2014, Schmidt et al 2015ab, 2016, 2017, Zeljenková et al 2014, 2016). SES, 
also known as Cohen’s 𝑑𝑑, is often used in meta-analyses to show the results of different variables in 
the same plot. Reporting and graphically displaying effect sizes was described in Schmidt et al (2016) 
as a way ‘to avoid the yes/no decision trap of statistical tests and to illustrate the size of effects in the 
context of biological relevance’. However, in the absence of clear limit values for biological relevance, 
these authors had to build on the arbitrary EFSA example, where effects of ±1 SD were assumed to 
be unlikely to be of toxicological importance. Schmidt et al (2016) already concluded that the pooled 
standard deviation SD of individual measurements ‘is a priori not expected to be directly related to 
biological relevance’, and Schmidt et al (2017) warned that ‘it should therefore be kept in mind that 
future decisions on relevant equivalence limits may influence the equivalence results’. The results of 
the current G-TwYST study, where 98% of all intervals extended outside the ±1 SD limits, confirms 
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the pattern observed in GRACE and in G-TwYST studies A and B. Whereas, displaying the confidence 
intervals indeed gives a richer view on the results than just reporting yes/no decisions, the scale of 
the SES plots does not seem the best choice for equivalence assessments. As Hong et al (2017) 
remark, the value of SES to support data interpretation is limited. Alternatively scaled effect sizes, 
such as those presented in section 4.1 (Figure 6 - Figure 9) can be preferred, because the scaling 
factor (the equivalence limit) is based on data analysis of in this case historical data, rather than 
being an arbitrary value. It can be noted, however, that this approach was not available for the 
GRACE project, because of lack of historical data in the same test facility. 
Factorial analyses for single variables allowed to consider effects pooled over more than two groups, 
thus providing more powerful tests for main effects in the absence of interaction. However, this 
approach was in the current work restricted to the testing of differences. In principle, it could be 
further developed for the equivalence tests. 
Most statistical analyses in this report have considered variables one by one, collecting the results 
only in a joint table or plot for ease of interpretation. However, toxicologists often stress that effects 
should be judged together. Wherever a prior hypothesis exists that links multiple variables, these 
may sometimes be translated in a function of those variables. For example, there is a biological 
connection between the pancreas and the regulation of glucose, which leads to a prior expectation 
of a negative correlation between pancreas weight and serum glucose. It may then be sensible to 
perform difference and equivalence testing for an additional variable such as the ratio or log-ratio of 
these variables. Such ratios have not been defined in the current study. 
Another tool to study variables together is pairwise plotting of results per experimental unit. In 
section 4.6 (Figure 32 - Figure 39) this was done for three variables related to liver damage and three 
variables related to kidney damage. The rationale was that correlations between variables would 
show up in these plots, but this was hardly observed in these cases. To assist in the interpretation, 
the effects were plotted together with proposed target effect sizes. Most effects were below these 
limits also at the cage level (as was already observed for the means in section 4.2). We may conclude 
that correlations between these variables related to the same organ are nevertheless not prominent 
as long as the effects are within the targeted range. Of course, correlations could be (and are 
expected to be) more evident for effect sizes that would exceed the limits by large amounts. 
A more detailed approach to testing than reported here would also be possible based on a more 
detailed consultation with toxicologists. For example, nephrotoxic effects can lead to decreased or 
increased kidney weights. However, in both of these cases, the toxicologists would expect to see 
increased urea (Urea) and/or creatinine (Crea) levels. In addition, there might be a decreased level of 
glucose in the urine (Glu) or an increased level of amino acids, but these effects are less predictable. 
Increases in Urea or Crea may indicate nephrotoxic effects that are not yet discernible as deviating 
kidney weights. It is concluded that increased Urea and/or Crea levels are the primary indicators of 
kidney damage, and only increased levels represent a toxicological concern. Considering observed 
normal ranges, an increase by 50% in at least one of the two key variables could be seen as 
potentially concerning, and provide a level to be used as equivalence limit. Specific hypotheses to be 
tested for the differences Δ (on the log scale) between the treatment groups (GM vs. comparator) 
would then be as follows. 
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Difference tests:  
 𝐻𝐻0:   𝐸𝐸(Δ𝑈𝑈𝑈𝑈𝑊𝑊𝑎𝑎) = 0 vs. 𝐻𝐻1:   𝐸𝐸(Δ𝑈𝑈𝑈𝑈𝑊𝑊𝑎𝑎) > 0 
 𝐻𝐻0:   𝐸𝐸(Δ𝐶𝐶𝑈𝑈𝑊𝑊𝑎𝑎) = 0 vs. 𝐻𝐻1:   𝐸𝐸(Δ𝐶𝐶𝑈𝑈𝑊𝑊𝑎𝑎) > 0 
Equivalence tests:  
 𝐻𝐻0:   𝐸𝐸(Δ𝑈𝑈𝑈𝑈𝑊𝑊𝑎𝑎) = 𝐸𝐸𝐿𝐿𝑈𝑈𝑈𝑈𝑊𝑊𝑎𝑎 vs 𝐻𝐻1:   𝐸𝐸(Δ𝑈𝑈𝑈𝑈𝑊𝑊𝑎𝑎) < 𝐸𝐸𝐿𝐿𝑈𝑈𝑈𝑈𝑊𝑊𝑎𝑎 
 𝐻𝐻0:   𝐸𝐸(Δ𝐶𝐶𝑈𝑈𝑊𝑊𝑎𝑎) = 𝐸𝐸𝐿𝐿𝐶𝐶𝑈𝑈𝑊𝑊𝑎𝑎 vs. 𝐻𝐻1:   𝐸𝐸(Δ𝐶𝐶𝑈𝑈𝑊𝑊𝑎𝑎) < 𝐸𝐸𝐿𝐿𝐶𝐶𝑈𝑈𝑊𝑊𝑎𝑎 
where 𝐸𝐸𝐿𝐿𝑈𝑈𝑈𝑈𝑊𝑊𝑎𝑎 =  𝐸𝐸𝐿𝐿𝐶𝐶𝑈𝑈𝑊𝑊𝑎𝑎 = log (1.5). 
In cases when a difference is found or an equivalence cannot be shown, the other variables (kidney 
weight, Glu, amino acids) may provide further interpretation to the toxicologist. These variables are 
therefore considered as secondary: the results can be summarised in terms of absolute values and 
confidence intervals for Δ (also shown graphically), but they would not be part of the testing 
framework based on primary variables. However, fine-tuning of statistical analyses as suggested here 
demands a large investment of time from both toxicologists and statisticians, and it will be very 
difficult to perform such exercises across the whole spectrum of endpoints. 
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outlier test at the 1% level applied to the residuals; these values were not considered to 
be outliers (the values with a white background in Table 8). 
Figure 6 Equivalence testing of GM 50% maize feeds versus the corresponding non-GM control 
50% maize feed for males. For estimates on the left of zero the 50% feed has a smaller 
mean than the corresponding control feed. Also see Table 11 / Figure 10 / Figure 11. 
Figure 7 EQ testing of 50% maize feeds versus the corresponding 33% feeds for males, and for the 
GM 33% feeds versus the non-GM 33% feed. For estimates on the left of zero the 50% 
feed has a smaller mean than the 33% feed. Also see Table 12 / Figure 18 / Figure 12 / 
Figure 13. 
Figure 8 Equivalence testing of GM 50% maize feeds versus the corresponding non-GM control 
50% maize feed for females. For estimates on the left of zero the 50% feed has a smaller 
mean than the corresponding control feed. Also see Table 13 / Figure 14 / Figure 15. 
Figure 9 EQ testing of 50% maize feeds versus the corresponding 33% feeds for females, and for 
the GM 33% feeds versus the non-GM 33% feed. For estimates on the left of zero the 50% 
feed has a smaller mean than the 33% feed. Also see Table 14 / Figure 18 / Figure 16 / 
Figure 17. 
Figure 10 Confidence intervals for the ratio of NK11-/50 and NK50- vs the Con50 feed for males with 
intervals for equivalence limits (see text). 
Figure 11 Confidence intervals for the ratio of NK11+/50 and NK50+ vs the Con50 feed for males 
with intervals for equivalence limits (see text). 
Figure 12 Confidence intervals for the ratio of NK50- and NK50+ vs the corresponding 33% feed for 
males with intervals for equivalence limits (see text). 
Figure 13 Confidence intervals for the ratio of NK33- and NK33+ vs the Con33 feed for males with 
intervals for equivalence limits (see text). 
Figure 14 Confidence intervals for the ratio of NK11-/50 and NK50- vs the Con50 feed for females 
with intervals for equivalence limits (see text). 
Figure 15 Confidence intervals for the ratio of NK11+/50 and NK50+ vs the Con50 feed for females 
with intervals for equivalence limits (see text). 
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Figure 16 Confidence intervals for the ratio of NK50- and NK50+ vs corresponding 33% feed for 
females with intervals for equivalence limits (see text). 
Figure 17 Confidence intervals for the ratio of NK33- and NK33+ vs the Con33 feed for females with 
intervals for equivalence limits (see text). 
Figure 18 Confidence intervals for the ratio of the two control feeds for males and females with 
intervals for the equivalence limits (see text). 
Figure 19 Residual variance (sig2F or σF2) in the current G-TwYST B study as a percentage of the 
residual variance (sig2E or σE2) in the historical GRACE studies for males (top panel) and 
females (bottom panel). 
Figure 20 90% confidence intervals for the ratio of two means for selected variables for males along 
with equivalence intervals defined by targeted effect sizes of Hong et al (2017). 
Figure 21 90% confidence intervals for the ratio of two means for selected variables for females 
along with equivalence intervals defined by targeted effect sizes of Hong et al (2017). 
Figure 22 Classical approach to statistical analysis of data in long-term toxicity studies (copied from 
OECD 2012). 
Figure 23 Confidence intervals for Standardized Effect Sized (SES) for male rats for GMO feeds 
NK11-/50 and NK50- versus the non-GM control feed Con50. 
Figure 24 Confidence intervals for Standardized Effect Sized (SES) for male rats for GMO feeds 
NK11+/50 and NK50+ versus the non-GM control feed Con50. 
Figure 25 Confidence intervals for Standardized Effect Sized (SES) for male rats for GMO feeds 
NK50- versus NK33- and for NK50+ versus NK33+. 
Figure 26 Confidence intervals for Standardized Effect Sized (SES) for male rats for GMO feeds 
NK33- and NK33+ versus the non-GM control feed Con33. 
Figure 27 Confidence intervals for Standardized Effect Sized (SES) for female rats for GMO feeds 
NK11-/50 and NK50- versus the non-GM control feed Con50. 
Figure 28 Confidence intervals for Standardized Effect Sized (SES) for female rats for GMO feeds 
NK11+/50 and NK50+ versus the non-GM control feed Con50. 
Figure 29 Confidence intervals for Standardized Effect Sized (SES) for female rats for GMO feeds 
NK50- versus NK33- and for NK50+ versus NK33+. 
Figure 30 Confidence intervals for Standardized Effect Sized (SES) for female rats for GMO feeds 
NK33- and NK33+ versus the non-GM control feed Con33. 
Figure 31 Confidence intervals for Standardized Effect Sized (SES) for male and female rats for the 
non-GM control feed Con50 versus the non-GM control feed Con33. 
Figure 32 Pairwise results for variables with set target effect sizes related to liver damage in males. 
Points represent the ratio of the cage means for the comparison given at the top of each 
column. Horizontal and vertical lines represent a ratio of 1 and the target effect sizes from 
Hong et al (2017). 
Figure 33 Pairwise results for variables with set target effect sizes related to liver damage in males. 
Points represent the ratio of the cage means for the comparison given at the top of each 
column. Horizontal and vertical lines represent a ratio of 1 and the target effect sizes from 
Hong et al (2017). 
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Figure 34 Pairwise results for variables with set target effect sizes related to kidney damage in 
males. Points represent the ratio of the cage means for the comparison given at the top of 
each column. Horizontal and vertical lines represent a ratio of 1 and the target effect sizes 
from Hong et al (2017). 
Figure 35 Pairwise results for variables with set target effect sizes related to kidney damage in 
males. Points represent the ratio of the cage means for the comparison given at the top of 
each column. Horizontal and vertical lines represent a ratio of 1 and the target effect sizes 
from Hong et al (2017). 
Figure 36 Pairwise results for variables with set target effect sizes related to liver damage in 
females. Points represent the ratio of the cage means for the comparison given at the top 
of each column. Horizontal and vertical lines represent a ratio of 1 and the target effect 
sizes from Hong et al (2017). 
Figure 37 Pairwise results for variables with set target effect sizes related to liver damage in 
females. Points represent the ratio of the cage means for the comparison given at the top 
of each column. Horizontal and vertical lines represent a ratio of 1 and the target effect 
sizes from Hong et al (2017). 
Figure 38 Pairwise results for variables with set target effect sizes related to kidney damage in 
females. Points represent the ratio of the cage means for the comparison given at the top 
of each column. Horizontal and vertical lines represent a ratio of 1 and the target effect 
sizes from Hong et al (2017). 
Figure 39 Pairwise results for variables with set target effect sizes related to kidney damage in 
females. Points represent the ratio of the cage means for the comparison given at the top 
of each column. Horizontal and vertical lines represent a ratio of 1 and the target effect 
sizes from Hong et al (2017). 
Figure 40 Observed ratio between NK50 feeds and the Con50 feed compared to the ratio between 
NK33 feeds and the Con33 feed. The red dots are for endpoints with a significant 
difference between NK50+ and NK50- and/or between NK33+ and NK33-. 
Figure 41 Residual standard error of an ANOVA for the five 50% feeds compared to the residual 
standard error of an ANOVA for the three 33% feeds. 
Figure 42 Observed ratio divided by the residual standard error for the 50% feeds as compared to 
the observed ratio divided by the residual standard error for the 33% feeds. 
 
 
 
 
